Citation Report

List of articles citing

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarke

DOI: 10.1016/s1474-4422(12)70291-0
Lancet Neurology, The, 2013, 12, 207-16.

Source: https://exaly.com/paper-pdf/55193327/citation-report.pdf
Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2239	Ushering in the study and treatment of preclinical Alzheimer disease. **2013**, 9, 371-81		103
2238	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. **2013**, 108, 21-43		368
2237	□H-deprenyl and □H-PIB autoradiography show different laminar distributions of astroglia and fibrillar ⊞amyloid in Alzheimer brain. **2013**, 10, 90		38
2236	Dementia: Mild cognitive impairment--amyloid and beyond. **2013**, 9, 493-5		3
2235	The therapeutics of Alzheimer's disease: where we stand and where we are heading. **2013**, 74, 328-36		91
2234	CSF ⊞synuclein improves diagnostic and prognostic performance of CSF tau and A⊞n Alzheimer's disease. **2013**, 126, 683-97		75
2233	FDG PET and cognitive symptoms of dementia. **2013**, 1, 247-260		14
2232	Quantifying an amyloid ⊞model for Alzheimer's disease. *Lancet Neurology, The*, **2013**, 12, 327-8	24.1	1
2231	The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia?. **2013**, 37, 2676-88		98
2230	Amyloid imaging in atypical presentations of Alzheimer's disease. **2013**, 13, 412		29
2229	Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. **2013**, 13, 415		75
2228	Alzheimer disease and stroke: Cognitive and neuroimaging predictors of AD and stroke. **2013**, 9, 605-6		8
2227	Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. **2013**, 521, 4124-44		180
2226	Cerebral amyloid PET imaging in Alzheimer's disease. **2013**, 126, 643-57		79
2225	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. **2013**, 110, E4502-9		253
2224	Amyloid PET Imaging: MCI and AD. **2013**, 8, 431-45		2
2223	Biomarker modeling of Alzheimer's disease. **2013**, 80, 1347-58		586

2222	Drug development in dementia. **2013**, 76, 260-6		2
2221	Biomarkers for Alzheimer's: the sequel of an original model. *Lancet Neurology, The*, **2013**, 12, 126-8	24.1	9
2220	Longitudinal change in CSF Tau and A biomarkers for up to 48 months in ADNI. **2013**, 126, 659-70		139
2219	Aerobic fitness and cognitive function in midlife: an association mediated by plasma insulin. **2013**, 28, 727-30		7
2218	Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunochemistry. **2013**, 3, 70		12
2217	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer disease. **2013**, 1, 279-288		2
2216	Brains from non-Alzheimer's individuals containing amyloid deposits accelerate A deposition in vivo. **2013**, 1, 76		27
2215	Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. **2013**, 17, 726-34		442
2214	Do preclinical Alzheimer's disease criteria work?. *Lancet Neurology, The*, **2013**, 12, 933-5	24.1	6
2213	Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. **2013**, 17, 510-6		27
2212	Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. **2013**, 34, 2827-34		52
2211	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. **2013**, 2, 497-511		74
2210	Arterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study. **2013**, 2, 630-6		65
2209	Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia. **2013**, 3, 155-62		160
2208	Amyloid deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *Lancet Neurology, The*, **2013**, 12, 357-67	24.1	1336
2207	Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. *Lancet Neurology, The*, **2013**, 12, 469-82	24.1	139
2206	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- changes occur before increases of tau in cerebrospinal fluid. **2013**, 126, 631-41		103
2205	Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. **2013**, 5, 26		1

2204	Mild cognitive impairment due to Alzheimer disease in the community. **2013**, 74, 199-208	175
2203	Reply: The amyloid cascade is not the only pathway to AD. **2013**, 9, 356	8
2202	Can tauopathy shake the amyloid cascade hypothesis?. **2013**, 9, 356	7
2201	Alzheimer disease: the quest for Alzheimer disease genes--focus on CSF tau. **2013**, 9, 368-70	3
2200	Amyloid-╫positron emission tomography imaging probes: a critical review. **2013**, 36, 613-31	56
2199	MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study. **2013**, 3,	56
2198	Immunological aspects and anti-amyloid strategy for Alzheimer's dementia. **2013**, 64, 603-8	2
2197	Implications of presymptomatic change in thalamus and caudate in Alzheimer's disease. **2013**, 136, e258	3
2196	Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer's disease. **2013**, 136, e259	3
2195	Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. **2013**, 136, 2217-27	94
2194	Neuroimaging and the search for a cure for Alzheimer disease. **2013**, 269, 671-91	37
2193	Zerebrale Bildgebung bei Demenzen: State-of-the-Art. **2013**, 40, 200-212	1
2192	Cerebrospinal fluid tau levels predict prognosis in non-inherited frontotemporal dementia. **2014**, 13, 224-9	20
2191	The role of ╫amyloid in alzheimer's disease-related neurodegeneration. **2013**, 33, 12910-1	19
2190	The PREVENT research programme--a novel research programme to identify and manage midlife risk for dementia: the conceptual framework. **2013**, 25, 748-54	13
2189	The clinical neuroscience of the ageing brain cognitive diseases: a marching revolution. **2013**, 26, 632-3	
2188	The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. **2013**, 26, 646-55	16
2187	Impact of brain aging and neurodegeneration on cognition: evidence from MRI. **2013**, 26, 640-5	21

2186	Alzheimer's disease. **2013**, 33, 313-29	61
2185	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. **2013**, 81, 1732-40	142
2184	Epilepsy: Psychiatric comorbidities and premature death in epilepsy. **2013**, 9, 606-8	5
2183	CSF biomarker changes precede symptom onset of mild cognitive impairment. **2013**, 81, 1753-8	74
2182	Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. **2013**, 3, 219-229	39
2181	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. **2013**, 5, 48	100
2180	Calmodulin levels in blood cells as a potential biomarker of Alzheimer's disease. **2013**, 5, 55	19
2179	Evaluation of Cognitive Impairment in Older Adults. **2013**, 11, 482-500	8
2178	Interview: Understanding the complex pathways from normal cognition to dementia: the role of neuroimaging. **2013**, 3, 413-416	
2177	Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. **2013**, 5, 55	95
2176	Characterization of resting state activity in MCI individuals. **2013**, 1, e135	32
2175	Cognitive declines precede and predict functional declines in aging and Alzheimer's disease. **2013**, 8, e73645	47
2174	Traumatic brain injury, neuroimaging, and neurodegeneration. **2013**, 7, 395	128
2173	Drug therapies for Alzheimer's disease. **2013**, 2, 78-83	
2172	Gray and white matter changes in subjective cognitive impairment, amnestic mild cognitive impairment and Alzheimer's disease: a voxel-based analysis study. **2014**, 9, e104007	22
2171	Neuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegeneration. **2014**, 9, e104973	43
2170	Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease. **2014**, 9, e105784	13
2169	Might cortical hyper-responsiveness in aging contribute to Alzheimer's disease?. **2014**, 9, e105962	4

2168	CSF Biomarkers of Alzheimer Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. **2014**, 2014, 1-14	11
2167	Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. **2014**, 6, 47	74
2166	Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. **2014**, 6, 71	34
2165	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. **2014**, 6, 145	23
2164	Genetic variation modifies risk for neurodegeneration based on biomarker status. **2014**, 6, 183	14
2163	Synchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer's disease?. **2014**, 6, 234	17
2162	Why looking at the whole hippocampus is not enough-a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. **2014**, 8, 95	73
2161	Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction. **2014**, 8, 921	19
2160	The toxicity mechanisms of action of A 25-35 in isolated rat cardiac myocytes. **2014**, 19, 12242-57	4
2159	Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. **2014**, 4,	11
2158	Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative. **2014**, 10, 929-52	36
2157	Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease. **2014**, 10, 439-51	22
2156	Biomarkers for predicting cognitive decline in those with normal cognition. **2014**, 40, 587-94	27
2155	Neuropathology of Dementia Disorders. **2014**, 04,	7
2154	Editorial: Current updates on association between Alzheimer's disease and type 2 diabetes mellitus--volume II. **2014**, 13, 377-82	1
2153	Amyloid imaging in Alzheimer's disease: a literature review. **2014**, 18, 723-40	8
2152	Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?. **2014**, 15, 38-49	1
2151	Models of amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. **2014**, 9, 51	172

2150	The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results. **2014**, 14, 254	42
2149	Age-related deficit accumulation and the risk of late-life dementia. **2014**, 6, 54	69
2148	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. **2014**, 4, e419	32
2147	Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. **2014**, 8, 1151-69	33
2146	Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability. **2016**, 26, 695-707	63
2145	Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. **2014**, 55, 347-65	28
2144	Aging, Overview. **2014**, 76-80	0
2143	Promise and challenge: the lens model as a biomarker for early diagnosis of Alzheimer's disease. **2014**, 2014, 826503	15
2142	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. **2014**, 10, S430-52	57
2141	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. **2014**, 82, 1768-75	42
2140	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. **2014**, 85, 266-73	40
2139	The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. **2014**, 71, 1520-8	63
2138	Preclinical biomarkers in Alzheimer disease: a sum greater than the parts. **2014**, 71, 1357-8	3
2137	A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. **2014**, 2014, 785039	37
2136	Amyloidosis and neurodegeneration in Alzheimer disease: who's on first?. **2014**, 82, 1756-7	14
2135	Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. **2014**, 10, e1003956	105
2134	Association of hypometabolism and amyloid levels in aging, normal subjects. **2014**, 82, 1959-67	60
2133	Serum metabolomic biomarkers of dementia. **2014**, 4, 252-62	37

2132	Molecular imaging of Alzheimer disease pathology. **2014**, 35, S12-7	13
2131	A data-driven model of biomarker changes in sporadic Alzheimer's disease. **2014**, 137, 2564-77	149
2130	Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. **2014**, 137, 2578-87	101
2129	Cortical thickness mediates the effect of ß-amyloid on episodic memory. **2014**, 82, 761-7	33
2128	Tracking the earliest pathologic changes in Alzheimer disease. **2014**, 82, 1576-7	16
2127	New tools for the evaluation of patients with neurodegenerative diseases. **2014**, 4, 403-5	
2126	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. **2014**, 9, 597-613	2
2125	Development of novel PET probe [□□C](R,R)HAPT and its stereoisomer [□□C](S,S)HAPT for vesicular acetylcholine transporter imaging: a PET study in conscious monkey. **2014**, 68, 283-92	6
2124	Cognitive decline and brain pathology in aging--need for a dimensional, lifespan and systems vulnerability view. **2014**, 55, 244-54	33
2123	Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. **2014**, 14, 98-106	36
2122	Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. **2014**, 57, 18-24	27
2121	Resting-state networks in Alzheimer's disease and Parkinson's disease. **2014**, 13, 186-8	27
2120	Tau PET imaging in Alzheimer's disease. **2014**, 14, 500	119
2119	Pittsburgh compound B retention and progression of cognitive status--a meta-analysis. **2014**, 21, 1060-1067	13
2118	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. **2014**, 2, 26	65
2117	Validity of the montreal cognitive assessment as a screen for mild cognitive impairment and dementia in African Americans. **2014**, 27, 199-203	53
2116	White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration. **2014**, 71, 1547-54	45
2115	PART and SNAP. **2014**, 128, 773-6	68

2114	Intracellular Aβpathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. **2014**, 2, 61	62
2113	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. **2014**, 6, 41	30
2112	Memory difficulties are not always a sign of incipient dementia: a review of the possible causes of loss of memory efficiency. **2014**, 112, 71-81	43
2111	Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. **2014**, 55, 2003-11	42
2110	Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. **2014**, 73, 948-53	25
2109	Effect of 1 night of total sleep deprivation on cerebrospinal fluid βamyloid 42 in healthy middle-aged men: a randomized clinical trial. **2014**, 71, 971-7	229
2108	Synergistic effect of βamyloid and neurodegeneration on cognitive decline in clinically normal individuals. **2014**, 71, 1379-85	227
2107	Alzheimer's Disease. **2014**, 122-127	5
2106	Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. **2014**, 20, 422-33	21
2105	Is it dangerous or beneficial to drink coffee? Reflections on a meta-analysis on risk at birth and a population study on risk in late life. **2014**, 29, 665-6	3
2104	Developments in Tau PET Imaging. **2014**, 41, 547-53	40
2103	Machine Learning in Medical Imaging. **2014**,	5
2102	Emerging βamyloid pathology and accelerated cortical atrophy. **2014**, 71, 725-34	43
2101	Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease. **2014**, 28, 2620-31	31
2100	Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. **2014**, 71, 872-7	63
2099	Preclinical and Translational PET/MR Imaging. **2014**, 55, 11S-18S	51
2098	Dementia with Lewy bodies: basis of cingulate island sign. **2014**, 83, 801-9	111
2097	Double compression: a vision for compressing morbidity and caregiving in dementia. **2014**, 54, 901-8	4

2096	A distinct subfraction of A‖s responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. **2014**, 131, 356-68	22
2095	The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. **2014**, 1842, 1219-31	411
2094	Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. **2014**, 2, 246-55	331
2093	Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease. **2014**, 35, 1973-81	38
2092	Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease. **2014**, 5, 178-87	68
2091	Multiple instance learning for classification of dementia in brain MRI. **2014**, 18, 808-18	109
2090	Genetic modification of the relationship between phosphorylated tau and neurodegeneration. **2014**, 10, 637-645.e1	18
2089	The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. **2014**, 88, 677-81	23
2088	A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. **2014**, 10, 571-81	136
2087	Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. **2014**, 35, 143-51	85
2086	Biomarkers in amyloid-‖mmunotherapy trials in Alzheimer's disease. **2014**, 39, 189-201	54
2085	Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography. **2014**, 133, 85-93	25
2084	Biomarker modelling of early molecular changes in Alzheimer's disease. **2014**, 18, 213-27	4
2083	Huntington disease: natural history, biomarkers and prospects for therapeutics. **2014**, 10, 204-16	600
2082	Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. **2014**, 50, 534-44	236
2081	Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment. **2014**, 41, 739-48	21
2080	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. **2014**, 41, 1190-8	7
2079	Neurodegenerative Diseases. **2014**,	2

2078	Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. **2014**, 34, 5200-10	56
2077	Time for tau. **2014**, 137, 1570-1	10
2076	Mild cognitive impairment: a concept in evolution. **2014**, 275, 214-28	744
2075	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. **2014**, 10, 844-52	1219
2074	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. **2014**, 117, 20-40	412
2073	Cerebrospinal fluid amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. **2014**, 76, 223-30	88
2072	Characterization of intermediate steps in amyloid beta (A production under near-native conditions. **2014**, 289, 1540-50	72
2071	A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative. **2014**, 75, 527-33	26
2070	Biobanking of CSF: international standardization to optimize biomarker development. **2014**, 47, 288-92	68
2069	Emerging therapeutics for Alzheimer's disease. **2014**, 54, 381-405	63
2068	Non-invasive brain stimulation of the right inferior frontal gyrus may improve attention in early Alzheimer's disease: a pilot study. **2014**, 346, 318-22	64
2067	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. **2014**, 10, 779-89	19
2066	The evolution of preclinical Alzheimer's disease: implications for prevention trials. **2014**, 84, 608-22	429
2065	Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. **2014**, 10, 690-703	24
2064	APOE 4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?. **2014**, 10, 619-29	41
2063	Intrinsic brain activity of cognitively normal older persons resembles more that of patients both with and at risk for Alzheimer's disease than that of healthy younger persons. **2014**, 4, 323-36	2
2062	Longitudinal PET-MRI reveals amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. **2014**, 20, 1485-92	87
2061	The emerging agenda of stratified medicine in neurology. **2014**, 10, 15-26	22

2060	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. **2014**, 37, 629-41		32
2059	A (68)Ga complex based on benzofuran scaffold for the detection of β-amyloid plaques. **2014**, 24, 4834-7		18
2058	Resting-state functional MR imaging: a new window to the brain. **2014**, 272, 29-49		223
2057	The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia. **2014**, 14, 498		10
2056	The role of olfactory challenge tests in incipient dementia and clinical trial design. **2014**, 14, 479		17
2055	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. **2014**, 35, 338-48		100
2054	Functional and Structural MRI in Alzheimer's Disease: A Multimodal Approach. **2014**, 371-422		
2053	Disruption of resting functional connectivity in Alzheimer's patients and at-risk subjects. **2014**, 14, 491		32
2052	Structural imaging measures of brain aging. **2014**, 24, 271-89		144
2051	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. **2014**, 142, 262-8		21
2050	Emotional and behavioral symptoms in neurodegenerative disease: a model for studying the neural bases of psychopathology. **2014**, 10, 581-606		103
2049	Innate immune activation in neurodegenerative disease. **2014**, 14, 463-77		799
2048	Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. *Lancet Neurology, The*, **2014**, 13, 997-1005	24.1	246
2047	Ghrelin: a link between ageing, metabolism and neurodegenerative disorders. **2014**, 72 Pt A, 72-83		49
2046	The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations. **2014**, 24, 300-12		26
2045	Neuroimaging of the aging brain: introduction to the special issue of neuropsychology review. **2014**, 24, 267-70		4
2044	How does it STAC up? Revisiting the scaffolding theory of aging and cognition. **2014**, 24, 355-70		409
2043	Alzheimer-Demenz: Praxis und neue Entwicklungen. **2014**, 16, 40-51		

2042	Vasculaire oorzaken van dementie; de waarde van het levensloopperspectief. **2014**, 2, 48-56	
2041	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. **2014**, 11, 120	66
2040	Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. **2014**, 6, 16	96
2039	Dynamic cerebral autoregulation and tissue oxygenation in amnestic mild cognitive impairment. **2014**, 41, 765-78	66
2038	Neural compensation in older people with brain amyloid-β deposition. **2014**, 17, 1316-8	123
2037	Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. **2014**, 83, 1613-9	40
2036	Development and characterization of an aged onset model of Alzheimer's disease in Drosophila melanogaster. **2014**, 261, 772-81	18
2035	[Mild neurocognitive disorder - a disease? Against]. **2014**, 85, 632-4	0
2034	Amyloid imaging in depression: a predictor of Alzheimer's disease?. **2014**, 41, 711-3	1
2033	Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. **2014**, 34 Suppl 1, S64-9	73
2032	Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. **2014**, 137, 1550-61	109
2031	Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. **2014**, 55, 47S-55S	46
2030	Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort. **2014**, 39, 49-61	18
2029	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. **2014**, 137, 1533-49	83
2028	MRI in Psychiatry. **2014**,	2
2027	Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis. **2014**, 4, 299-311	100
2026	White matter hyperintensities as early and independent predictors of Alzheimer's disease risk. **2014**, 42 Suppl 4, S393-400	37
2025	The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden. **2014**, 273, 175-84	52

2024	Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. **2014**, 35, 808-18	31
2023	Developing novel blood-based biomarkers for Alzheimer's disease. **2014**, 10, 109-14	111
2022	White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. **2014**, 35, 2263-71	45
2021	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. **2014**, 35, 2096-106	85
2020	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. **2014**, 10, 713-723.e2	204
2019	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. **2014**, 4, 508-16	41
2018	Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. **2014**, 35, 2249-62	100
2017	Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. **2014**, 4, 164-73	88
2016	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. **2014**, 88, 426-49	84
2015	Neuronal activity regulates extracellular tau in vivo. **2014**, 211, 387-93	319
2014	Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. **2014**, 10, S122-45	194
2013	Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease. **2014**, 35, 2486-2494	45
2012	Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. **2014**, 10, 684-9	49
2011	Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. **2014**, 10, S55-61	30
2010	Estimating long-term multivariate progression from short-term data. **2014**, 10, S400-10	101
2009	Qualification of a surrogate matrix-based absolute quantification method for amyloid-β in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. **2014**, 41, 441-51	77
2008	Disturbed default mode network connectivity patterns in Alzheimer's disease associated with visual processing. **2014**, 41, 1229-38	17
2007	Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias. **2014**, 42, 211-26	32

2006	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. **2014**, 6, 36	19
2005	Novel plasma biomarker surrogating cerebral amyloid deposition. **2014**, 90, 353-64	81
2004	Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms. **2014** , 13, 163-5	9
2003	Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. **2015**, 43, 1393-402	20
2002	Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected]. **2014**, 93, e150	48
2001	Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. **2014**, 82, 1605-12	100
2000	How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?. **2014**, 13, 197-9	3
1999	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. **2015**, 21, 841-50	37
1998	Is late-onset Alzheimer's disease really a disease of midlife?. **2015**, 1, 122-130	59
1997	Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology. **2015**, 74, 1086-92	19
1996	Physical Activity and Amyloid-β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment. **2015**, 63, 1634-9	30
1995	Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics. **2015**, 1346, 71-80	13
1994	Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment. **2015**, 69, 741-51	10
1993	Cognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old. **2015**, 29, 1569-77	34
1992	Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease. **2015**, 48, 1043-50	25
1991	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. **2015**, 5, 16404	79
1990	Aberrant intra- and inter-network connectivity architectures in Alzheimer's disease and mild cognitive impairment. **2015**, 5, 14824	68
1989	Absence of practice effects in preclinical Alzheimer's disease. **2015**, 29, 940-8	73

1988	Selective activators of protein phosphatase 5 target the auto-inhibitory mechanism. **2015**, 35,	13
1987	Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers. **2016**, 49, 187-199	7
1986	Impaired Parahippocampus Connectivity in´Mild Cognitive Impairment and´Alzheimer's Disease. **2016**, 49, 1051-64	31
1985	Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease. **2016**, 49, 93-100	25
1984	Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. **2015**, 46, 63-73	65
1983	[Amyloid and tau imaging, its present and future]. **2015**, 146, 144-9	2
1982	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. **2015**, 48, 433-41	28
1981	Oxidative Stress and Aberrant Cell Cycle in Alzheimer's Disease Lymphocytes: Diagnostic Prospects. **2015**, 46, 329-50	34
1980	Simultaneous PET-MRI Studies of the Concordance of Atrophy and Hypometabolism in Syndromic Variants of Alzheimer's Disease and Frontotemporal Dementia: An Extended Case Series. **2015**, 46, 639-53	12
1979	Subjective Memory Complaints in APOEe4 Carriers are Associated with High Amyloid-Burden. **2016**, 49, 1115-22	40
1978	Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions. **2015**, 47, 149-56	39
1977	Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. **2015**, 125, 350-64	97
1976	Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. **2015**, 44, 809-13	36
1975	Biomarkers in Sporadic and Familial Alzheimer's Disease. **2015**, 47, 291-317	61
1974	New Perspectives on Alzheimer's Disease and Nutrition. **2015**, 46, 1111-27	47
1973	Increased CSF Aduring the very early phase of cerebral Adeposition in mouse models. **2015**, 7, 895-903	29
1972	Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool for Alzheimer's Disease Diagnostics. **2015**, 46, 1007-20	9
1971	Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. **2015**, 47, 231-42	101

1970	Are We Ready? The Construct of Subjective Cognitive Impairment and its Utilization in Clinical Practice: A Preliminary UK-Based Service Evaluation. **2015**, 48 Suppl 1, S25-31	12
1969	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. **2015**, 46, 889-99	11
1968	Prospective longitudinal study of frailty transitions in a community-dwelling cohort of older adults with cognitive impairment. **2015**, 15, 175	29
1967	Intrinsic Brain Activity and Resting State Networks. **2015**, 1-52	0
1966	A practical guideline for intracranial volume estimation in patients with Alzheimer's disease. **2015**, 16 Suppl 7, S8	20
1965	Tau (-)orientierte Therapien der Alzheimer-Demenz. **2015**, 16, 44-50	
1964	Epistasis analysis links immune cascades and cerebral amyloidosis. **2015**, 12, 227	8
1963	Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in APP(swe)/PS1 mice. **2015**, 10, 27	55
1962	Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects. **2015**, 7, 58	21
1961	The domestic cat as a natural animal model of Alzheimer's disease. **2015**, 3, 78	37
1960	Detection of Alzheimer's disease signature in MR images seven years before conversion to dementia: Toward an early individual prognosis. **2015**, 36, 4758-70	32
1959	Blood Protein Markers of Neocortical Amyloid-Burden: A Candidate Study Using SOMAscan Technology. **2015**, 46, 947-61	40
1958	Thyroid-Stimulating Hormone and Mild Cognitive Impairment: Results of the Heinz Nixdorf Recall Study. **2016**, 49, 797-807	10
1957	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. **2015**, 47, 205-14	39
1956	Age and amyloid effects on human central nervous system amyloid-beta kinetics. **2015**, 78, 439-53	98
1955	Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. **2015**, 36, 2826-41	68
1954	The effect of beta-amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal. **2015**, 36, 2514-26	20
1953	Association of Body Fat Percentage and Waist-hip Ratio With Brain Cortical Thickness: A Study Among 1777 Cognitively Normal Subjects. **2015**, 29, 279-86	9

1952	Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age. **2015**, 28, 144-52	26
1951	Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment. **2015**, 48, 123-33	6
1950	The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. **2016**, 13, 53-67	43
1949	A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease. **2015**, 11, 132-41	13
1948	An Eye on Brain Integrity: Acute Optic Neuritis Affects Resting State Functional Connectivity. **2015**, 56, 2541-6	18
1947	Editorial: Prevention Strategies Targeting Different Preclinical Stages of Alzheimer's Disease. **2015**, 12, 504-6	3
1946	Altered Neural Activity during Semantic Object Memory Retrieval in Amnestic Mild Cognitive Impairment as Measured by Event-Related Potentials. **2015**, 46, 703-17	10
1945	Analysis of the posterior cingulate cortex with [18F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer's disease: Correlations and differences between the two methods. **2015**, 9, 385-393	5
1944	Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. **2015**, 45, 27-33	33
1943	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. **2016**, 49, 659-69	26
1942	Role of Hybrid Brain Imaging in Neuropsychiatric Disorders. **2015**, 5, 577-614	8
1941	Bioinformatics Mining and Modeling Methods for the Identification of Disease Mechanisms in Neurodegenerative Disorders. **2015**, 16, 29179-206	37
1940	The fornix in mild cognitive impairment and Alzheimer's disease. **2015**, 7, 1	147
1939	Potentials and limits to enhance cognitive functions in healthy and pathological aging by tDCS. **2015**, 9, 355	44
1938	BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid. **2015**, 9, 382	15
1937	The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease. **2015**, 6, 90	15
1936	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. **2015**, 6, 142	18
1935	Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. **2015**, 6, 236	77

1934	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. **2015**, 6, 256	10
1933	Barriers to developing a valid rodent model of Alzheimer's disease: from behavioral analysis to etiological mechanisms. **2015**, 9, 245	16
1932	Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease. **2015**, 46, 167-78	15
1931	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. **2015**, 12, 712-22	104
1930	Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis. **2015**, 46, 17-34	49
1929	Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population. **2015**, 10, e0123743	23
1928	Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer's Disease. **2015**, 10, e0142756	54
1927	Optical coherence tomography in neurodegenerative and other neurologic diseases. 128-144	
1926	Neuroimaging in Dementias. **2015**, 107-118	
1925	Midlife CAIDE dementia risk score and dementia-related brain changes up to 30 years later on magnetic resonance imaging. **2015**, 44, 93-101	25
1924	Recent Progress in the Identification of Non-Invasive Biomarkers to Support the Diagnosis of Alzheimer□ Disease in Clinical Practice and to Assist Human Clinical Trials. **2015**,	0
1923	First effects of rising amyloid-□n transgenic mouse brain: synaptic transmission and gene expression. **2015**, 138, 1992-2004	49
1922	Cocaine shapes chromatin landscapes via Tet1. **2015**, 18, 478-80	2
1921	Systems biology of neurodegenerative diseases. **2015**, 7, 758-75	32
1920	Diagnostic Test Accuracy Studies in Dementia. **2015**,	5
1919	Multi-resolution statistical analysis of brain connectivity graphs in preclinical Alzheimer's disease. **2015**, 118, 103-17	38
1918	Subjective memory impairment in older adults predicts future dementia independent of baseline memory performance: Evidence from the Betula prospective cohort study. **2015**, 11, 1385-92	92
1917	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. **2015**, 11, 1191-201	59

1916	Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review. **2015**, 25, 413-23	16
1915	Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study. **2015**, 53, 453-60	10
1914	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. **2015**, 18, 800-6	435
1913	TREM2 in CNS homeostasis and neurodegenerative disease. **2015**, 10, 43	81
1912	Impact of Arterial Aging on Early and Late Stages of Brain Damage. **2015**, 195-200	
1911	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. **2015**, 138, 2020-33	227
1910	The Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy. **2015**, 290, 30670-83	77
1909	Amyloid burden and sleep blood pressure in amnestic mild cognitive impairment. **2015**, 85, 1922-9	22
1908	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. **2015**, 1, 412-9	66
1907	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. **2015**, 36, 1605.e13-20	22
1906	Universal screening test based on analysis of circulating organ-enriched microRNAs: a novel approach to diagnostic screening. **2015**, 15, 329-38	4
1905	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. **2015**, 111, 562-79	193
1904	Sugihara causality analysis of scalp EEG for detection of early Alzheimer's disease. **2015**, 7, 258-65	39
1903	Synthesis and biological evaluation of 123I-labeled pyridyl benzoxazole derivatives: novel β-amyloid imaging probes for single-photon emission computed tomography. **2015**, 5, 1009-1015	10
1902	Cortical hypermetabolism in MCI subjects: a compensatory mechanism?. **2015**, 42, 447-58	64
1901	Morphometric and histologic substrates of cingulate integrity in elders with exceptional memory capacity. **2015**, 35, 1781-91	71
1900	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. **2015**, 11, 511-22	45
1899	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusion-Tensor and Magnetic Resonance Imaging Data. **2015**, 25, 738-47	62

1898	Evolving brain structural changes in PSEN1 mutation carriers. **2015**, 36, 1261-70	27
1897	Hippocampal atrophy is associated with subjective memory decline: The PATH Through Life study. **2015**, 23, 446-55	44
1896	The hypothalamus in Alzheimer's disease: a Golgi and electron microscope study. **2015**, 30, 478-87	49
1895	Central artery stiffness, baroreflex sensitivity, and brain white matter neuronal fiber integrity in older adults. **2015**, 110, 162-70	34
1894	Innate immunity in Alzheimer's disease. **2015**, 16, 229-36	458
1893	Brain structure and function as mediators of the effects of amyloid on memory. **2015**, 84, 1136-44	33
1892	Low-intensity daily walking activity is associated with hippocampal volume in older adults. **2015**, 25, 605-15	99
1891	White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients. **2015**, 41, 102-9	55
1890	Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. **2015**, 64, S51-7	15
1889	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. **2015**, 36, 1765.e7-1765.e16	63
1888	The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. **2015**, 105, 357-68	36
1887	Building a roadmap for developing combination therapies for Alzheimer's disease. **2015**, 15, 327-33	39
1886	The impact of cognitive reserve on brain functional connectivity in Alzheimer's disease. **2015**, 44, 243-50	80
1885	The influence of chronic ibuprofen treatment on proteins expressed in the mouse hippocampus. **2015**, 752, 61-8	7
1884	A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. **2015**, 11, 1246-59	46
1883	NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A□tau, and □synuclein. **2015**, 349, 1255555	564
1882	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. **2015**, 11, 865-84	132
1881	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. **2015**, 11, 772-91	53

1880	Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. **2015**, 11, 730-3		38
1879	The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. **2015**, 11, 1510-1519		62
1878	Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. **2015**, 11, 986-93		11
1877	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. **2015**, 11, 734-9		49
1876	Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. **2015**, 36, 2568-76		129
1875	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. **2015**, 138, 2701-15		86
1874	Alzheimer's Disease Neuroimaging Initiative: A decade of progress in Alzheimer's disease. **2015**, 11, 727-9		7
1873	Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. **2015**, 36, 1619-1628		27
1872	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. *Lancet Neurology, The*, **2015**, 14, 804-813	24.1	74
1871	Biomarkers for Alzheimer's disease: a controversial topic. *Lancet Neurology, The*, **2015**, 14, 781-783	24.1	8
1870	Predictors of Clinical Progression of Subjective Memory Impairment in Elderly Subjects: Data from the Clinical Research Centers for Dementia of South Korea (CREDOS). **2015**, 40, 158-65		19
1869	White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters. **2015**, 36, 2447-57		34
1868	Altered whole-brain white matter networks in preclinical Alzheimer's disease. **2015**, 8, 660-6		61
1867	Cerebrospinal fluid tau and amyloid-β-42 in patients with dementia. **2015**, 138, 2716-31		105
1866	CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. **2015**, 138, 2383-98		105
1865	Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome. **2015**, 30, 192-200		25
1864	Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. **2015**, 85, 898-904		128
1863	Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes. **2015**, 36, 2501-8		21

1862	Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. **2015**, 36, 2687-701	35
1861	Should we screen for cognitive decline and dementia?. **2015**, 82, 28-35	15
1860	Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome. **2015**, 36, 2907.e1-10	21
1859	Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics. **2015**, 29, 519-28	5
1858	Tract-specific white matter degeneration in aging: the Rotterdam Study. **2015**, 11, 321-30	127
1857	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. **2015**, 11, 757-71	132
1856	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. **2015**, 11, 823-31	41
1855	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. **2015**, 11, 792-814	167
1854	Voxelwise Relationships Between Distribution Volume Ratio and Cerebral Blood Flow: Implications for Analysis of ♯Amyloid Images. **2015**, 56, 1042-7	10
1853	PET Quantification of Tau Pathology in Human Brain with 11C-PBB3. **2015**, 56, 1359-65	77
1852	Clearance systems in the brain-implications for Alzheimer disease. **2015**, 11, 457-70	759
1851	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. **2015**, 11, 740-56	101
1850	Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. **2015**, 85, 144-53	28
1849	Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?. **2015**, 43-44, 25-37	160
1848	Amyloid Tracers. **2015**, 633-639	
1847	Neuronal hyperactivity--A key defect in Alzheimer's disease?. **2015**, 37, 624-32	109
1846	Alzheimer□ Disease and the Search for Environmental Risk Factors. **2015**, 315-327	
1845	Alzheimer's disease clinical trials: past failures and future opportunities. **2015**, 5, 297-309	11

1844	Vascular risk factors, cerebrovascular reactivity, and the default-mode brain network. **2015**, 115, 7-16	43
1843	Regional cortical atrophy in depression and neurocognitive disorders. **2015**, 23, 437-9	
1842	Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. **2015**, 592, 54-8	58
1841	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. **2015**, 25, 3050-9	65
1840	Gaussian process classification of Alzheimer's disease and mild cognitive impairment from resting-state fMRI. **2015**, 112, 232-243	116
1839	Immunotherapeutic approaches for Alzheimer's disease. **2015**, 85, 1162-76	197
1838	[Cognitive deficits in unipolar major depression]. **2015**, 86, 99-113; quiz 114-5	12
1837	Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection"). **2015**, 12, 449-54	23
1836	The use of amyloid imaging in clinical praxis: a critical review. **2015**, 3, 7-11	4
1835	Insights into cognitive aging and Alzheimer□ disease using amyloid PET and structural MRI scans. **2015**, 3, 65-74	6
1834	Advances in Alzheimer's disease drug development. **2015**, 13, 62	62
1833	Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. **2015**, 3, 14	122
1832	Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. **2015**, 21, 768-75	36
1831	A call for new thoughts about what might influence human brain aging: aging, apolipoprotein E, and amyloid. **2015**, 72, 500-2	2
1830	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. **2015**, 138, 761-71	173
1829	Age, Sex, and APOE □4 Effects on Memory, Brain Structure, and □Amyloid Across the Adult Life Span. **2015**, 72, 511-9	229
1828	Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. **2015**, 72, 316-24	112
1827	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. **2015**, 11, 1417-1429	116

1826	Toward stem cell-based phenotypic screens for neurodegenerative diseases. **2015**, 11, 339-50	55
1825	Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer's disease as well as in wild-type mice. **2015**, 291, 1-11	37
1824	Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. **2015**, 39, 154-66	21
1823	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. **2015**, 72, 571-81	73
1822	Alzheimer amyloid peptide a□2 regulates gene expression of transcription and growth factors. **2015**, 44, 613-24	35
1821	Sugar and Alzheimer's disease: a bittersweet truth. **2015**, 18, 477-8	12
1820	Plasma amyloid-□and risk of Alzheimer's disease in the Framingham Heart Study. **2015**, 11, 249-57.e1	66
1819	Effects of Aerobic Training on Cognition and Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment. **2015**, 46, 747-60	21
1818	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. **2015**, 72, 699-706	54
1817	Estimating Intracranial Volume in Brain Research: An Evaluation of Methods. **2015**, 13, 427-41	27
1816	18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease. **2015**, 40, e111-6	15
1815	Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. **2015**, 72, 546-53	75
1814	Cerebral cortical A□2 and PHF-□n 325 consecutive brain autopsies stratified by diagnosis, location, and APOE. **2015**, 74, 100-9	19
1813	Alzheimer□ Disease and Mechanism-Based Attempts to Enhance Cognition. **2015**, 193-231	
1812	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. **2015**, 11, 751-67	79
1811	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. **2015**, 36, 1771-9	30
1810	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. **2015**, 113, 61-9	26
1809	Amyloid biomarkers in Alzheimer's disease. **2015**, 36, 297-309	320

1808	Isolated, subtle, neurological abnormalities in neurologically and cognitively healthy aging subjects. **2015**, 262, 1328-39	8
1807	Tau immunotherapy for Alzheimer's disease. **2015**, 21, 394-402	192
1806	Serum Amyloid-Beta Levels are Increased in Patients with Chronic Obstructive Pulmonary Disease. **2015**, 28, 346-51	15
1805	Association of plasma β-amyloid with MRI markers of structural brain aging the 3-City Dijon study. **2015**, 36, 2663-70	14
1804	Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment. **2015**, 11, 1489-1499	42
1803	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. **2015**, 7, 59	80
1802	Empirically Derived Trajectories to Dementia Over 15 Years of Follow-up Identified by Using Mixed Membership Models. **2015**, 182, 366-74	7
1801	Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults. **2015**, 78, 63-72	28
1800	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. **2015**, 138, 3747-59	128
1799	Memory complaints and risk of cognitive impairment after nearly 2 decades among older women. **2015**, 85, 1852-8	73
1798	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. **2015**, 46, 2661-4	51
1797	Clustering-initiated factor analysis application for tissue classification in dynamic brain positron emission tomography. **2015**, 35, 1104-11	2
1796	A simulation system for biomarker evolution in neurodegenerative disease. **2015**, 26, 47-56	8
1795	Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. **2015**, 1, 160-169	26
1794	Role of βAmyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. **2015**, 72, 1475-83	19
1793	Late-life memory trajectories in relation to incident dementia and regional brain atrophy. **2015**, 262, 2484-90	19
1792	Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. **2015**, 1, 339-348	23
1791	Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. **2015**, 35, 1485-93	24

1790	In vivo fluorescence imaging of β-amyloid plaques with push-pull dimethylaminothiophene derivatives. **2015**, 51, 17124-7		42
1789	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. **2015**, 34, 303-313		2
1788	Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution. **2015**, 36, 1635-41		36
1787	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. *Lancet Neurology, The*, **2015**, 14, 1037-53	24.1	172
1786	Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer's Disease Brains. **2015**, 58, 7241-57		36
1785	Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease. **2015**, 138, 3089-99		39
1784	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. **2015**, 72, 1275-80		152
1783	Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice. **2015**, 31, 491-504		22
1782	GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. **2015**, 138, 3076-88		88
1781	FDG-PET Contributions to the Pathophysiology of Memory Impairment. **2015**, 25, 326-55		17
1780	Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). **2015**, 290, 26043-50		266
1779	The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. **2015**, 81, 49-65		82
1778	The Case for Stage-Specific Frailty Interventions Spanning Community Aging to Cognitive Impairment. **2015**, 16, 1003.e13-9		8
1777	Suspected non-AD pathology in mild cognitive impairment. **2015**, 36, 3152-3162		49
1776	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. **2015**, 123, 149-64		48
1775	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. **2015**, 34, 303-13		11
1774	Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. **2015**, 14, 4834-43		6
1773	Plasma levels of apolipoprotein E and risk of dementia in the general population. **2015**, 77, 301-11		96

1772	Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. **2015**, 51, 14-8		41
1771	Alzheimer Disease. **2015**, 321-338		3
1770	An Introduction: A Clinical Neuroscientist and Disorders of the Brain. **2015**, 1-11		
1769	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. **2015**,		13
1768	Adverse vascular risk is related to cognitive decline in older adults. **2015**, 44, 1361-73		44
1767	Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. **2015**, 36, 60-7		69
1766	Tau imaging: early progress and future directions. *Lancet Neurology, The*, **2015**, 14, 114-24	24.1	360
1765	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. **2015**, 36, 273-82		26
1764	Statistically quantified measurement of an Alzheimer's marker by surface-enhanced Raman scattering. **2015**, 8, 567-74		29
1763	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. **2015**, 11, 58-69		271
1762	Diabetes and cognition. **2015**, 31, 101-15, ix		69
1761	Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. **2015**, 19, 154-63		34
1760	Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits. **2015**, 51, 661-71		30
1759	Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. **2015**, 11, 394-403.e1		63
1758	Multiple Brain Markers are Linked to Age-Related Variation in Cognition. **2016**, 26, 1388-400		114
1757	Imaging of Alzheimer's disease: Part 1. **2016**,		
1756	Blood-based Amyloid and Tau Biomarker Tests For Alzheimer's Disease. **2016**, 4, 4-13		
1755	Mechanisms underlying Alzheimer□ disease. **2016**, 3, 85-92		0

1754 [Not Available]. **2016**, 19, 74-82 2

1753 Impairment of fine motor dexterity in mild cognitive impairment and Alzheimer's disease dementia: association with activities of daily living. **2016**, 38, 235-8 36

1752 Centered Kernel Alignment Enhancing Neural Network Pretraining for MRI-Based Dementia Diagnosis. **2016**, 2016, 9523849 12

1751 The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. **2016**, 53, 1523-38 40

1750 A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β Driven Inflammation in Down Syndrome. **2016**, 15, 434-47 20

1749 Imaging Alzheimer's disease pathophysiology with PET. **2016**, 10, 79-90 21

1748 Soluble Amyloid-β42 Stimulates Glutamate Release through Activation of the α7 Nicotinic Acetylcholine Receptor. **2016**, 53, 337-47 24

1747 Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. **2016**, 13, 307-16 11

1746 The New Criteria for Alzheimer's Disease - Implications for Geriatricians. **2016**, 19, 66-73 10

1745 Curcumin against amyloid pathology in mental health and brain composition. **2016**, 487-505

1744 Killing Me Softly: Connotations to Unfolded Protein Response and Oxidative Stress in Alzheimer's Disease. **2016**, 2016, 1805304 20

1743 A Dietary Treatment Improves Cerebral Blood Flow and Brain Connectivity in Aging apoE4 Mice. **2016**, 2016, 6846721 42

1742 Connected Language in Late Middle-Aged Adults at Risk for Alzheimer's Disease. **2016**, 54, 1539-1550 33

1741 Nanomaterials for Neurology: State-of-the-Art. **2016**, 15, 1306-1324 9

1740 Alzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States. **2016**, 8, 15 22

1739 Implications of GABAergic Neurotransmission in Alzheimer's Disease. **2016**, 8, 31 129

1738 Exercise-Related Changes of Networks in Aging and Mild Cognitive Impairment Brain. **2016**, 8, 47 47

1737 In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy. **2016**, 8, 55 13

1736	Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease. **2016**, 8, 139	23
1735	Impact of Long-Term Endurance Training vs. Guideline-Based Physical Activity on Brain Structure in Healthy Aging. **2016**, 8, 155	24
1734	Neural Correlates for Apathy: Frontal-Prefrontal and Parietal Cortical- Subcortical Circuits. **2016**, 8, 289	55
1733	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. **2016**, 10, 20	44
1732	Labeling Pathological Tau: An Important Quest for the Unknown. **2016**, 10, 253	
1731	Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease. **2016**, 4, 62	52
1730	Biomarker f□ die Alzheimer-Erkrankung in der klinischen Praxis. **2016**, 27, 46-52	
1729	Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351. **2016**, 11, e0158460	65
1728	Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes. **2016**, 11, e0161969	277
1727	What can imaging tell us about cognitive impairment and dementia?. **2016**, 8, 240-54	26
1726	Methods for the Specific Detection and Quantitation of Amyloid-□Oligomers in Cerebrospinal Fluid. **2016**, 53, 53-67	21
1725	Tau PET Imaging for Dementia in Clinical Practice. **2016**, 65, 517-522	
1724	Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging. **2016**, 29, 405-11	11
1723	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. **2016**, 139 Suppl 2, 224-236	15
1722	Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction. **2016**, 124, 353-61	73
1721	In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. **2016**, 80, 247-58	266
1720	Resistance of Cu(A□16) to Copper Capture by Metallothionein-3 Supports a Function for the A□42 Peptide as a Synaptic CuII Scavenger. **2016**, 128, 8375-8378	6
1719	Resistance of Cu(A□-16) to Copper Capture by Metallothionein-3 Supports a Function for the A□-42 Peptide as a Synaptic Cu(II) Scavenger. **2016**, 55, 8235-8	42

1718	On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey. **2016**, 71, 1-29	76
1717	Hippocampal sub-regional shape and physical activity in older adults. **2016**, 26, 1051-60	33
1716	Spatial Navigation in Preclinical Alzheimer's Disease. **2016**, 52, 77-90	101
1715	The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial. **2016**, 52, 1299-310	31
1714	Kicking Back Cognitive Ageing: Leg Power Predicts Cognitive Ageing after Ten Years in Older Female Twins. **2016**, 62, 138-49	18
1713	Midlife Physical Activity and Cognition Later in Life: A Prospective Twin Study. **2016**, 54, 1303-1317	9
1712	Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. **2016**, 54, 1135-1146	53
1711	Topographical Information-Based High-Order Functional Connectivity and Its Application in Abnormality Detection for´Mild Cognitive Impairment. **2016**, 54, 1095-1112	70
1710	Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. **2016**, 51, 1249-56	9
1709	Longitudinal Study of Impaired Intra- and Inter-Network Brain Connectivity in Subjects at High Risk for Alzheimer's Disease. **2016**, 52, 913-27	35
1708	Visual Rating of Posterior Atrophy as´a´Marker of Progression to Dementia in´Mild Cognitive Impairment Patients. **2017**, 55, 137-146	4
1707	Better Objective Sleep Quality in Older Adults with High Subjective Memory Decline. **2016**, 53, 943-53	12
1706	Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects. **2017**, 55, 343-358	8
1705	Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer's Disease. **2016**, 22, 991-1004	9
1704	Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. **2016**, 22, 978-990	13
1703	CSF sTREM2: marking the tipping point between preclinical AD and dementia?. **2016**, 8, 437-8	2
1702	Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares. **2016**, 54, 359-71	22
1701	Staging Alzheimer's Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers. **2016**, 54, 983-993	26

1700	Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. **2016**, 8, 369ra178	155
1699	What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?. **2016**, 51, 793-800	7
1698	Preclinical Amyloid-Þand Axonal Degeneration Pathology in Delirium. **2017**, 55, 371-379	22
1697	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-Þ**2017**, 55, 333-342	12
1696	Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. **2016**, 29, 749-755	7
1695	Increased Intrinsic Activity of Medial-Temporal Lobe Subregions is Associated with Decreased Cortical Thickness of Medial-Parietal Areas in Patients with Alzheimer's Disease Dementia. **2016**, 51, 313-26	12
1694	Altered Executive Function in Pre-Mild Cognitive Impairment. **2016**, 54, 933-940	25
1693	Perspective from the Alzheimer's Association: Neuroimaging Professional Interest Area of ISTAART continues impact on the field. **2016**, 5, 1-2	
1692	Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior. **2016**, 22, 968-977	11
1691	FDG-PET in der Differenzialdiagnostik neurodegenerativer Demenzerkrankungen. **2016**, 39, 287-298	1
1690	NO2 inhalation promotes Alzheimer's disease-like progression: cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication. **2016**, 6, 22429	38
1689	Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. **2016**, 8, 51	14
1688	Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. **2016**, 52, 1403-13	11
1687	Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. **2016**, 50, 873-86	75
1686	Looking for Neuroimaging Markers in Frontotemporal Lobar Degeneration Clinical Trials: A Multi-Voxel Pattern Analysis Study in Granulin Disease. **2016**, 51, 249-62	25
1685	Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. **2016**, 53, 921-32	54
1684	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. **2016**, 43, 23-33	35
1683	Imaging the accumulation and suppression of tau pathology using multiparametric MRI. **2016**, 39, 184-94	35

1682	Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. **2016**, 12, 623-30	29
1681	PET Imaging of Tau Deposition in the Aging Human Brain. **2016**, 89, 971-982	619
1680	White matter hyperintensities are more highly associated with preclinical´Alzheimer's disease than imaging and cognitive markers of´neurodegeneration. **2016**, 4, 18-27	48
1679	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. **2016**, 39, 99-107	18
1678	Amyloid Imaging in Dementia and Related Disorders. **2016**, 89-102	
1677	Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease. **2016**, 4, 14-7	19
1676	A multivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging. **2016**, 134, 658-670	48
1675	Regional brain stiffness changes across the Alzheimer's disease spectrum. **2016**, 10, 283-90	104
1674	Thalamic pathology and memory loss in early Alzheimer's disease: moving the focus from the medial temporal lobe to Papez circuit. **2016**, 139, 1877-90	167
1673	Subtle learning and memory impairment in an idiopathic rat model of Alzheimer's disease utilizing cholinergic depletions and β-amyloid. **2016**, 1646, 12-24	11
1672	Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. **2016**, 39, 57-79	73
1671	Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. **2016**, 139, 1226-36	229
1670	Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. **2016**, 139, 1539-50	275
1669	Brain imaging of neurovascular dysfunction in Alzheimer's disease. **2016**, 131, 687-707	124
1668	Alzheimer's disease: a mathematical model for onset and progression. **2017**, 34, 193-214	25
1667	Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia. **2016**, 47, 1201-6	62
1666	Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. **2016**, 86, 1887-96	37
1665	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. **2016**, 44, 1-8	65

1664	Immunotherapy and Biomarkers in Neurodegenerative Disorders. **2016**,	3
1663	Impact of APOE-e4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. **2016**, 38, 14-20	26
1662	Neuroinflammation in Alzheimer's disease: Current evidence and future´directions. **2016**, 12, 719-32	632
1661	Dynamics of biomarkers in relation to aging and mortality. **2016**, 156, 42-54	21
1660	Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of ß-amyloid-42 aggregation. **2016**, 26, 3330-3335	12
1659	Ropren treatment reverses anxiety-like behavior and monoamines levels in gonadectomized rat model of Alzheimer's disease. **2016**, 83, 1444-1455	10
1658	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-ß in a multicentre European memory clinic study. **2016**, 139, 2540-53	93
1657	[Diagnostic criteria. Benefits of early diagnosis]. **2016**, 51 Suppl 1, 7-11	4
1656	Cognitive variability-A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative. **2016**, 4, 47-55	16
1655	NEUROIMÁGENES EN DEMENCIAS. **2016**, 27, 338-356	1
1654	Regional tau deposition measured by [F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. **2016**, 8, 38	35
1653	fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications. **2016**, 699-739	4
1652	Emerging drugs to reduce abnormal ß-amyloid protein in Alzheimer's disease patients. **2016**, 21, 377-391	43
1651	Air Pollution and Health in the Republic of Korea ??????????????????????????. **2016**, 128-149	1
1650	Whole-brain analysis reveals increased neuroanatomical asymmetries in dementia for hippocampus and amygdala. **2016**, 139, 3253-3266	73
1649	Cortical thickness in relation to clinical symptom onset in preclinical AD. **2016**, 12, 116-22	40
1648	Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. **2016**, 68, e67-e94	329
1647	Dementias. **2016**, 138, 123-51	23

1646	Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability. **2016**, 7, 325-340	68
1645	Tau physiology and pathomechanisms in frontotemporal lobar degeneration. **2016**, 138 Suppl 1, 71-94	52
1644	Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities. **2016**, 18, 85	126
1643	Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. **2016**, 43, 2219-2227	48
1642	Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. **2016**, 12, 1216-1225	17
1641	Untangling tau imaging. **2016**, 4, 39-42	1
1640	Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta. **2016**, 139, 324-332	18
1639	Cognitive screening instruments for the diagnosis of mild cognitive impairment. **2016**, 20, 21-26	20
1638	Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder. **2016**, 18, 71-7	8
1637	The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease. **2016**, 136, 457-74	228
1636	An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. **2016** , 26, 264-8	2
1635	Classifying anatomical subtypes of subjective memory impairment. **2016**, 48, 53-60	14
1634	Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease. **2016**, 4, 99-106	39
1633	Reductions in the mitochondrial enzyme □ketoglutarate dehydrogenase complex in neurodegenerative disease - beneficial or detrimental?. **2016**, 139, 823-838	16
1632	Network-Based Statistic Show Aberrant Functional Connectivity in Alzheimer's Disease. **2016**, 10, 1182-1188	15
1631	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. **2016**, 73, 1185-1191	40
1630	Longitudinal □Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. **2016**, 73, 1192-1200	63
1629	The amyloid hypothesis of Alzheimer's disease at 25 years. **2016**, 8, 595-608	2876

1628	Distinct pathways for cognitive decline in the presence of Alzheimer's disease pathology or cerebrovascular disease. **2016**, 139, 2340-1	5
1627	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. **2016**, 60, 354-361	33
1626	Plasma ╫amyloid in Alzheimer's disease and vascular disease. **2016**, 6, 26801	290
1625	Machine Learning Applied to Alzheimer Disease. **2016**, 281, 665-668	21
1624	Alpha band disruption in the AD-continuum starts in the Subjective Cognitive Decline stage: a MEG study. **2016**, 6, 37685	41
1623	Systems genetics identifies Hp1bp3 as a novel modulator of cognitive aging. **2016**, 46, 58-67	24
1622	Alzheimer's disease diagnostics by adaptation of 3D convolutional network. **2016**,	93
1621	Tau and tauopathies. **2016**, 126, 238-292	292
1620	Amyloid-╫deposition and regional grey matter atrophy rates in dementia with Lewy bodies. **2016**, 139, 2740-2750	51
1619	Genetic and degenerative disorders primarily causing dementia. **2016**, 135, 525-564	3
1618	Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice. **2016**, 136, 971-84	13
1617	Neuroimaging Advances in Alzheimer's Disease. **2016**, 263-282	0
1616	Progressive Supranuclear Palsy and Related Parkinsonian Disorders. **2016**, 283-300	1
1615	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between ╫Amyloid and Tauopathy. **2016**, 73, 1070-7	179
1614	Tau and ╫Amyloid-The Malignant Duo. **2016**, 73, 1049-50	3
1613	Domain adaptation for Alzheimer's disease diagnostics. **2016**, 139, 470-479	64
1612	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. **2016**, 80, 379-87	65
1611	Mild cognitive impairment and Alzheimer's disease. **2016**, 133-139	

1610	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. **2016**, 6, e952	33
1609	Amyloid deposition in younger adults is linked to episodic memory performance. **2016**, 87, 2562-2566	16
1608	Alzheimer's disease severity, objectively determined and measured. **2016**, 4, 159-168	9
1607	Tau and A imaging, CSF measures, and cognition in Alzheimer's disease. **2016**, 8, 338ra66	418
1606	Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review. **2016**, 255, 145-155	53
1605	Impaired episodic memory network in subjects at high risk for Alzheimer's disease. **2016**, 2016, 4017-4020	3
1604	The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model. **2016**, 7, 12082	40
1603	Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A pathological molecules. **2016**, 6, 28912	29
1602	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. **2016**, 73, 1230-1237	96
1601	Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling. **2016**, 9, 92	27
1600	Non-invasive screening for early Alzheimer's disease diagnosis by a sensitively immunomagnetic biosensor. **2016**, 6, 25155	41
1599	Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications. **2016**, 281, 337-356	225
1598	Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. **2016**, 7, 11934	547
1597	Dementia overview. **2016**, 132-139	
1596	Genetic Risk as a Marker of Amyloid- and Tau Burden in Cerebrospinal Fluid. **2017**, 55, 1417-1427	12
1595	High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. **2016**, 8, 22	26
1594	Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients. **2016**, 37, 1189-96	6
1593	Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab. **2016**, 53, 535-46	4

1592	Type 2 Diabetes, Obesity, and Risk for Dementia: Recent Insights into Brain Insulin Resistance and Hypometabolism. **2016**, 3, 293-300	3
1591	Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort. **2016**, 37, 1636-42	25
1590	PET Imaging as a Diagnostic Tool in Alzheimer□ Disease. **2016**, 199-213	
1589	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. **2016**, 139, 2249-60	125
1588	The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain. **2016**, 31, 99-105	6
1587	Synthesis and evaluation of copper-64 labeled benzofuran derivatives targeting □amyloid aggregates. **2016**, 24, 3618-23	11
1586	The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer□ Disease. **2016**, 1-22	
1585	Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer□ Disease. **2016**, 385-436	1
1584	Molecular Imaging in Alzheimer Clinical Trials. **2016**, 523-563	
1583	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. **2016**, 139, 2261-74	27
1582	Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease. **2016**, 30, 295-337	10
1581	Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease. **2016**, 46, 68-75	18
1580	Relative impact of amyloid-□lacunes, and downstream imaging markers on cognitive trajectories. **2016**, 139, 2516-27	34
1579	Frailty as a Predictor of Alzheimer Disease, Vascular Dementia, and All Dementia Among Community-Dwelling Older People: A Systematic Review and Meta-Analysis. **2016**, 17, 881-8	112
1578	Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease. **2016**, 2, 132-9	8
1577	Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns. **2016**, 2, 58-67	48
1576	Quantitative multimodal multiparametric imaging in Alzheimer's disease. **2016**, 3, 29-37	8
1575	Cerebrospinal fluid ratios with A□2 predict preclinical brain □amyloid accumulation. **2016**, 2, 27-38	35

1574	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. **2016**, 42, 124-31		23
1573	Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia. **2016**, 57, 208-16		29
1572	Alzheimer's disease due to loss of function: A new synthesis of the available data. **2016**, 143, 36-60		85
1571	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. **2016**, 79, 929-39		247
1570	Brain Events Underlying Episodic Memory Changes in Aging: A Longitudinal Investigation of Structural and Functional Connectivity. **2016**, 26, 1272-1286		67
1569	Different Scales of Cortical Organization are Selectively Targeted in the Progression to Alzheimer's Disease. **2016**, 26, 1650003		12
1568	Revisiting supersaturation as a factor determining amyloid fibrillation. **2016**, 36, 32-9		43
1567	Suspected non-Alzheimer disease pathophysiology--concept and controversy. **2016**, 12, 117-24		174
1566	Cascading network failure across the Alzheimer's disease spectrum. **2016**, 139, 547-62		265
1565	Profiling the human hippocampal proteome at all pathologic stages of´Alzheimer's disease. **2016**, 12, 654-68		98
1564	Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease. **2016**, 41, 68-79		10
1563	The pattern of amyloid accumulation in the brains of adults with Down syndrome. **2016**, 12, 538-45		101
1562	Amyloid imaging using fluorine-19 magnetic resonance imaging ((19)F-MRI). **2016**, 30, 85-94		20
1561	Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons. **2016**, 1862, 878-86		93
1560	Cerebral perfusion in the predementia stages of Alzheimer's disease. **2016**, 26, 506-14		69
1559	Alzheimer's disease biomarker states. *Lancet Neurology, The*, **2016**, 15, 25-6	24.1	2
1558	Default mode network connectivity is linked to cognitive functioning and CSF A¶-42 levels in Alzheimer's disease. **2016**, 62, 125-32		14
1557	Alzheimer's disease lymphocytes: potential for biomarkers?. **2016**, 10, 1-4		16

1556	Paradigm shift: semantic memory decline as a biomarker of preclinical Alzheimer's disease. **2016**, 10, 5-8	19
1555	Diagnosis and treatment of vascular damage in dementia. **2016**, 1862, 869-77	11
1554	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. **2016**, 12, 292-323	832
1553	Subjective Cognitive Decline: Mapping Functional and Structural Brain Changes-A Combined Resting-State Functional and Structural MR Imaging Study. **2016**, 281, 185-92	56
1552	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. **2016**, 12, 614-22	30
1551	Cerebrospinal Biomarkers in Alzheimer Disease-Potential Roles as Markers of Prognosis and Neuroplasticity. **2016**, 73, 508-10	3
1550	CSF biomarkers in neurodegenerative and vascular dementias. **2016**, 138-140, 36-53	27
1549	Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: The Rotterdam Study. **2016**, 617, 139-42	20
1548	Pathology of the Aging Brain in Domestic and Laboratory Animals, and Animal Models of Human Neurodegenerative Diseases. **2016**, 53, 327-48	74
1547	Trajectories of decline in cognition and daily functioning in preclinical dementia. **2016**, 12, 144-153	67
1546	Cognitive Decline in Presymptomatic Alzheimer Disease. **2016**, 73, 384-5	6
1545	Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. **2016**, 37, 663-72	35
1544	Neuroimaging biomarkers in Alzheimer's disease and other dementias. **2016**, 30, 4-16	27
1543	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. **2016**, 38, 104-111	10
1542	Amyloid-β Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease. **2016**, 88, 2755-62	76
1541	Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β Positive Subjects in the Alzheimer's Disease Continuum. **2016**, 16, 87-94	25
1540	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. **2016**, 16, 259-77	30
1539	Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. **2016**, 73, 104-15	39

1538	Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. **2016**, 12, 281-91	34
1537	Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins. **2016**, 6, e719	22
1536	Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease. **2016**, 34, 681-707	11
1535	Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. **2016**, 12, 805-14	42
1534	Common Sense Model Factors Affecting African Americans' Willingness to Consult a Healthcare Provider Regarding Symptoms of Mild Cognitive Impairment. **2016**, 24, 537-46	7
1533	Differential Effects of Structural Modifications on the Competition of Chalcones for the PIB Amyloid Imaging Ligand-Binding Site in Alzheimer's Disease Brain and Synthetic Aβ Fibrils. **2016**, 7, 171-6	3
1532	Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. **2016**, 186, 375-84	53
1531	Alzheimer's disease: the amyloid hypothesis on trial. **2016**, 208, 1-3	92
1530	MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. **2016**, 37, 26-37	35
1529	Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease. **2016**, 57, 608-14	46
1528	Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. **2016**, 131, 549-69	95
1527	Is amyloid-β harmful to the brain? Insights from human imaging studies. **2016**, 139, 23-30	67
1526	Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data. **2016**, 73, 107-13	5
1525	Developing therapeutic vaccines against Alzheimer's disease. **2016**, 15, 401-15	46
1524	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. **2016**, 73, 85-92	129
1523	Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains. **2016**, 53, 5066-78	17
1522	Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. **2016**, 36, 43-51	56
1521	Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease. **2016**, 266, 587-97	10

1520	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. **2016**, 6, 1-8	14
1519	Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. **2016**, 86, 50-8	48
1518	Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. **2016**, 18, 204-11	27
1517	Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. **2016**, 18, 258-66	23
1516	Microglia in Alzheimer's disease: A multifaceted relationship. **2016**, 55, 138-150	71
1515	The neuropathology and cerebrovascular mechanisms of dementia. **2016**, 36, 172-86	176
1514	Thyrotropin and Alzheimer's Disease Risk in the Elderly: a Systematic Review and Meta-Analysis. **2016**, 53, 1229-1236	4
1513	APOE ε4 associated with preserved executive function performance and maintenance of temporal and cingulate brain volumes in younger adults. **2017**, 11, 194-204	11
1512	Realising the Potential of Urine and Saliva as Diagnostic Tools in Sport and Exercise Medicine. **2017**, 47, 11-31	39
1511	[Connections between sleep and Alzheimer's disease : Insomnia, amnesia and amyloid]. **2017**, 88, 215-221	7
1510	Validation of the Spanish-language version of the Relevant Outcome Scale for Alzheimer's Disease. **2017**, 32, 417-423	2
1509	Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice. **2017**, 322, 280-287	19
1508	Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. **2017**, 22, 306-311	86
1507	Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. **2017**, 22, 287-295	44
1506	Reduced global brain metabolism but maintained vascular function in amnestic mild cognitive impairment. **2017**, 37, 1508-1516	26
1505	Relationship between F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults. **2017**, 31, 531-543	9
1504	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. **2017**, 56, 687-697	36
1503	Validation of F-FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners. **2017**, 15, 151-163	25

1502	Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. **2017**, 25, 551-560	9
1501	Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP/PS1 transgenic mice. **2017**, 119, 7-14	2
1500	Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid accumulation in cognitively normal subjects. **2017**, 13, 209-214	12
1499	Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography Imaging. **2017**, 25, 342-353	21
1498	Antioxidative and neuroprotective activities of peanut sprout extracts against oxidative stress in SK-N-SH cells. **2017**, 7, 64-69	4
1497	Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk. **2017**, 6, 136-142	14
1496	Cognitive complaints in older adults at risk for Alzheimer's disease are associated with altered resting-state networks. **2017**, 6, 40-49	36
1495	Nec-1 alleviates cognitive impairment with reduction of A and tau abnormalities in APP/PS1 mice. **2017**, 9, 61-77	74
1494	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of Amyloid in an Animal Model of Alzheimer's Disease. **2017**, 25, 153-164	10
1493	[F]FDG PET signal is driven by astroglial glutamate transport. **2017**, 20, 393-395	144
1492	Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits. **2017**, 1863, 991-1001	38
1491	Protein biomarker druggability profiling. **2017**, 66, 241-247	2
1490	[Amyloid positron-emission-tomography with [F]-florbetaben in the diagnostic workup of dementia patients]. **2017**, 88, 156-161	7
1489	Tau passive immunization inhibits not only tau but also A pathology. **2017**, 9, 1	101
1488	In vivo near-infrared fluorescence imaging of amyloid- plaques with a dicyanoisophorone-based probe. **2017**, 961, 112-118	27
1487	Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease. **2017**, 43, 393-408	81
1486	Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies. **2017**, 29, 545-555	35
1485	What can the topology of white matter structural networks tell us about mild cognitive impairment?. **2017**, 12, 35-50	1

1484	Tau PET imaging: present and future directions. **2017**, 12, 19	172
1483	Detecting and Managing Neuropsychiatric Symptoms in Dementia. **2017**, 62, 158-160	2
1482	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. **2017**, 9, 10	104
1481	Recent Progress in Alzheimer's Disease Research, Part 1: Pathology. **2017**, 57, 1-28	47
1480	Future Directions in Imaging Neurodegeneration. **2017**, 17, 9	11
1479	Convergent Results from Neuropsychology and from Neuroimaging in Patients with Mild Cognitive Impairment. **2017**, 43, 144-154	6
1478	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ‡**2017**, 13, 1004-1012	96
1477	Amyloid and tau PET demonstrate region-specific associations in normal older people. **2017**, 150, 191-199	49
1476	Lack of a Role for Alzheimer's Disease Pathology in Late-Life Depression, or Just No Relationship With Amyloid?. **2017**, 174, 197-198	3
1475	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. **2017**, 56, 1437-1449	23
1474	Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer's disease. **2017**, 152, 60-77	70
1473	Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. **2017**, 131, 1-15	29
1472	Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-‰ pathway. **2017**, 305, 108-114	58
1471	Predicting probable Alzheimer's disease using linguistic deficits and biomarkers. **2017**, 18, 34	53
1470	High-Field 3 T Imaging of Alzheimer‰ Disease. **2017**, 255-269	1
1469	The Hippocampus from Cells to Systems. **2017**,	7
1468	Comparisons of neurodegeneration over time between healthy ageing and Alzheimer's disease cohorts via Bayesian inference. **2017**, 7, e012174	7
1467	Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance. **2017**, 9, 6	15

1466	Age-Related Differences in the Human Hippocampus: Behavioral, Structural and Functional Measures. **2017**, 167-208	8
1465	Emerging biomarkers and screening for cognitive frailty. **2017**, 29, 1075-1086	31
1464	Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology. **2017**, 90, 12-20	23
1463	Yes we can analyse amyloid images - Now What?. **2017**, 44, 822-824	2
1462	Is sporadic Alzheimer's disease a developmental disorder?. **2017**, 143, 396-408	33
1461	Early-Onset Alzheimer Disease. **2017**, 35, 263-281	117
1460	Preclinical models of Alzheimer□ disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. **2017**, 115-156	1
1459	Conscientiousness is Negatively Associated with Grey Matter Volume in Young APOE e4-Carriers. **2017**, 56, 1135-1144	8
1458	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. **2017**, 74, 718-726	87
1457	Data-driven regions of interest for longitudinal change in three variants of frontotemporal lobar degeneration. **2017**, 7, e00675	16
1456	Emerging amyloid and tau targeting treatments for Alzheimer's disease. **2017**, 17, 697-711	8
1455	Is Tau Imaging More Than Just Upside-Down F-FDG Imaging?. **2017**, 58, 1357-1359	14
1454	Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. **2017**, 17, 683-695	19
1453	Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. **2017**, 27, 305-325	54
1452	Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study. **2017**, 74, 712-718	236
1451	Candidate gene analysis for Alzheimer's disease in adults with Down syndrome. **2017**, 56, 150-158	16
1450	Human anterolateral entorhinal cortex volumes are associated with cognitive decline in aging prior to clinical diagnosis. **2017**, 57, 195-205	55
1449	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. **2017**, 88, 908-916	45

1448	Impact of multiple pathologies on the threshold for clinically overt dementia. **2017**, 134, 171-186		248
1447	Atrial fibrillation as a risk factor for cognitive decline and dementia. **2017**, 38, 2612-2618		95
1446	Neuro-degeneration profile of Alzheimer's patients: A brain morphometry study. **2017**, 15, 15-24		34
1445	Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias. **2017**, 12, 351-359		17
1444	Novel Benzothiazole Derivatives as Fluorescent Probes for Detection of β-Amyloid and α-Synuclein Aggregates. **2017**, 8, 1656-1662		26
1443	Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults. **2017**, 32, 320-328		10
1442	Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. *Lancet Neurology, The*, **2017**, 16, 435-444	24.1	174
1441	Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease. **2017**, 36, 2720-2734		11
1440	Cognitive Screening Instruments. **2017**,		20
1439	Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. **2017**, 106, 222-234		33
1438	Alzheimer's Disease Diagnosis Using Landmark-Based Features From Longitudinal Structural MR Images. **2017**, 21, 1607-1616		81
1437	Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health. **2017**, 58, 979-992		42
1436	Effect of GAPT extract on expression of tau protein and its phosphorylation related enzymes in hippocampal neurons of APPV717I transgenic mice. **2017**, 23, 605-610		3
1435	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. **2017**, 58, 14-29		66
1434	Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. **2017**, 74, 933-940		86
1433	Re-imagining Alzheimer's disease - the diminishing importance of amyloid and a glimpse of what lies ahead. **2017**, 143, 432-444		57
1432	Effect of Kidney Dysfunction on Cerebral Cortical Thinning in Elderly Population. **2017**, 7, 2337		5
1431	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. **2017**, 56, 172-179		107

1430	Resting-state network dysfunction in Alzheimer's disease: A systematic review and meta-analysis. **2017**, 8, 73-85	166
1429	Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update. **2017**, 15, 247-263	40
1428	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. **2017**, 140, 748-763	194
1427	Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia. **2017**, 59, 67-75	28
1426	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. **2017**, 58, 1293-1302	25
1425	Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. **2017**, 12, 33	33
1424	Lithium and memantine improve spatial memory impairment and neuroinflammation induced by amyloid 1-42 oligomers in rats. **2017**, 141, 84-92	23
1423	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. **2017**, 27, 4237-4246	23
1422	The midlife cognitive profiles of adults at high risk of late-onset Alzheimer's disease: The PREVENT study. **2017**, 13, 1089-1097	35
1421	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. **2017**, 55, 78-90	30
1420	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. **2017**, 55, 177-189	14
1419	MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. **2017**, 35, 2015-2024	14
1418	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. **2017**, 13, e1-e85	157
1417	Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease. **2017**, 13, 1143-1153	65
1416	Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid (1-42) in mice. **2017**, 77, 23-31	51
1415	Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later. **2017**, 74, 583-590	33
1414	Association between tau deposition and antecedent amyloid- accumulation rates in normal and early symptomatic individuals. **2017**, 140, 1499-1512	71
1413	Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer's disease. **2017**, 36, 88-104	28

1412	Longitudinal Cognitive Outcomes of Clinical Phenotypes of Late-Life Depression. **2017**, 25, 1123-1134	44
1411	Parental family history of dementia in relation to subclinical brain disease and dementia risk. **2017**, 88, 1642-1649	27
1410	Aberrant interhemispheric functional connectivity within default mode network and its relationships with neurocognitive features in cognitively normal APOE ε4 elderly carriers. **2017**, 29, 805-814	9
1409	Neurobiological and Psychological Aspects of Brain Recovery. **2017**,	1
1408	Radiological-Pathological Correlation in Alzheimer's Disease: Systematic Review of Antemortem Magnetic Resonance Imaging Findings. **2017**, 57, 575-601	31
1407	A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. **2017**, 7, 44368	15
1406	The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues. **2017**, 52, 132-140	26
1405	In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. **2017**, 36, 50-63	84
1404	New Insights Into Brain Mechanisms Underlying Neuropsychiatric Symptoms in Alzheimer Disease. **2017**, 25, 580-581	3
1403	Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging. **2017**, 57, 765-773	20
1402	Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. **2017**, 52, 228-242	26
1401	The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology. **2017**, 52, 141-152	33
1400	Neural Correlates of Brain Reserve: A Neuroimaging Perspective. **2017**, 119-128	
1399	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. **2017**, 60, 809-817	40
1398	Introduction to Cognitive Screening Instruments: Rationale and Desiderata. **2017**, 3-13	6
1397	The Usage of Cognitive Screening Instruments: Test Characteristics and Suspected Diagnosis. **2017**, 315-339	4
1396	Inflammasome activation and innate immunity in Alzheimer's disease. **2017**, 27, 220-222	79
1395	Synergistic interaction between amyloid and tau predicts the progression to dementia. **2017**, 13, 644-653	57

1394	Development of [C]/[H]THK-5351 - A potential novel carbon-11 tau imaging PET radioligand. **2017**, 46, 50-53	12
1393	Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. **2017**, 51, 141-147	29
1392	Differential diagnosis of mild cognitive impairment and Alzheimer's disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry. **2017**, 13, 470-482	85
1391	Search for Alzheimer's disease biomarkers in blood cells: hypotheses-driven approach. **2017**, 11, 917-931	29
1390	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. **2017**, 60, 1025-1034	21
1389	CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer's disease. **2017**, 7, 13728	36
1388	Imaging Biomarkers in Alzheimer's Disease: A Practical Guide for Clinicians. **2017**, 1, 71-88	8
1387	Alzheimer's disease prevention: from risk factors to early intervention. **2017**, 9, 71	218
1386	Brain glucose metabolism and its relation to amyloid load in middle-aged adults with childhood-onset epilepsy. **2017**, 137, 69-72	5
1385	Network Disruption in the Preclinical Stages of Alzheimer's Disease: From Subjective Cognitive Decline to Mild Cognitive Impairment. **2017**, 27, 1750041	45
1384	Changes in connectivity of the posterior default network node during visual processing in mild cognitive impairment: staged decline between normal aging and Alzheimer's disease. **2017**, 124, 1607-1619	10
1383	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. **2017**, 97, 143-159	105
1382	Personality Change in the Preclinical Phase of Alzheimer Disease. **2017**, 74, 1259-1265	78
1381	Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. **2017**, 8, 1214	348
1380	Impact of Amyloid Burden on Regional Functional Synchronization in the Cognitively Normal Older Adults. **2017**, 7, 14690	12
1379	The vascular facet of late-onset Alzheimer's disease: an essential factor in a complex multifactorial disorder. **2017**, 30, 623-629	7
1378	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. **2017**, 82, 706-718	99
1377	Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. **2017**, 7, e00776	22

1376	The role of the immune system in Alzheimer disease: Etiology and treatment. **2017**, 40, 84-94		86
1375	Amyloid Beta Peptides Block New Synapse Assembly by Nogo Receptor-Mediated Inhibition of T-Type Calcium Channels. **2017**, 96, 355-372.e6		22
1374	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. **2017**, 60, 1119-1128		21
1373	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. **2017**, 60, 1387-1395		15
1372	Molecular imaging in early diagnosis, differential diagnosis and follow-up of patients with neurodegenerative diseases. **2017**, 5, 465-471		6
1371	Alzheimer's-related cortical atrophy is associated with postoperative delirium severity in persons without dementia. **2017**, 59, 55-63		22
1370	Sleep Disturbance, Cognitive Decline, and Dementia: A Review. **2017**, 37, 395-406		84
1369	Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. **2017**, 89, 1382-1390		104
1368	Complexity analysis of cortical surface detects changes in future Alzheimer's disease converters. **2017**, 38, 5905-5918		21
1367	Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?. **2017**, 38, 956-966		93
1366	Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. **2017**, 16, 564-574		20
1365	Ensemble transfer learning for Alzheimer's disease diagnosis. **2017**, 2017, 3102-3105		4
1364	Combination of Aβ Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition. **2017**, 187, 2886-2894		7
1363	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. **2017**, 16, 418-428		19
1362	Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. **2017**, 16, 439-446		21
1361	The chronic and evolving neurological consequences of traumatic brain injury. *Lancet Neurology, The*, **2017**, 16, 813-825	24.1	207
1360	Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [F]-FEOBV. **2017**, 22, 1531-1538		62
1359	A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?. **2017**, 6, 5-13		22

1358	Assessment of amyloid ß in pathologically confirmed frontotemporal dementia syndromes. **2017**, 9, 10-20	29
1357	Identifying incipient dementia individuals using machine learning and amyloid imaging. **2017**, 59, 80-90	61
1356	Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease. **2017**, 7, 107-114	19
1355	Early functional network alterations in asymptomatic elders at risk for Alzheimer's disease. **2017**, 7, 6517	44
1354	Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in community-dwelling older adults. **2017**, 3, 471-479	27
1353	Tau positron emission tomography using [F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. **2017**, 59, 210-219	35
1352	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aß oligomers. **2017**, 28, 2623-2636	59
1351	Tau-imaging in neurodegeneration. **2017**, 130, 114-123	26
1350	Neutral merocyanine dyes: for in vivo NIR fluorescence imaging of amyloid-ß plaques. **2017**, 53, 9910-9913	28
1349	Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker. **2018**, 61, 79-89	18
1348	Alzheimer's Disease: Past, Present, and Future. **2017**, 23, 818-831	219
1347	Dual Mechanism of Toxicity for Extracellular Injection of Tau Oligomers versus Monomers in Human Tau Mice. **2017**, 59, 743-751	11
1346	Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status. **2018**, 61, 373-388	14
1345	18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). **2017**, 11, CD012216	23
1344	iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid ß Combination for Alzheimer's Disease. **2017**, 21, 2304-2312	109
1343	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. **2018**, 61, 509-513	4
1342	Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps. **2017**, 8, 958-970	35
1341	Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. **2017**, 60, 1641-1652	13

1340	Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia. **2017**, 19, 46	15
1339	Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology. **2017**, 8, 1464	67
1338	Validation of the Spanish-language version of the Relevant Outcome Scale for Alzheimer's Disease. **2017**, 32, 417-423	
1337	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. **2017**, 57, 133-142	54
1336	Contrast-enhanced MR microscopy of amyloid plaques in five mouse models of amyloidosis and in human Alzheimer's disease brains. **2017**, 7, 4955	18
1335	Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline. **2017**, 58, 120-128	18
1334	A clinicopathological approach to the diagnosis of dementia. **2017**, 13, 457-476	138
1333	Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. **2017**, 89, 445-453	108
1332	Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography. **2017**, 60, 7350-7370	51
1331	Semi-automatic synthesis and biodistribution of N-(2-F-fluoropropionyl)-bis(zinc (II)-dipicolylamine) (F-FP-DPAZn2) for AD model imaging. **2017**, 17, 27	2
1330	Association between total-Tau and brain atrophy one year after first-ever stroke. **2017**, 17, 107	7
1329	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. **2017**, 9, 17	19
1328	Genetic variation in neurodegenerative diseases and its accessibility in the model organism Caenorhabditis elegans. **2017**, 11, 12	13
1327	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. **2017**, 58, 747-762	8
1326	Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease. **2017**, 1655, 23-32	21
1325	Genetic resilience to amyloid related cognitive decline. **2017**, 11, 401-409	18
1324	An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer's disease. **2017**, 124, 41-47	130
1323	Genetic and environmental influences on cortical mean diffusivity. **2017**, 146, 90-99	21

1322	Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. **2017**, 35, 250-264	30
1321	Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. **2017**, 11, 383-390	38
1320	Cognitive reserve and cortical thickness in preclinical Alzheimer's disease. **2017**, 11, 357-367	36
1319	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. **2017**, 13, 531-540	64
1318	Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. **2017**, 13, 468-492	84
1317	Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. **2017**, 13, 186-195	61
1316	Longitudinal brain structural changes in preclinical Alzheimer's disease. **2017**, 13, 499-509	38
1315	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. **2017**, 27, 1169-1175	65
1314	An approach to studying the neural correlates of reserve. **2017**, 11, 410-416	86
1313	Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. **2017**, 22, 13-23	64
1312	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. **2017**, 54, 5550-5562	81
1311	Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer's disease. **2017**, 32, 50-57	45
1310	Hippocampal shape alterations are associated with regional A load in cognitively normal elderly individuals. **2017**, 45, 1241-1251	5
1309	Microglia-derived ASC specks cross-seed amyloid- n Alzheimer's disease. **2017**, 552, 355-361	411
1308	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid- Burden in Down Syndrome. **2018**, 61, 631-644	21
1307	The Cerebrospinal Fluid A -42/A -40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. **2017**, 60, 561-576	54
1306	The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report. **2017**, 60, 341-347	4
1305	Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. **2017**, 3, 668-677	67

1304	Amnestic mild cognitive impairment. 217-231	
1303	H-MRS metabolites and rate of β-amyloid accumulation on serial PET in clinically normal adults. **2017**, 89, 1391-1399	12
1302	[Clinical assessment and diagnostic tools]. **2017**, 52 Suppl 1, 34-38	1
1301	Current Clinical Issues and Future Perspectives of Dementia in the Aging Society. **2017**, 44, 360-369	
1300	Systems healthcare: a holistic paradigm for tomorrow. **2017**, 11, 142	16
1299	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. **2017**, 9, 84	42
1298	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. **2017**, 9, 67	18
1297	Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. **2017**, 357, j2709	152
1296	Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. **2017**, 357, j2353	177
1295	Therapie der Alzheimer-Demenz – was kommt?. **2017**, 19, 36-44	
1294	Randomized Deep Learning Methods for Clinical Trial Enrichment and Design in Alzheimer's Disease. **2017**, 341-378	1
1293	In Vitro Quantified Determination of β-Amyloid 42 Peptides, a Biomarker of Neuro-Degenerative Disorders, in PBS and Human Serum Using a Simple, Cost-Effective Thin Gold Film Biosensor. **2017**, 7,	11
1292	Applying Translational Bioinformatics for Biomarker Discovery. **2017**, 55-65	
1291	Autophagy and Proteostasis: A Unifying Theory of Neurodegenerative Disease. **2017**, 6, 3-18	
1290	Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition. **2017**, 59, 695-705	32
1289	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. **2017**, 22,	63
1288	Amyloid β-Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease. **2017**, 109-143	5
1287	Visualizing Hyperactivation in Neurodegeneration Based on Prefrontal Oxygenation: A Comparative Study of Mild Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. **2017**, 9, 287	39

1286	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside. **2017**, 7,	12
1285	Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. **2017**, 18,	111
1284	Theta and Alpha Alterations in Amnestic Mild Cognitive Impairment in Semantic Go/NoGo Tasks. **2017**, 9, 160	15
1283	Cerebral Blood Flow and Amyloid-β Interact to Affect Memory Performance in Cognitively Normal Older Adults. **2017**, 9, 181	37
1282	Non-aggregated Aβ25-35 Upregulates Primary Astrocyte Proliferation. **2017**, 11, 301	3
1281	Detection of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Longitudinal Brain MRI. **2017**, 11, 16	22
1280	Impact of Resveratrol on Glucose Control, Hippocampal Structure and Connectivity, and Memory Performance in Patients with Mild Cognitive Impairment. **2017**, 11, 105	42
1279	Enhanced Data Representation by Kernel Metric Learning for Dementia Diagnosis. **2017**, 11, 413	6
1278	Imaging of Tau Pathology Using Magnetic Resonance Imaging Textural Analysis. **2017**, 11, 599	6
1277	Alzheimer's Disease?. **2017**,	1
1276	Mixed dementia: A review of the evidence. **2017**, 11, 364-370	45
1275	Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype. **2017**, 57, 447-459	9
1274	Dissociating Normal Aging from Alzheimer's Disease: A View from Cognitive Neuroscience. **2017**, 57, 331-352	66
1273	Alzheimer's amyloid-βA2T variant and its N-terminal peptides inhibit amyloid-βfibrillization and rescue the induced cytotoxicity. **2017**, 12, e0174561	19
1272	Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. **2017**, 12, e0185926	62
1271	Contribution of cognitive performance and cognitive decline to associations between socioeconomic factors and dementia: A cohort study. **2017**, 14, e1002334	40
1270	Automated segmentation of gray and white matter regions in brain MRI images for computer aided diagnosis of neurodegenerative diseases. **2017**,	1
1269	Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid βpeptide levels. **2017**, 9, 57	104

1268	On the path to 2025: understanding the Alzheimer's disease continuum. **2017**, 9, 60	197
1267	Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment. **2017**, 9, 99	3
1266	Die Progression wird nicht gebremst. **2017**, 19, 30-30	
1265	Human iPSC Models in Drug Discovery: Opportunities and Challenges. **2017**, 48-73	4
1264	Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting. **2016**, 6, 465-476	5
1263	Regional Differences in Amyloid Deposition between 11C-Pib PET Positive Patients with and without Elevated Striatal Amyloid Uptake. **2017**, 07,	3
1262	Increasing Body Mass Index at Midlife is Associated with Increased Cortical Thinning in Alzheimer's Disease-Vulnerable Regions. **2017**, 59, 113-120	11
1261	Hippocampal Volumetry as a Biomarker for Dementia in People with Low Education. **2016**, 6, 486-499	7
1260	A Multi-Cohort Study of ApoE e4 and Amyloid-Effects on the Hippocampus in Alzheimer's Disease. **2017**, 56, 1159-1174	25
1259	Living Alone with Alzheimer's Disease: Data from SveDem, the Swedish Dementia Registry. **2017**, 58, 1265-1272	29
1258	Aging and Age-Associated Diseases: Translational Bioinformatics and Systems Biology Methods. **2017**, 153-166	
1257	Sexual dimorphism of frailty and cognitive impairment: Potential underlying mechanisms (Review). **2017**, 16, 3023-3033	9
1256	Technical Considerations on Scanning and Image Analysis for Amyloid PET in Dementia. **2017**, 73, 298-308	
1255	Categorization and Aging. **2017**, 673-686	2
1254	Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease. **2017**, 130, 2978-2990	38
1253	Role of Sleep Disturbance in the Trajectory of Alzheimer's Disease. **2017**, 15, 89-99	25
1252	Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects. **2017**, 8, 16122-16143	82
1251	Subjective Cognitive Decline and Alzheimer's Disease Spectrum Disorder. **2017**, 16, 40-47	11

1250 Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer Disease. **2018**, 93-106 1

1249 Alzheimer's Disease and Mild Cognitive Impairment. **2018**, 445-482

1248 Positron Emission Tomography (PET) Imaging. **2018**, 164-187

1247 Effects of physical activity on delayed memory measures in randomized controlled trials with nonclinical older, mild cognitive impairment, and dementia participants. **2018**, 40, 874-886 3

1246 Joint associations of amyloidosis and cortical thickness with cognition. **2018**, 65, 121-131 21

1245 Biomarkers for Preclinical Alzheimer Disease. **2018**,

1244 The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. **2018**, 288, 226-333 17

1243 Age-accelerated cognitive decline in asymptomatic adults with CSF amyloid. **2018**, 90, e1306-e1315 37

1242 Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. **2018**, 141, 1470-1485 52

1241 A Network of Genetic Effects on Non-Demented Cognitive Aging: Alzheimer's Genetic Risk (CLU + CR1 + PICALM) Intensifies Cognitive Aging Genetic Risk (COMT + BDNF) Selectively for APOEe4 Carriers. **2018**, 62, 887-900 10

1240 Development of a High-Sensitivity Method for the Measurement of Human Nasal A 2, Tau, and Phosphorylated Tau. **2018**, 62, 737-744 7

1239 Coronary heart disease, heart failure, and the risk of dementia: A systematic review and meta-analysis. **2018**, 14, 1493-1504 58

1238 Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies. **2018**, 33, 1130-1138 24

1237 Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE 4 genotype. **2018**, 141, 1828-1839 53

1236 Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein. **2018**, 8, 6209 12

1235 Subthreshold Amyloid Predicts Tau Deposition in Aging. **2018**, 38, 4482-4489 73

1234 Low Cerebrospinal Fluid A 2 and A 0 are Related to White Matter Lesions in Cognitively Normal Elderly. **2018**, 62, 1877-1886 9

1233 White Matter Reference Region in PET Studies of C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid- Deposition. **2018**, 59, 1583-1589 21

1232	Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease. **2018**, 141, 1871-1883		33
1231	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. **2018**, 64, S3-S22		74
1230	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. **2018**, 82, 293-323		38
1229	Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. **2018**, 26, 347-357		48
1228	Topographic staging of tau positron emission tomography images. **2018**, 10, 221-231		23
1227	Neurocognitive Function after Cardiac Surgery: From Phenotypes to Mechanisms. **2018**, 129, 829-851		79
1226	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. **2018**, 14, 535-562		3155
1225	Cortical microstructure in young onset Alzheimer's disease using neurite orientation dispersion and density imaging. **2018**, 39, 3005-3017		55
1224	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. **2018**, 39, 3143-3151		26
1223	Aggregated A□-42 Is Selectively Toxic for Neurons, Whereas Glial Cells Produce Mature Fibrils with Low Toxicity in Drosophila. **2018**, 25, 595-610.e5		13
1222	Prevalence of preclinical Alzheimer disease: Comparison of current classification systems. **2018**, 90, e1682-e1691		48
1221	A Combination of Essential Fatty Acids, Panax Ginseng Extract, and Green Tea Catechins Modifies Brain fMRI Signals in Healthy Older Adults. **2018**, 22, 837-846		14
1220	Prediction and Early Detection of Alzheimer's Dementia: Professional Disclosure Practices and Ethical Attitudes. **2018**, 62, 145-155		16
1219	Precision pharmacology for Alzheimer's disease. **2018**, 130, 331-365		60
1218	Multimodal neuroimaging and behavioral assessment of □synuclein polymorphism rs356219 in older adults. **2018**, 66, 32-39		5
1217	Clinical significance of visually equivocal amyloid PET findings from the Alzheimer's Disease Neuroimaging Initiative cohort. **2018**, 29, 553-558		5
1216	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurology, The*, **2018**, 17, 241-250	24.1	224
1215	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. **2018**, 45, 1021-1030		20

1214	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. **2018**, 62, 417-427	4
1213	Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects. **2018**, 62, 165-174	5
1212	Medicinal uses, pharmacology, and phytochemistry of Convolvulaceae plants with central nervous system efficacies: A systematic review. **2018**, 32, 823-864	21
1211	Sleep and cognitive decline: A prospective nondemented elderly cohort study. **2018**, 83, 472-482	49
1210	A sensitive gold nanoparticle-based aptasensor for colorimetric detection of A□40 oligomers. **2018**, 10, 641-645	17
1209	Extravascular CD3+ T Cells in Brains of Alzheimer Disease Patients Correlate with Tau but Not with Amyloid Pathology: An Immunohistochemical Study. **2018**, 18, 49-56	61
1208	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. **2018**, 90, e940-e946	19
1207	Validation of prognostic biomarker scores for predicting progression of dementia in patients with amnestic mild cognitive impairment. **2018**, 39, 297-303	6
1206	[Biomarker-based diagnostics of Alzheimer's disease : Concept of suspected non-Alzheimer pathology]. **2018**, 89, 345-358	4
1205	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. **2018**, 75, 548-556	98
1204	Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging. **2018**, 344, 103-109	104
1203	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. **2018**, 23, 188-197	3
1202	Impaired Functional Criticality of Human Brain during Alzheimer's Disease Progression. **2018**, 8, 1324	15
1201	The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. **2018**, 10, 130-142	97
1200	Amyloid pathology in the progression to mild cognitive impairment. **2018**, 64, 76-84	17
1199	Both hyper- and hypo-activation to cognitive challenge are associated with increased beta-amyloid deposition in healthy aging: A nonlinear effect. **2018**, 166, 285-292	16
1198	Role of the peripheral innate immune system in the development of Alzheimer's disease. **2018**, 107, 59-66	77
1197	Subject-specific multi-poroelastic model for exploring the risk factors associated with the early stages of Alzheimer's disease. **2018**, 8, 20170019	25

1196	Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. **2017**, 7, 374-385	20
1195	Review: Neurodegenerative processes in temporal lobe epilepsy with hippocampal sclerosis: Clinical, pathological and neuroimaging evidence. **2018**, 44, 70-90	45
1194	Alzheimer's Disease Assessment: A Review and Illustrations Focusing on Item Response Theory Techniques. **2018**, 25, 360-373	13
1193	A mediates F-actin disassembly in dendritic spines leading to cognitive deficits in Alzheimer's disease. **2018**, 38, 1085-1099	68
1192	Time-to-event data with time-varying biomarkers measured only at study entry, with applications to Alzheimer's disease. **2018**, 37, 914-932	2
1191	Inferior Parietal Cortex Hypoperfusion is the Most Specific Imaging Marker for AD Patients With Positive CSF Biomarker Assays in a Memory Clinic in France. **2018**, 32, 89-93	1
1190	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. **2018**, 14, 652-663	11
1189	Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. **2018**, 175, 530-537	106
1188	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. **2018**, 5, 162-171	23
1187	Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. **2018**, 107, 169-177	22
1186	DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. **2018**, 14, 664-679	17
1185	Discrete Pools of Oligomeric Amyloid- Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. **2018**, 188, 739-756	10
1184	An Antimicrobial Peptide and Its Neuronal Receptor Regulate Dendrite Degeneration in Aging and Infection. **2018**, 97, 125-138.e5	51
1183	Exercise Training for Preventing Dementia, Mild Cognitive Impairment, and Clinically Meaningful Cognitive Decline: A Systematic Review and Meta-analysis. **2018**, 73, 1504-1511	40
1182	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. **2018**, 73, 1244-1250	19
1181	Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid- nduced pathology. **2018**, 10, 1	57
1180	Change of Amyloid- -42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal´Pressure Hydrocephalus. **2018**, 63, 989-1002	11
1179	Dual-radiotracer translational SPECT neuroimaging. Comparison of three methods for the simultaneous brain imaging of D and 5-HT receptors. **2018**, 176, 528-540	4

1178	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. **2018**, 45, 1470-1486		15
1177	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. **2018**, 378, 1691-1703		370
1176	A preclinical perspective on the enhanced vulnerability to Alzheimer's disease after early-life stress. **2018**, 8, 172-185		22
1175	Amyloid-β a reflection of risk or a preclinical marker?. **2018**, 14, 319-320		6
1174	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. **2018**, 28, 340-349		18
1173	Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area. **2018**, 8, e019362		40
1172	Mediterranean Diet in Preventing Neurodegenerative Diseases. **2018**, 7, 10-20		50
1171	Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. **2018**, 10, 245-252		34
1170	Longitudinal tau PET in ageing and Alzheimer's disease. **2018**, 141, 1517-1528		194
1169	Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. **2018**, 90, e1501-e1509		29
1168	Amyloid-βIncreases Tau by Mediating Sirtuin 3 in Alzheimer's Disease. **2018**, 55, 8592-8601		36
1167	Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities. **2018**, 32, 101-106		9
1166	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. **2018**, 221-252		1
1165	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. **2018**, 67, 95-98		40
1164	White matter abnormalities and cognition in patients with conflicting diagnoses and CSF profiles. **2018**, 90, e1461-e1469		8
1163	Memory decline accompanies subthreshold amyloid accumulation. **2018**, 90, e1452-e1460		80
1162	The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *Lancet Neurology, The*, **2018**, 17, 434-444	24.1	101
1161	Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population. **2018**, 45, 1442-1448		12

1160	Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia. **2018**, 75, 672-680	95
1159	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. **2018**, 141, 1201-1217	46
1158	Quantitative sodium MR imaging: A review of its evolving role in medicine. **2018**, 168, 250-268	56
1157	Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. **2018**, 55, 3451-3476	13
1156	Self-reported confusion is related to global and regional β-amyloid: data from the Women's healthy ageing project. **2018**, 12, 78-86	3
1155	Elevated glycemia and brain glucose utilization predict BDNF lowering since early life. **2018**, 38, 447-455	7
1154	Functional neuroanatomical associations of working memory in early-onset Alzheimer's disease. **2018**, 33, 176-184	5
1153	Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. **2018**, 38, 904-918	26
1152	Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease. **2018**, 125, 797-807	23
1151	Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease. **2018**, 46 Suppl 1, S15-S18	14
1150	Cognitive evaluation of patients with glaucoma and its comparison with individuals with Alzheimer's disease. **2018**, 38, 1839-1844	5
1149	Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. **2018**, 77, 328-335	58
1148	Dementia risk and prevention by targeting modifiable vascular risk factors. **2018**, 144, 565-581	38
1147	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A´serial magnetic resonance imaging study. **2018**, 14, 43-53	28
1146	Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. **2018**, 62, 1403-1416	316
1145	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease. **2018**, 28, 3638-3649	21
1144	Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging. **2018**, 83, 377-387	61
1143	Development of a safe and scalable route towards a tau PET tracer precursor. **2018**, 26, 970-976	3

1142	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. **2018**, 19, 244-328	148
1141	Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer's disease. **2018**, 33, 657-666	15
1140	Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. **2018**, 14, 178-186	140
1139	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. **2018**, 61, 75-81	29
1138	The age-related slow increase in amyloid pathology in APP.V717I mice activates microglia, but does not alter hippocampal neurogenesis. **2018**, 61, 112-123	6
1137	CSF Aβ but not p-Tau differentiates aMCI from SCI. **2018**, 1678, 27-31	6
1136	Body mass index is associated with cortical thinning with different patterns in mid- and late-life. **2018**, 42, 455-461	31
1135	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. **2018**, 18, 25-35	23
1134	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. **2018**, 17, 452-464	83
1133	Evidence that iron accelerates Alzheimer's pathology: a CSF biomarker study. **2018**, 89, 456-460	46
1132	Physical Activity in Preventing Alzheimer's Disease and Cognitive Decline: A Narrative Review. **2018** , 48, 29-44	19
1131	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. **2018**, 61, 198-206	25
1130	Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. **2018**, 39, 971-984	24
1129	Intranasal insulin in Alzheimer's disease: Food for thought. **2018**, 136, 196-201	53
1128	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. **2018**, 32, 75-86	33
1127	Comparison of Different Hypotheses Regarding the Spread of Alzheimer's Disease Using Markov Random Fields and Multimodal Imaging. **2018**, 65, 731-746	5
1126	The effect of white matter hyperintensities on cognition is mediated by cortical atrophy. **2018**, 64, 25-32	45
1125	A probabilistic atlas of human brainstem pathways based on connectome imaging data. **2018**, 169, 227-239	43

1124	Biomarkers of Cognitive Impairment: Brain Cortical Thickness, Volumetrics, and Cerebrospinal Fluid. **2018**, 32, 255-257	1
1123	Amyloid β oligomers (Aβos) in Alzheimer's disease. **2018**, 125, 177-191	72
1122	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. **2018**, 14, 352-366	72
1121	Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease. **2018**, 125, 193-201	3
1120	Spatiotemporal Distribution of β-Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities. **2018**, 59, 822-827	26
1119	Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. **2018**, 14, 634-643	21
1118	Geriatric Anesthesia: Age-Dependent Changes in the Central and Peripheral Nervous Systems. **2018** , 145-160	
1117	Stress induced neural reorganization: A conceptual framework linking depression and Alzheimer's disease. **2018**, 85, 136-151	33
1116	The Long Journey of Alzheimer's Disease. **2018**, 35, 218-227	1
1115	Using eye scans to diagnose preclinical Alzheimer's. **2018**, 20, 514-516	
1114	Hyperpolarized [1-13C] pyruvate MR spectroscopy detect altered glycolysis in the brain of a cognitively impaired mouse model fed high-fat diet. **2018**, 11, 74	7
1113	Topological Biomarker of Alzheimer□ Disease. **2018**,	
1112	Generation and quality control of lipidomics data for the alzheimer's disease neuroimaging initiative cohort. **2018**, 5, 180263	29
1111	Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial. **2018**, 5, 202-206	3
1110	Modeling Spatial and Temporal Patterns of APOE □4 Mediated Glucose Uptake in Mild Cognitive Impairment and Normal Controls. **2018**, 51, 396-401	1
1109	Common Variants in and Correlation to CSF-related Phenotypes in Alzheimer's Disease. **2018**, 12, 946	6
1108	3 .Neuropathologie und molekulare Mechanismen. **2018**, 35-122	0
1107	Segmentation Tool for Extracting Gray and White Matter Regions in Brain MRI Images for Cognitive Diseases. **2018**,	1

1106	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. **2018**, 2, igy025	10
1105	Topics in Cognitive Rehabilitation in the TBI Post-Hospital Phase. **2018**,	
1104	Dementia. **2018**, 159, 303-321	9
1103	Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. **2018**, 10, 657-668	9
1102	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. **2018**, 10, 669-677	11
1101	Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer's Disease. **2018**, 66, 1223-1234	20
1100	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. **2018**, 32, 1193-1225	6
1099	The Network Degeneration Hypothesis: Spread of Neurodegenerative Patterns Along Neuronal Brain Networks. **2018**, 59, 1645-1648	15
1098	Building Cost-effective Model For Predicting ╫Amyloid Burden by Combination of Cortical Thickness, Volume, and Neuropsychological Assessment Measures. **2018**,	
1097	Computer-assisted prediction of clinical progression in the earliest stages of AD. **2018**, 10, 726-736	8
1096	European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. **2019**, 8, e021017	38
1095	Altered Functional Network Affects Amyloid and Structural Covariance in Alzheimer's Disease. **2018**, 2018, 8565620	10
1094	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. **2018**, 10, 409	20
1093	Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. **2018**, 8, e023664	17
1092	Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. **2018**, 13, e0207885	59
1091	The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. **2019**, 85, 181-193	100
1090	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. **2019**, 40, 1618-1631	26
1089	Neuropsychiatric Symptoms of Post-concussion Syndrome (PCS) and Chronic Traumatic Encephalopathy (CTE). **2018**, 87-94	

1088	Alterations in Brain Network Topology and Structural-Functional Connectome Coupling Relate to Cognitive Impairment. **2018**, 10, 404	22
1087	Current state of Alzheimer's fluid biomarkers. **2018**, 136, 821-853	236
1086	Current Knowledge and Clinical Application of Brain Imaging in Alzheimer's Disease. **2018**, 57, 12	1
1085	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. **2018**, 18, 859-869	13
1084	Neurological signs as early determinants of dementia and predictors of mortality among older adults in Latin America: a 10/66 study using the NEUROEX assessment. **2018**, 18, 163	4
1083	Multimodal Assessment of Neural Substrates in Computerized Cognitive Training: A Preliminary Study. **2018**, 14, 454-463	3
1082	Imaging the evolution and pathophysiology of Alzheimer disease. **2018**, 19, 687-700	194
1081	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. **2018**, 141, 3065-3080	72
1080	Speech Registration in Symptomatic Memory Impairment. **2018**, 10, 201	1
1079	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. **2018**, 18, 847-857	47
1078	Cognitive Changes after Surgery in Clinical Practice. **2018**,	1
1077	The role of brain vasculature in neurodegenerative disorders. **2018**, 21, 1318-1331	338
1076	Multimodal neuroimaging study of cerebrovascular disease, amyloid deposition, and neurodegeneration in Alzheimer's disease progression. **2018**, 10, 638-646	7
1075	Inflammation: Bridging Age, Menopause and APOE4 Genotype to Alzheimer's Disease. **2018**, 10, 312	31
1074	Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. **2018**, 21, 1341-1349	178
1073	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. **2018**, 141, 3233-3248	15
1072	Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer's Disease: A Pilot Study. **2018**, 15, 820-827	9
1071	CSF A but not p-Tau, Predicted Progression from Amnestic MCI to Alzheimer's Disease Dementia. **2018**, 20, 491-497	4

1070	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. **2018**, 10, 112	27
1069	Changes in Cerebrospinal Fluid Tau and β-Amyloid Levels in Diabetic and Prediabetic Patients: A Meta-Analysis. **2018**, 10, 271	9
1068	Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. **2018**, 136, 663-689	101
1067	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. **2018**, 141, 3443-3456	49
1066	β-Amyloid Accumulation Slows Earlier than Expected in Preclinical Alzheimer's Disease Patients. **2018**, 38, 9123-9125	5
1065	Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex. **2018**, 136, 901-917	36
1064	Multiphysics of Prionlike Diseases: Progression and Atrophy. **2018**, 121, 158101	43
1063	Predict Disease Progression With Reaction Rate Equation Modeling of Multimodal MRI and PET. **2018**, 10, 306	1
1062	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. **2018**, 33, 655-675	3
1061	Alterations in Intra- and Interregional Intrinsic Brain Connectivity Are Differentially Associated with Memory Performance in Amnestic Mild Cognitive Impairment. **2018**, 46, 229-242	4
1060	An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease. **2018**, 91, e1402-e1412	39
1059	Modeling and prediction of clinical symptom trajectories in Alzheimer's disease using longitudinal data. **2018**, 14, e1006376	54
1058	The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. **2018**, 10,	68
1057	Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. **2018**, 8, 277-289	16
1056	Associations between Prospective and Retrospective Subjective Memory Complaints and Neuropsychological Performance in Older Adults: The Finger Study. **2018**, 24, 1099-1109	6
1055	Nanotheranostics and theranostic nanomedicine for diseases and cancer treatment. **2018**, 41-68	2
1054	An updated Alzheimer hypothesis: Complement C3 and risk of Alzheimer's disease-A cohort study of 95,442 individuals. **2018**, 14, 1589-1601	19
1053	Nonlinear model with random inflection points for modeling neurodegenerative disease progression. **2018**, 37, 4721-4742	2

1052	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. **2018**, 84, 648-658	137
1051	Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers. **2018**, 10, 629-637	12
1050	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. **2018**, 65, 1345-1352	18
1049	Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. **2018**, 10, 86	8
1048	A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease. **2018**, 8,	7
1047	"Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game. **2018**, 10, 53	13
1046	Relationship Between Amyloid-Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. **2018**, 65, 1313-1325	14
1045	Rethinking the Reserve with a Translational Approach: Novel Ideas on the Construct and the Interventions. **2018**, 65, 1065-1078	12
1044	Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study. **2018**, 10, 88	9
1043	Mitochondria at the Base of Neuronal Innate Immunity in Alzheimer and Parkinson Diseases. **2018**,	1
1042	The Hypothalamus in Alzheimer Disease. **2018**,	1
1041	Chasing the start of sporadic Alzheimer's disease running in families. **2018**, 141, 1589-1591	2
1040	Longitudinal analysis for Alzheimer's disease diagnosis using RNN. **2018**,	18
1039	Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and F-FDG PET. **2018**, 288, 198-206	42
1038	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. **2018**, 64, S633-S646	27
1037	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging. **2018**, 75, 999-1007	60
1036	From Subjective Cognitive Decline to Alzheimer's Disease: The Predictive Role of Neuropsychological Assessment, Personality Traits, and Cognitive Reserve. A 7-Year Follow-Up Study. **2018**, 63, 1523-1535	48
1035	Curvilinear locus coeruleus functional connectivity trajectories over the adult lifespan: a 7T MRI study. **2018**, 69, 167-176	15

1034	Blood biomarkers in Alzheimer's disease. **2018**,	2
1033	Staging of amyloid ₱t-tau, regional atrophy rates, and cognitive change in a nondemented cohort: Results of serial mediation analyses. **2018**, 10, 382-393	13
1032	Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer's disease. **2018**, 4, 395-413	30
1031	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. **2018**, 91, e313-e318	43
1030	Virtual cognitive training in healthy aging and mild cognitive impairment. **2018**, 215-235	3
1029	Structural and Functional Imaging. **2018**, 103-136	1
1028	Broadening the scope of epidemiologic dementia research. **2018**, 33, 617-620	2
1027	Clinical Research on Alzheimer's Disease: Progress and Perspectives. **2018**, 34, 1111-1118	64
1026	Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. **2018**, 82, 163-185	23
1025	Sex-specific genetic predictors of Alzheimer's disease biomarkers. **2018**, 136, 857-872	48
1024	Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy. **2018**, 8, e01016	12
1023	In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease. **2018**, 143-170	1
1022	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. **2018**, 14, 1313-1333	61
1021	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. **2018**, 91, e859-e866	116
1020	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. **2018**, 10, 72	25
1019	Proposal for a hierarchical, multidimensional, and multivariate approach to investigate cognitive aging. **2018**, 71, 179-188	15
1018	Impact of Nitric Oxide Bioavailability on the Progressive Cerebral and Peripheral Circulatory Impairments During Aging and Alzheimer's Disease. **2018**, 9, 169	22
1017	Phenotypic Heterogeneity in Dementia: A Challenge for Epidemiology and Biomarker Studies. **2018**, 6, 181	27

1016	Alzheimer's disease diagnostics by a 3D deeply supervised adaptable convolutional network. **2018**, 23, 584-596	78
1015	Tocotrienol-Rich Fraction of Palm Oil Improves Behavioral Impairments and Regulates Metabolic Pathways in A₱P/PS1 Mice. **2018**, 64, 249-267	10
1014	An age-old story of dementia. **2018**, 559, S2-S3	40
1013	A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease. **2018**, 63, 783-796	37
1012	Exosomes as possible spread factor and potential biomarkers in Alzheimer's disease: current concepts. **2018**, 12, 1025-1033	14
1011	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. **2018**, 10, 71	141
1010	Plasma amyloid-ǂlevels, cerebral atrophy and risk of dementia: a population-based study. **2018**, 10, 63	25
1009	Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods. **2018**, 65, 421-431	18
1008	Mild Cognitive Impairment in Clinical Practice: A Review Article. **2018**, 33, 500-507	58
1007	Serum Hepatocyte Growth Factor Is Associated with Small Vessel Disease in Alzheimer's Dementia. **2018**, 10, 8	8
1006	Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study. **2018**, 10, 60	8
1005	Leisure-Time Physical Activity Is Associated With Reduced Risk of Dementia-Related Mortality in Adults With and Without Psychological Distress: The Cohort of Norway. **2018**, 10, 151	5
1004	Amyloid-ǂTau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. **2018**, 10, 193	9
1003	The Pathoconnectivity Profile of Alzheimer's Disease: A Morphometric Coalteration Network Analysis. **2017**, 8, 739	18
1002	Tau Depletion in APP Transgenic Mice Attenuates Task-Related Hyperactivation of the Hippocampus and Differentially Influences Locomotor Activity and Spatial Memory. **2018**, 12, 124	18
1001	Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review. **2018**, 12, 215	50
1000	Event-related potentials during sustained attention and memory tasks: Utility as biomarkers for mild cognitive impairment. **2018**, 10, 452-460	14
999	Amyloid involvement in subcortical regions predicts cognitive decline. **2018**, 45, 2368-2376	25

998 Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET. **2018**, 63, 603-615 9

997 Cellular Receptors of Amyloid β Oligomers (Aβs) in Alzheimer's Disease. **2018**, 19, 28

996 A New Tool for Clinical Neuroscience-Synaptic Imaging. **2018**, 75, 1181-1183 4

995 Alzheimer's disease pathology in Nasu-Hakola disease brains. **2018**, 7, 32-36 10

994 The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. **2018**, 10, 64 31

993 Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation. **2018**, 65, 221-230 29

992 Molecular imaging in dementia: Past, present, and future. **2018**, 14, 1522-1552 40

991 Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer's Disease. **2018**, 9, 729-744 20

990 The development and validation of tau PET tracers: current status and future directions. **2018**, 6, 305-316 102

989 Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. **2018**, 10, 67 18

988 Alzheimer's disease: Only prevention makes sense. **2018**, 48, e13005 25

987 Aerobic training modulates salience network and default mode network metabolism in subjects with mild cognitive impairment. **2018**, 19, 616-624 2

986 Lack of genetic support for shared aetiology of Coronary Artery Disease and Late-onset Alzheimer's disease. **2018**, 8, 7102 5

985 A Longitudinal Imaging Genetics Study of Neuroanatomical Asymmetry in Alzheimer's Disease. **2018**, 84, 522-530 31

984 Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. **2018**, 73, 964-973 5

983 The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. **2018**, 64, 149-169 7

982 In Situ Monitoring the Aggregation Dynamics of Amyloid-β Protein Aβ42 in Physiological Media via a Raman-Based Frequency Shift Method.. **2018**, 1, 814-824 11

981 Evidence for Reduced Autobiographical Memory Episodic Specificity in Cognitively Normal Middle-Aged and Older Individuals at Increased Risk for Alzheimer's Disease Dementia. **2018**, 24, 1073-1083 25

980	Atrophy in Distributed Networks Predicts Cognition in Alzheimer's Disease and Type 2 Diabetes. **2018**, 65, 1301-1312	8
979	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. **2018**, 8, e01080	9
978	Differentiation of Glial Cells From hiPSCs: Potential Applications in Neurological Diseases and Cell Replacement Therapy. **2018**, 12, 239	26
977	Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study. **2018**, 46, 90-99	6
976	Increasing beta-amyloid deposition in cognitively healthy aging predicts nonlinear change in BOLD modulation to difficulty. **2018**, 183, 142-149	6
975	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. **2018**, 65, 977-988	13
974	Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism. **2018**, 65, 1147-1157	13
973	Distinguishing the precision of spatial recollection from its success: Evidence from healthy aging and unilateral mesial temporal lobe resection. **2018**, 119, 101-106	17
972	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. **2018**, 10, 76	56
971	How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. **2018**, 91, 395-402	35
970	Allocentric and Egocentric Spatial Processing in Middle-Aged Adults at High Risk of Late-Onset Alzheimer's Disease: The PREVENT Dementia Study. **2018**, 65, 885-896	20
969	A 'Comprehensive Visual Rating Scale' for predicting progression to dementia in patients with mild cognitive impairment. **2018**, 13, e0201852	5
968	The Involvement of A□2 and Tau in Nucleolar and Protein Synthesis Machinery Dysfunction. **2018**, 12, 220	17
967	Metastable neural dynamics in Alzheimer's disease are disrupted by lesions to the structural connectome. **2018**, 183, 438-455	19
966	Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. **2018**, 117, 62-71	12
965	Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci. **2018**, 141, 2167-2180	34
964	A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information. **2018**, 63, 1383-1393	8
963	Relationship between frailty and Alzheimer's disease biomarkers: A´scoping review. **2018**, 10, 394-401	22

962	Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. **2018**, 141, 2475-2485	54
961	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. **2018**, 13, e0195838	34
960	Update on biomarkers for amyloid pathology in Alzheimer's disease. **2018**, 12, 799-812	39
959	The Neuroimaging of Brain Diseases. **2018**,	
958	Development and validation of a novel dementia of Alzheimer's type (DAT) score based on metabolism FDG-PET imaging. **2018**, 18, 802-813	22
957	Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer's disease. **2018**, 89, 1208-1214	17
956	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. **2018**, 75, 1062-1070	70
955	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. **2018**, 14, 1171-1183	236
954	An Optimization Approach Based on Collective Correlation Coefficient for Biomarker Extraction in the Classification of Alzheimer□ Disease. **2018**, 165-171	
953	Heterogeneity of structural and functional imaging patterns of advanced brain aging revealed via machine learning methods. **2018**, 71, 41-50	38
952	[The importance of molecular imaging (PET) in the diagnostics of dementia]. **2018**, 89, 843-856	2
951	Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer's Disease Corresponding to Brain Networks: a Prospective Cohort Study. **2019**, 21, 140-148	9
950	H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease. **2019**, 13, 925-932	10
949	In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. **2019**, 60, 93-99	106
948	A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression. **2019**, 105, 436-447	3
947	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. **2019**, 74, 877-883	10
946	Stability analysis of a steady state of a model describing Alzheimer's disease and interactions with prion proteins. **2019**, 78, 57-81	3
945	Dementia Risk Elevates Brain Activity During Memory Retrieval: A Functional MRI Analysis of Middle Aged and Older Adults. **2019**, 70, 1005-1023	7

944	Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. **2019**, 15, 1208-1217	25
943	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. **2019**, 24, 101949	9
942	Advances in screening instruments for Alzheimer's disease. **2019**, 2, 88-93	12
941	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid ₱Associated Cognitive Decline in Older Adults. **2019**, 34, 585-598	11
940	A joint model for multiple dynamic processes and clinical endpoints: Application to Alzheimer's disease. **2019**, 38, 4702-4717	2
939	Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. **2019**, 366, l4414	56
938	HENA, heterogeneous network-based data set for Alzheimer's disease. **2019**, 6, 151	9
937	Unilateral Focused Ultrasound-Induced Blood-Brain Barrier Opening Reduces Phosphorylated Tau from The rTg4510 Mouse Model. **2019**, 9, 5396-5411	32
936	Default Mode Network Connectivity Moderates the Relationship Between the APOE Genotype and Cognition and Individualizes Identification Across the Alzheimer's Disease Spectrum. **2019**, 70, 843-860	9
935	Measures of obesity are associated with MRI markers of brain aging: The Northern Manhattan Study. **2019**, 93, e791-e803	15
934	Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. **2019**, 39, 7428-7437	12
933	Liver Dysfunction as a Novel Player in Alzheimer's Progression: Looking Outside the Brain. **2019**, 11, 174	39
932	Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer's Disease and Multiple Sclerosis. **2019**, 13, 355	36
931	Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. **2019**, 10, 3758	240
930	Optimized dual-time-window protocols for quantitative [F]flutemetamol and [F]florbetaben PET studies. **2019**, 9, 32	19
929	Using deep Siamese neural networks for detection of brain asymmetries associated with Alzheimer's Disease and Mild Cognitive Impairment. **2019**, 64, 190-199	27
928	Relationships Between Diffusion Tensor Imaging and Cerebrospinal Fluid Metrics in Early Stages of the Alzheimer's Disease Continuum. **2019**, 70, 965-981	10
927	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. **2019**, 82, 110-119	4

926 [Anti-tau therapies-what can be expected?]. **2019**, 90, 891-897 0

925 Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Cognitively Healthy Older Adults. **2019**, 27, 1360-1371 4

924 Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer's disease. **2019**, 201, 116043 18

923 Association of Methionine to Homocysteine Status With Brain Magnetic Resonance Imaging Measures and Risk of Dementia. **2019**, 76, 1198-1205 21

922 Tau and atrophy: domain-specific relationships with cognition. **2019**, 11, 65 16

921 Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. **2019**, 24, 101954 19

920 An artificial neural network model for clinical score prediction in Alzheimer disease using structural neuroimaging measures. **2019**, 44, 246-260 17

919 Systemic inflammation impairs microglial A‡clearance through NLRP3 inflammasome. **2019**, 38, e101064 116

918 Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. **2019**, 11, 463-471 15

917 Applications of Neuroimaging Biomarkers in CNS Drug Development. **2019**, 115-158

916 Lessons Learned From Public Private Partnerships and Consortia: The ADNI Paradigm. **2019**, 239-246

915 Diagnostic Test Accuracy Studies in Dementia. **2019**, 10

914 Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-‡ neocortical deposition. **2019**, 46, 2090-2098 7

913 Leveraging nonlinear dynamic models to predict progression of neuroimaging biomarkers. **2019**, 75, 1240-1252

912 Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. **2019**, 16, 600-610 24

911 Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment. **2019**, 29, 721-729 2

910 Coffee intake and decreased amyloid pathology in human brain. **2019**, 9, 270 27

909 Tau deposition is associated with functional isolation of the hippocampus in aging. **2019**, 10, 4900 39

908	Cerebral Amyloid Quantification in Cognitively Normal Korean Adults Using F-18 Florbetaben PET. **2019**, 53, 334-339	0
907	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. **2019**, 123, 808-817	7
906	Developments and debates on latent variable modeling in diagnostic studies when there is no gold standard. **2019**, 1-18	
905	Progressive Circuit Changes during Learning and Disease. **2019**, 104, 37-46	7
904	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. **2019**, 15, 1458-1467	11
903	Hypersynchronization in mild cognitive impairment: the 'X' model. **2019**, 142, 3936-3950	28
902	Association of Apolipoprotein E e4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. **2019**, 2, e1913909	22
901	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. **2019**, 86, 866-877	20
900	Heterogeneous Data Management, Polystores, and Analytics for Healthcare. **2019**,	4
899	Mortality after the death of a parent in adulthood: a register-based comparison of two ethno-linguistic groups. **2018**,	5
898	Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. **2019**, 72, 1119-1127	12
897	Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer's disease. **2019**, 19, 264	6
896	Validation of the Chinese version of the memory binding test for distinguishing amnestic mild cognitive impairment from cognitively normal elderly individuals. **2019**, 31, 1721-1730	5
895	Individualized clinical management of patients at risk for Alzheimer's dementia. **2019**, 15, 1588-1602	24
894	Diagnosis of Dementia and Cognitive Impairment. **2019**, 9,	2
893	Machine Learning-Based Framework for Differential Diagnosis Between Vascular Dementia and Alzheimer's Disease Using Structural MRI Features. **2019**, 10, 1097	14
892	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. **2019**, 11, e11170	113
891	Computed Tomography Assessment of Brain Atrophy in Centenarians. **2019**, 16,	6

890	Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. **2019**, 93, e1474-e1484	23
889	Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF. **2019**, 11, 282	5
888	Amyloid-Dependent Inactivation of the Mitochondrial Electron Transport Chain at Low Transmembrane Potential: An Ameliorating Process in Hypoxia-Associated Neurodegenerative Disease?. **2019**, 72, 663-675	2
887	Trifluoromethyl Dihydrothiazine-Based Secretase (BACE1) Inhibitors with Robust Central Amyloid Reduction and Minimal Covalent Binding Burden. **2019**, 14, 1894-1910	5
886	AD molecular: Imaging tau aggregates with positron emissions tomography. **2019**, 165, 107-138	7
885	Predicting incident dementia 3-8´years after brief cognitive tests in the UK Biobank prospective study of 500,000 people. **2019**, 15, 1546-1557	11
884	Diagnosis of mild cognitive impairment using multiple neuroimaging modalities in addition to the Mini-Mental State Examination. **2019**, 19, 1193-1197	3
883	Levels of Tc17 cells in thymic epithelial cell tumors associated with autoimmune diseases.. **2019**, 3, 8	
882	High-Normal Adolescent Fasting Plasma Glucose Is Associated With Poorer Midlife Brain Health: Bogalusa Heart Study. **2019**, 104, 4492-4500	7
881	Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review. **2019**, 50, 9-18	32
880	Age-Related Changes of the Neurovascular Unit in the Cerebral Cortex of Alzheimer Disease Mouse Models: A Neuroanatomical and Molecular Study. **2019**, 78, 101-112	9
879	Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. **2019**, 53, 187-200	11
878	Pathways of Prevention: A Scoping Review of Dietary and Exercise Interventions for Neurocognition. **2019**, 5, 3-38	5
877	Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults. **2019**, 84, 90-97	3
876	Volatile Oil from Acorus gramineus Ameliorates the Injury Neurons in the Hippocampus of Amyloid Beta 1-42 Injected Mice. **2019**, 302, 2261-2270	4
875	Encephalopathy induced by Alzheimer brain inoculation in a non-human primate. **2019**, 7, 126	16
874	Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION): study design, cohort description, and preliminary data. **2019**, 131, 501-508	2
873	The bivariate distribution of amyloid- and tau: relationship with established neurocognitive clinical syndromes. **2019**, 142, 3230-3242	77

872	Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: A 52-week randomized controlled trial. **2019**, 5, 441-449	6
871	Exercise Training in Amnestic Mild Cognitive Impairment: A One-Year Randomized Controlled Trial. **2019**, 71, 421-433	28
870	Intracerebral Injection of Extracellular Vesicles from Mesenchymal Stem Cells Exerts Reduced A‖ Plaque Burden in Early Stages of a Preclinical Model of Alzheimer's Disease. **2019**, 8,	38
869	Correlation of Early-Phase F-18 Florapronal PET with F-18 FDG PET in Alzheimer's Disease and Normal Brain. **2019**, 53, 328-333	0
868	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. **2019**, 83, 42-53	23
867	Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology. **2019**, 71, 281-290	6
866	Tau pathology in cognitively normal older adults. **2019**, 11, 637-645	21
865	Differential Associations Between Volumes of Atrophic Cortical Brain Regions and Memory Performances in Early and Late Mild Cognitive Impairment. **2019**, 11, 245	8
864	Trends in Biomathematics: Mathematical Modeling for Health, Harvesting, and Population Dynamics. **2019**,	0
863	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. **2019**, 11, 679-689	31
862	M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera. **2019**, 9, 13990	17
861	Accelerated Ovarian Failure as a Unique Model to Study Peri-Menopause Influence on Alzheimer's Disease. **2019**, 11, 242	10
860	Plasma A‖2 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment. **2019**, 9, 13984	26
859	Viewpoint on the role of tissue maintenance in ageing: focus on biomarkers of bone, cartilage, muscle, and brain tissue maintenance. **2019**, 56, 100964	4
858	When time's arrow doesn't bend: APOE-‖ influences episodic memory before old age. **2019**, 133, 107180	2
857	Developmental Aspects of Glucose and Calcium Availability on the Persistence of Memory Function Over the Lifespan. **2019**, 11, 253	3
856	Age-Dependent Relationship Between Plasma A‖0 and A‖2 and Total Tau Levels in Cognitively Normal Subjects. **2019**, 11, 222	15
855	Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer's disease. **2019**, 19, 154-170	18

854	Longitudinal association between brain volume change and gait speed in a general population. **2019**, 118, 26-30		5
853	High Selectivity and Sensitivity of Oligomeric p-Phenylene Ethynylenes for Detecting Fibrillar and Prefibrillar Amyloid Protein Aggregates. **2019**, 10, 1813-1825		17
852	Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. **2019**, 11, 7		27
851	Detecting Microglial Density With Quantitative Multi-Compartment Diffusion MRI. **2019**, 13, 81		36
850	[Early detection of Alzheimer's disease and approaches for prevention]. **2019**, 62, 255-260		5
849	Fornix white matter glia damage causes hippocampal gray matter damage during age-dependent limbic decline. **2019**, 9, 1060		25
848	Neuroimaging in dementia. Clinicalâ€radiological correlation. **2019**, 61, 66-81		
847	Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. **2019**, 137, 599-617		129
846	Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project. *Lancet Neurology, The*, **2019**, 18, 177-184	24.1	129
845	Sex differences in Alzheimer's disease: Understanding the molecular impact. **2019**, 1719, 194-207		24
844	Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. **2019**, 72, 7-14		18
843	Tau immunotherapies for Alzheimer's disease. **2019**, 28, 545-554		30
842	Sleep as a Potential Biomarker of Tau and β-Amyloid Burden in the Human Brain. **2019**, 39, 6315-6324		70
841	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. **2019**, 321, 2316-2325		115
840	Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. **2019**, 74, 413-420		35
839	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. **2019**, 142, 2096-2112		47
838	Long-term efficacy of Chinese medicine Bushen Capsule on cognition and brain activity in patients with amnestic mild cognitive impairment. **2019**, 146, 104319		9
837	Environment-Sensitive Near-Infrared Probe for Fluorescent Discrimination of Aβ and Tau Fibrils in AD Brain. **2019**, 62, 6694-6704		23

836	Enabling biodegradable functional biomaterials for the management of neurological disorders. **2019**, 148, 219-238	9
835	F-labeled benzimidazopyridine derivatives for PET imaging of tau pathology in Alzheimer's disease. **2019**, 27, 3587-3594	7
834	Disruptions of the olfactory and default mode networks in Alzheimer's disease. **2019**, 9, e01296	9
833	Synthesis and evaluation of novel two-photon fluorescence probes for in vivo imaging of amylin aggregates in the pancreas. **2019**, 170, 107615	4
832	Neuroimaging Biomarkers for Alzheimer's Disease. **2019**, 14, 21	69
831	Level of education mitigates the impact of tau pathology on neuronal function. **2019**, 46, 1787-1795	7
830	APOE Effect on Amyloid-PET Spatial Distribution, Deposition Rate, and Cut-Points. **2019**, 69, 783-793	7
829	Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women. **2019**, 80, 111-115	4
828	The relationship between domain-specific subjective cognitive decline and Alzheimer's pathology in normal elderly adults. **2019**, 81, 22-29	13
827	Neural correlates of early cognitive dysfunction in Parkinson's disease. **2019**, 6, 902-912	12
826	Analyzing Mild Cognitive Impairment Progression via Multi-view Structural Learning. **2019**, 656-668	0
825	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. **2019**, 15, 888-898	131
824	Differential medial temporal lobe and default-mode network functional connectivity and morphometric changes in Alzheimer's disease. **2019**, 23, 101860	10
823	Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography. **2019**, 19, 165	8
822	Functional Neural Correlates of Anosognosia in Mild Cognitive Impairment and Alzheimer's Disease: a Systematic Review. **2019**, 29, 139-165	26
821	Prediction of Alzheimer's Pathological Changes in Subjective Cognitive Decline Using the Self-report Questionnaire and Neuroimaging Biomarkers. **2019**, 18, 19-29	10
820	Expression of the amyloid-peptide in a single pair of C. elegans sensory neurons modulates the associated behavioural response. **2019**, 14, e0217746	3
819	Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. **2019**, 15, 951-960	14

818	Rev-erbs and Glia-Implications for Neurodegenerative Diseases. **2019**, 13, 1179069519853233	1
817	Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease. **2019**, 5, 208-215	15
816	β-synuclein in the pathophysiology of Alzheimer's disease. **2019**, 14, 23	87
815	Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum. **2019**, 34, 1138-1155	7
814	Atomic resolution map of the soluble amyloid beta assembly toxic surfaces. **2019**, 10, 6072-6082	37
813	Medial Temporal Lobe Disconnection and Hyperexcitability Across Alzheimer's Disease Stages. **2019**, 3, 103-112	24
812	Cognitive Profiling Related to Cerebral Amyloid Beta Burden Using Machine Learning Approaches. **2019**, 11, 95	9
811	Targeting Alzheimer's Disease in the Preclinical Stage. **2019**, 15, 602-603	
810	Predicting conversion from mild cognitive impairment to Alzheimer's disease using brain H-MRS and volumetric changes: A two- year retrospective follow-up study. **2019**, 23, 101843	19
809	Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. **2019**, 69, 551-559	3
808	Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies. **2019**, 142, 2068-2081	15
807	Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation. **2019**, 36, 424-436	18
806	A novel patch-based procedure for estimating brain age across adulthood. **2019**, 197, 618-624	13
805	Retinal Nerve Fiber Layer Thinning Is Associated With Brain Atrophy: A Longitudinal Study in Nondemented Older Adults. **2019**, 11, 69	19
804	Cognitive Impairments in Alzheimer's Disease and Other Neurodegenerative Diseases. **2019**, 267-290	2
803	Dementias. **2019**, 287-345	1
802	Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease. **2019**, 11, 46	48
801	Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease. **2019**, 69, 529-538	2

800	The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to A Plaques. **2019**, 27, 1293-1306.e6	216
799	Gray matter structural covariance networks changes along the Alzheimer's disease continuum. **2019**, 23, 101828	15
798	Fluorescence Chemicals To Detect Insoluble and Soluble Amyloid- Aggregates. **2019**, 10, 2647-2657	18
797	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. **2019**, 142, 1723-1735	82
796	An update on the interactions between Alzheimer's disease, autophagy and inflammation. **2019**, 705, 157-166	38
795	Age-Associated Changes in the Immune System and Blood?Brain Barrier Functions. **2019**, 20,	61
794	Functional connectivity and the sleep-deprived brain. **2019**, 246, 159-176	18
793	The effect of ApoE 4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. **2019**, 22, 101795	23
792	Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. **2019**, 365, l1495	80
791	Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease. **2019**, 11, 74	32
790	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. **2019**, 23, 101823	27
789	A and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. **2019**, 11,	55
788	Immune Signaling in Neurodegeneration. **2019**, 50, 955-974	105
787	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. **2019**, 11, 33	22
786	Clinical F-FDG and amyloid brain positron emission tomography/CT in the investigation of cognitive impairment: where are we now?. **2019**, 92, 20181027	4
785	Structure-Based Design of Selective Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. **2019**, 62, 5080-5095	17
784	Synapse loss and progress of Alzheimer's disease -A network model. **2019**, 9, 6555	40
783	Integrating Frailty and Cognitive Phenotypes: Why, How, Now What?. **2019**, 8, 97-106	10

782	Persistent Perioperative Neurocognitive Disorder. **2019**, 48-60	
781	The vexing complexity of the amyloidogenic pathway. **2019**, 28, 1177-1193	13
780	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. **2019**, 11, 25	14
779	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. **2019**, 11, 27	45
778	LY379268 Does Not Have Long-Term Procognitive Effects nor Attenuate Glutamatergic Signaling in APP/PS1 Mice. **2019**, 68, 1193-1209	5
777	Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles. **2019**, 14, e0211121	6
776	Genetic Overlap Between Alzheimer's Disease and Bipolar Disorder Implicates the MARK2 and VAC14 Genes. **2019**, 13, 220	20
775	Frontotemporal dementia is the leading cause of "true" A-/T+ profiles defined with A ratio. **2019**, 11, 161-169	7
774	Novelty processing and memory impairment in Alzheimer's disease: A review. **2019**, 100, 237-249	11
773	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. **2019**, 78, 178-185	36
772	Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles. **2019**, 10, 18	8
771	Lifespan Changes of the Human Brain In Alzheimer's Disease. **2019**, 9, 3998	49
770	Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. **2019**, 2019, 6216530	14
769	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. **2019**, 92, e1567-e1579	40
768	Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred. **2019**, 6, 112-120	21
767	Nanomaterials for Drug Delivery to the Central Nervous System. **2019**, 9,	59
766	CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. **2019**, 119, 445-452	13
765	Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis. **2019**, 68, 571-582	12

764	Increases in a Pro-inflammatory Chemokine, MCP-1, Are Related to Decreases in Memory Over Time. **2019**, 11, 25	32
763	Personality and Alzheimer's disease: An integrative review. **2019**, 10, 4-12	47
762	ApoE and clusterin CSF levels influence associations between APOE´genotype and changes in CSF tau, but not CSF A‖2, levels in´non-demented elderly. **2019**, 79, 101-109	12
761	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. **2019**, 22, 101777	17
760	White matter microstructural abnormalities and default network degeneration are associated with early memory deficit in Alzheimer's disease continuum. **2019**, 9, 4749	18
759	Multivariate Prediction of Hippocampal Atrophy in Alzheimer's Disease. **2019**, 68, 1453-1468	1
758	Detecting Diagnostic Biomarkers of Alzheimer's Disease by Integrating Gene Expression Data in Six Brain Regions. **2019**, 10, 157	9
757	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. **2019**, 15, 675-685	18
756	Synchrotron XRF imaging of Alzheimer's disease basal ganglia reveals linear dependence of high-field magnetic resonance microscopy on tissue iron concentration. **2019**, 319, 28-39	6
755	Delineating the topography of amyloid-associated cortical atrophy in Down syndrome. **2019**, 80, 196-202	6
754	Association of Midlife Diet With Subsequent Risk for Dementia. **2019**, 321, 957-968	35
753	Pattern of Altered Plasma Elemental Phosphorus, Calcium, Zinc, and Iron in Alzheimer's Disease. **2019**, 9, 3147	14
752	Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. **2019**, 33, 375-382	12
751	Diagnostische Kriterien und Diagnose der Demenz vom Alzheimer-Typ. **2019**, 2, 91-105	0
750	Predicting cognitive resilience from midlife lifestyle and multi-modal MRI: A 30-year prospective cohort study. **2019**, 14, e0211273	6
749	Screening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI. **2019**, 3, 31-45	4
748	Development of Gleevec Analogues for Reducing Production of ‖Amyloid Peptides through Shifting ‖Cleavage of Amyloid Precursor Proteins. **2019**, 62, 3122-3134	3
747	Preliminary Report on the Feasibility and Efficacy of the Modified Atkins Diet for Treatment of Mild Cognitive Impairment and Early Alzheimer's Disease. **2019**, 68, 969-981	39

746	The Hypothalamus in Alzheimer's Disease: A Golgi and Electron and Microscope Study. **2019**,	
745	Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau. **2019**, 80, 11-20	54
744	Development of a Stand-Alone Independent Graphical User Interface for Neurological Disease Prediction with Automated Extraction and Segmentation of Gray and White Matter in Brain MRI Images. **2019**, 2019, 9610212	2
743	Connectivity and morphology of hubs of the cerebral structural connectome are associated with brain resilience in AD- and age-related pathology. **2019**, 13, 1650-1664	6
742	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. **2019**, 380, 1408-1420	268
741	Greater Regional Cortical Thickness is Associated with Selective Vulnerability to Atrophy in Alzheimer's Disease, Independent of Amyloid Load and APOE Genotype. **2019**, 69, 145-156	3
740	Single-photon emission computed tomography (SPECT) perfusion and neuropsychological performance in mild cognitive impairment. **2019**, 41, 530-543	2
739	Common variants in Alzheimer's disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores.	9
738	Protein-protein interactions in neurodegenerative diseases: a conspiracy theory.	0
737	Association of social isolation, loneliness, and genetic risk with incidence of dementia: UK Biobank cohort study.	1
736	Disrupted structural connectivity in ArcAβ mouse model of Aβ amyloidosis.	1
735	Metabolic and haemodynamic resting-state connectivity of the human brain: a high-temporal resolution simultaneous BOLD-fMRI and FDG-fPET multimodality study.	2
734	Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer's disease, irrespective of fibrillar amyloid-beta pathology.	3
733	Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study.	1
732	The Impact of the Siemens Trio to Prisma Upgrade and Volumetric Navigators on MRI Indices: A Reliability Study with Implications for Longitudinal Study Designs.	0
731	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.	1
730	Dysregulation of the secretory pathway connects Alzheimer's disease genetics to aggregate formation.	1
729	Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer's disease.	0

728	Association of plasma proteins with rate of cognitive decline and dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies.	0
727	Age-accelerated cognitive decline in asymptomatic adults with CSF amyloid.	2
726	In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer disease dementia to young controls.	3
725	Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer disease.	1
724	BIN1 genetic risk factor for Alzheimer is sufficient to induce early structural tract alterations in entorhinal-hippocampal area and memory-related hippocampal multi-scale impairments.	4
723	Adipokines contribute to central-obesity related reductions in myelin-sensitive MRI indices in the fornix.	2
722	Biobank-wide association scan identifies risk factors for late-onset Alzheimer disease and endophenotypes.	7
721	Functional dissection of Alzheimer disease brain gene expression signatures in humans and mouse models.	3
720	Sleep is bi-directionally modified by amyloid beta oligomers.	2
719	Increasing objective cardiometabolic burden associated with attenuations in the P3b event-related potential component in older adults.	1
718	Addition of Genetics to Quantitative MRI Facilitates Earlier Prediction of Dementia: A Non-invasive Alternative to Amyloid Measures.	1
717	Staging Alzheimer disease in the brain and retina of B6.APP/PS1 mice by transcriptional profiling.	1
716	Predicting Alzheimer disease progression using deep recurrent neural networks.	3
715	Amyloid duration is associated with preclinical cognitive decline and tau PET.	3
714	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. **2021**, 28, 2147-2155	7
713	Brain investigation and brain conceptualization. **2013**, 28, 175-90	13
712	Blood will out: vascular contributions to Alzheimer's disease. **2018**, 128, 556-563	52
711	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, , and Cognitive Impairment. **2021**, 96, e975-e985	7

710	Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study. **2017**, 14, e1002265	45
709	Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. **2013**, 8, e68996	36
708	The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. **2014**, 9, e86558	82
707	Modeling test and treatment strategies for presymptomatic Alzheimer disease. **2014**, 9, e114339	3
706	Tracking Parkinson's Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. **2015**, 10, e0143923	17
705	An Anti-βAmyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. **2016**, 11, e0152471	24
704	Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression. **2016**, 11, e0154406	12
703	The nonlinear relationship between cerebrospinal fluid Aβ2 and tau in preclinical Alzheimer's disease. **2018**, 13, e0191240	23
702	The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. **2014**, 1, 181-202	39
701	Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. **2015**, 2, 128-135	24
700	Establishing Clinical Relevance in Preclinical Alzheimer's Disease. **2015**, 2, 85-87	7
699	Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. **2015**, 2, 82-84	7
698	Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. **2018**, 11, 1-12	5
697	Resting State BOLD Variability of the Posterior Medial Temporal Lobe Correlates with Cognitive Performance in Older Adults with and without Risk for Cognitive Decline. **2020**, 7,	10
696	Biomarkers in Alzheimer's disease: Evaluation of platelets, hemoglobin and vitamin B12. **2020**, 14, 35-40	3
695	[Predementia neurocognitive impairment in the elderly]. **2019**, 119, 10-17	1
694	[Mild cognitive impairment: what's next?]. **2019**, 119, 103-110	1
693	STARD1 and NPC1 expression as pathological markers associated with astrogliosis in post-mortem brains from patients with Alzheimer's disease and Down syndrome. **2020**, 12, 571-592	8

692	Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein. **2020**, 12, 1011-1033	25
691	High pulse pressure is a risk factor for prodromal Alzheimer's disease: a longitudinal study. **2020**, 12, 18221-18237	2
690	Preclinical progression of neurodegenerative diseases. **2018**, 80, 289-298	16
689	The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study. **2018**, 8, 1004-1019	15
688	Aggregated AA1-42 is Selectively Toxic for Neurons, Whereas Glial Cells Produce Mature Fibrils with Low Toxicity in Drosophila.	0
687	Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines. **2020**, 21, 819-836	4
686	Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. **2014**, 11, 773-84	82
685	Relationship Between the Japanese Version of the Montreal Cognitive Assessment and PET Imaging in Subjects with Mild Cognitive Impairment. **2019**, 16, 852-860	4
684	Role of TREM2 in Alzheimer's Disease and its Consequences on Amyloid, Tau and Neurofibrillary Tangles. **2019**, 16, 1216-1229	12
683	Interactions between Personality, Depression, Anxiety and Cognition to Understand Early Stage of Alzheimer's Disease. **2020**, 20, 782-791	5
682	From Light to Sound: Photoacoustic and Ultrasound Imaging in Fundamental Research of Alzheimer's Disease. **2020**, 4,	4
681	Randomized Comparison of Mobile and Web-Tools to Provide Dementia Risk Reduction Education: Use, Engagement and Participant Satisfaction. **2014**, 1, e4	16
680	The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?. **2014**, 16, 373-93	38
679	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. **2016**, 50, 249-60	39
678	Cognitive Reserve, Brain Reserve, APOEe4, and Cognition in Individuals with Subjective Cognitive Decline in the SILCODE Study. **2020**, 76, 249-260	5
677	Accurate BAPL Score Classification of Brain PET Images Based on Convolutional Neural Networks with a Joint Discriminative Loss Function **2020**, 10, 965	3
676	Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and -Methyl-d-Aspartate Receptor Antagonists. **2020**, 11,	3
675	Blood extracellular vesicles (EVs) of central nervous system origin: a window into the brain. **2020**, 15, 55-56	10

674	Multimodality Neuroimaging in Mild Cognitive Impairment: A Cross-sectional Comparison Study. **2018**, 21, 133-139	5
673	Toxic oligomer species of amyloid-‖n Alzheimer's disease, a timing issue. **2014**, 144, w14021	24
672	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. **2019**, 8,	27
671	Sleep is bi-directionally modified by amyloid beta oligomers. **2020**, 9,	14
670	Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. **2016**, 30, 361-372	46
669	Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort. **2020**, 8, e9498	1
668	What We Should Not Forget about Down Syndrome. **2021**, 11, 149-165	
667	The Association of Psychological Well-Being With Sensory and Cognitive Function and Neuronal Health in Aging Adults. **2021**, 8982643211046820	2
666	Dissociable effects of -4 and ‖amyloid pathology on visual working memory. **2021**, 1, 1002-1009	2
665	Beneficial effects of a nobiletin-rich formulated supplement of Sikwasa () peel on cognitive function in elderly Japanese subjects; A multicenter, randomized, double-blind, placebo-controlled study.. **2021**, 9, 6844-6853	3
664	Performance of Plasma Amyloid ‖Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China. **2021**, 13, 749649	2
663	Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia. **2021**, 8, 2083-2092	1
662	A quantitative model of sporadic axonal degeneration in the Drosophila visual system.	0
661	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease. **2021**, 1	0
660	Association Between Plasma Amyloid-‖and Neuropsychological Performance in Patients With Cognitive Decline. **2021**, 13, 736937	2
659	Sequential Pathway Inference for Multimodal Neuroimaging Analysis.. **2022**, 11, e433	
658	Education, APOE 4, and Cognition in Individuals with Subjective Cognitive Decline with Worry in the SILCODE Study. **2021**, 18, 492-498	
657	Exercise as a model to identify microRNAs linked to human cognition: a role for microRNA-409 and microRNA-501. **2021**, 11, 514	2

656	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. **2021**, 13, eabe5640	15
655	Untangling the relationship between microglia and tau in Alzheimer's disease. **2021**, 44, 927-929	
654	Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease. **2021**, 64, 15262-15279	2
653	Association of peripheral blood DNA methylation level with Alzheimer's disease progression. **2021**, 13, 191	5
652	Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease. **2021**, 13, 738971	2
651	Fish, -3 fatty acids, cognition and dementia risk: not just a fishy tale. **2021**, 1-14	0
650	Electroencephalography as a Non-Invasive Biomarker of Alzheimer's Disease: A Forgotten Candidate to Substitute CSF Molecules?. **2021**, 22,	1
649	In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. **2021**, 13, 178	1
648	Characterizing the Resilience Effect of Neurodegeneration for the Mechanistic Pathway of Alzheimer's Disease. **2021**, 84, 1351-1362	
647	Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum. **2021**, 13, 167	1
646	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. **2021**, 10,	2
645	Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild Cognitive Impairment. **2021**, 11,	0
644	Grey-matter brain healthcare quotient and cognitive function: A large cohort study of an MRI brain screening system in Japan. **2021**, 145, 97-104	3
643	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. **2014**, 131-157	
642	Alzheimer's Disease. **2014**, 35-40	
641	Alzheimer-Associated Pathology in the Extracellular Space. **2015**, 75-93	1
640	Introduction: Cellular Rhythms and Networks in Systems and Dynamical Medicine. **2015**, 1-12	
639	Future Prospects for Diagnostic Test Accuracy Studies in Dementia. **2015**, 127-142	

638 Geriatric Psychiatry. **2015**, 104-108

637 Auf hohem Niveau: Risiko Gedächtnissorgen. **2015**, 26, 41-45

636 (Neurobiology of) Dementia: Causes, Presentation and Management. **2016**, 1-20

635 Kognitive Einschränkungen und Demenzen. **2016**, 645-663

634 Dementia and Neurocognitive Disorders. **2016**, 1-10

633 Could Stem Cells Be Used to Treat or Model Alzheimer's Disease?. **2016**, 203-225 0

632 Human anterolateral entorhinal cortex volumes are associated with preclinical cognitive decline. 2

631 Dementia. **2017**, 367-380

630 Alzheimer's disease as a neuropathological continuum in clinical practice.. **2016**, 17, 305-309

629 (Neurobiology of) Dementia: Causes, Presentation, and Management. **2017**, 85-104

628 Dementia and Other Neurocognitive Disorders. **2017**, 226-252

627 Verubecestat. **2017**, 204-251

626 Encyclopedia of Geropsychology. **2017**, 646-655

625 Modeling Cognitive Trends in Preclinical Alzheimer's Disease (AD) via Distributions over Permutations. **2017**, 683-691

624 Actualités des facteurs de risque des démences. **2017**, 201, 731-738

623 Does genetic risk help to predict amyloid burden in a non-demented population? A Bayesian approach.

622 The Wisconsin Registry for Alzheimer's Prevention: A Review of findings and current directions. 0

621 TIMELINE OF BRAIN ALTERATIONS IN ALZHEIMER'S DISEASE ACROSS THE ENTIRE LIFESPAN.

620	Differential medial temporal lobe and default-mode network functional connectivity and morphometric changes in Alzheimer's Disease.	
619	CSF biomarkers are differentially related to structural and functional changes in dementia of the Alzheimer's type.	
618	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. **2018**, 235-248	
617	Alzheimer's Disease ?. **2018**,	
616	The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer's Disease. **2018**, 249-258	0
615	Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease.	1
614	Longitudinal increase in sleep problems is related to amyloid deposition in cortical regions with high HOMER1 gene expression.	
613	Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles.	
612	Mild Cognitive Impairment: Diagnosis and Treatment. **2019**, 323-331	
611	Multi-modal Latent Factor Exploration of Atrophy, Cognitive and Tau Heterogeneity in Alzheimer's Disease.	1
610	Alzheimer Disease: Convergence Result from a Discrete Model Towards a Continuous One. **2019**, 397-431	
609	A Positivity Predicts Cognitive Decline but Cognition Also Predicts Progression to A Positivity.	1
608	Future Prospects for Diagnostic Test Accuracy Studies in Dementia. **2019**, 163-179	
607	Nanotechnology-Mediated Nose-to-Brain Drug Delivery for Neurodegenerative Disorders. **2019**, 163-175	
606	Introduction. **2019**, 1-20	
605	SNIPE score can capture prodromal Alzheimer's in cognitively normal subjects.	2
604	Genetic risk score for Alzheimer's disease is associated with poor hearing.	
603	A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.	1

602	Tau pathology in cognitively normal older adults.	
601	Misfolded amyloid β42 induced impairment of the endosomal-lysosomal pathway revealed by real-time optical monitoring.	
600	Cardiorespiratory fitness predicts greater hippocampal volume and rate of episodic associative learning in older adults.	
599	Preserved wake-dependent cortical excitability dynamics predict cognitive fitness beyond age-related brain alterations.	
598	Distinct effects of amyloid and tau deposition on eigenvector centrality during hippocampal down-regulation: a real-time fMRI virtual reality closed-loop neurofeedback study with CSF biomarkers.	2
597	Alzheimer's disease. **2019**, 11, 52-60	2
596	Molecular estimation of neurodegeneration pseudotime in older brains.	1
595	Brain-age in midlife is associated with accelerated biological aging and cognitive decline in a longitudinal birth-cohort.	7
594	Mechanistic insights into the deleterious role of nasu-hakola disease associated TREM2 variants.	
593	Progressive impairments in executive function in the APP/PS1 model of Alzheimer's disease as measured by translatable touchscreen testing.	
592	Cholinergic-like neurons carrying PSEN1 E280A mutation from familial Alzheimer's disease reveal intraneuronal Aβ42 peptide accumulation, hyperphosphorylation of TAU, oxidative stress, apoptosis and Ca2+ flux dysregulation: Therapeutic Implications.	
591	Genome-wide association study identifies affecting the rate of CSF Aβ decline in non-demented elders. **2019**, 11, 5433-5444	3
590	Mathematical model shows how sleep may affect amyloid β fibrillization.	0
589	Detecting prodromal Alzheimer's disease with MRI through deep learning.	
588	Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer. **2019**, 15,	
587	A/T/N polygenic risk score for cognitive decline in old age.	1
586	Development and validation of a deep learning framework for Alzheimer's disease classification.	
585	Genetic risk of dementia modifies the impact of obesity on limbic white matter and spatial navigation behavior in cognitively healthy adults.	

584	ATN status in amnestic and non-amnestic Alzheimer disease and frontotemporal lobar degeneration.	
583	Assessment of Memory Impairment in Early Diagnosis of Alzheimer's Disease. **2019**, 16, 975-985	1
582	A Systems Biology Approach for the Identification of Active Molecular Pathways During the Progression of Alzheimer's Disease. **2020**, 1194, 303-314	1
581	Integrated analysis of the aging brain transcriptome and proteome in tauopathy.	
580	Clinical and biomarker changes in sporadic Alzheimer disease.	
579	Thiamine pyrophosphokinase deficiency induces Alzheimer pathology.	
578	Quantitative longitudinal predictions of Alzheimer disease by multi-modal predictive learning.	
577	Connectome-mediated prediction of future tau-PET burden in Alzheimer disease.	1
576	Bundle-specific associations between white matter microstructure and A and tau pathology at their connecting cortical endpoints in older adults at risk of Alzheimer disease.	
575	Predicting future regional tau accumulation in asymptomatic and early Alzheimer disease.	1
574	Physical Activity in Early- and Mid-Adulthood Are Independently Associated With Longitudinal Memory Trajectories in Later Life. **2021**, 76, 1495-1503	3
573	Transfer Learning for Alzheimer's Disease through Neuroimaging Biomarkers: A Systematic Review. **2021**, 21,	6
572	Hippocampal acidity and volume are differentially associated with spatial navigation in older adults. **2021**, 245, 118682	1
571	Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. **2021**, 18, 4148-4161	0
570	Potential causal effect of physical activity on reducing the risk of dementia: a 6-year cohort study from the Japan Gerontological Evaluation Study. **2021**, 18, 140	1
569	Metacognition, cortical thickness, and tauopathy in aging.	
568	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. **2021**, 13, e15098	4
567	Recent Advances in Molecular Pathways and Therapeutic Implications Targeting Mitochondrial Dysfunction for Alzheimer's Disease. **2021**, 1	3

566	Three major dimensions of human brain cortical ageing in relation to cognitive decline across the 8th decade of life.	2
565	Transcranial Magnetic Stimulation in Dementia: From Pathophysiology to Treatment. **2020**, 161-173	
564	Brain-wide functional networks associated with anatomically- and functionally-defined hippocampal subfields using ultrahigh-resolution fMRI.	
563	Diagnostic précoce et biomarqueurs biologiques de la maladie d'Alzheimer. **2020**, 20, 120S7-120S10	
562	Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study. **2021**, 23, e26284	1
561	Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid β on Neurodegeneration. **2021**, 35, 114-120	1
560	Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study (Preprint).	1
559	APOE Genotypes and Brain Imaging Classes in Normal Cognition, Mild Cognitive Impairment, and Alzheimer's Disease: A Longitudinal Study. **2020**, 17, 766-780	1
558	Physiopathologie de la maladie d'Alzheimer : le rôle central de la plaque amyloïde et de la protéine Tau. **2020**, 20, 120S2-120S6	
557	PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes. **2022**, 292, 118320	6
556	Assessing clinical progression from subjective cognitive decline to mild cognitive impairment with incomplete multi-modal neuroimages. **2021**, 75, 102266	3
555	Multivariate Data Analysis and Machine Learning for Prediction of MCI-to-AD Conversion. **2020**, 1194, 81-103	2
554	Multiplex Connectome Changes across the Alzheimer's Disease Spectrum Using Gray Matter and Amyloid Data.. **2022**,	1
553	Occupational Determinants of Cognitive Decline and Dementia. **2020**, 235-249	1
552	Structural changes in the aging brain. **2020**, 59-69	
551	Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association. **2020**, 19, 39-53	1
550	Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and mildly impaired older adults. **2020**, 1, zpaa006	4
549	Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application. **2020**, 367-379	1

548	Brain Network Functional Connectivity in Alzheimer's Disease and Frontotemporal Dementia. **2020**, 385-415	0
547	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. **2020**, 35, e361	5
546	Synchronous nonmonotonic changes in functional connectivity and white matter integrity in a rat model of sporadic Alzheimer's disease.	
545	Applications of Quantitative Perfusion and Permeability in the Brain. **2020**, 1, 369-403	
544	Use of cerebrospinal fluid in diagnosis of dementia. **2020**, 225-237	
543	Linear and nonlinear relationships between cognitive subdomains of ability discrepancy and Alzheimer's disease biomarkers. **2020**, 34, 211-226	4
542	Network efficiency predicts resilience to cognitive decline in elderly at risk for Alzheimer's.	
541	Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-Positron Emission Tomography. **2020**, 74, 101-112	
540	Facteurs de risque de la maladie d'Alzheimer et des maladies apparentées : approche parcours de vie. **2020**, 204, 217-223	
539	Potential of infrared microscopy to differentiate between dementia with Lewy bodies and Alzheimer's diseases using peripheral blood samples and machine learning algorithms. **2020**, 25, 1-15	
538	Communicability distance reveals hidden patterns of Alzheimer disease.	1
537	The Island Study Linking Ageing and Neurodegenerative Disease (ISLAND): a Prospective, Online, Public Health Cohort Study Targeting Dementia Risk Reduction (Preprint).	
536	Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife. **2021**, 97, e2328-e2339	1
535	Subjective cognitive decline-related worries modulate the relationship between global amyloid load and gray matter volume in preclinical Alzheimer's disease. **2021**, 1	
534	Ranking convolutional neural network for Alzheimer's disease mini-mental state examination prediction at multiple time-points. **2022**, 213, 106503	4
533	Biomedical Applications of Translational Optical Imaging: From Molecules to Humans. **2021**, 26,	
532	Dementia and Other Neurocognitive Disorders. 104-130	
531	Personality and Dementia Risk in England and Australia. **2020**, 33, 197-208	0

530	Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data.	
529	Fragile X Premutation rCGG Repeats Impairs Synaptic Growth and Synaptic Transmission at Drosophila larval Neuromuscular Junction.	
528	SPECT and PET in Vascular Dementia. **2021**, 563-575	
527	Temporal stability of the ventral attention network and general cognition along the Alzheimer's disease spectrum.	
526	New treatment strategies for Alzheimer's disease: is there a hope?. **2013**, 138, 449-60	20
525	Impact of C24:0 on actin-microtubule interaction in human neuronal SK-N-BE cells: evaluation by FRET confocal spectral imaging microscopy after dual staining with rhodamine-phalloidin and tubulin tracker green. **2015**, 30, 33-46	5
524	Genetic of Alzheimer's Disease: A Narrative Review Article. **2015**, 44, 892-901	9
523	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need. **2013**, 24, 97-104	3
522	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. **2017**, 14, 22-29	24
521	Tau and Pet/Mri Imaging Biomarkers for Detecting and Diagnosing Early Dementia. **2017**, 2,	2
520	Detection of Alzheimer's Disease. **2018**, 91, 291-300	17
519	Advances in diagnostic testing for Alzheimer disease. **2013**, 110, 401-5	2
518	Integrating Frailty and Cognitive Phenotypes: Why, How, Now What?. **2019**, 8, 97-106	9
517	Identification of Dysregulated Genes for Late-Onset Alzheimer's Disease Using Gene Expression Data in Brain. **2020**, 10,	
516	Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein. **2021**, 27, e934077	0
515	Role of caspases, apoptosis and additional factors in pathology of Alzheimer's disease. **2022**, 69-151	0
514	The landscape of metabolic brain alterations in Alzheimer's disease.	1
513	Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia. **2021**, 17, 1855-1867	2

512	A whole process interpretable and multi-modal deep reinforcement learning for diagnosis and analysis of Alzheimer's disease. **2021**,	0
511	Characteristics of Neural Network Changes in Normal Aging and Early Dementia. **2021**, 13, 747359	4
510	Apolipoprotein ε4 modifies obesity-related atrophy in the hippocampal formation of cognitively healthy adults.	
509	Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?. **2021**,	
508	Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology. **2021**, 12, 772836	2
507	Long-term prognosis and educational determinants of brain network decline in older adult individuals.. **2021**, 1, 1053-1067	4
506	Cognitive impairment and World Trade Centre-related exposures. **2021**,	4
505	Depressive symptom profiles predict dementia onset and brain pathology in older persons. The AGES-Reykjavik study.. **2021**, 111, 14-23	0
504	Evaluation of Intensive vs Standard Blood Pressure Reduction and Association With Cognitive Decline and Dementia: A Systematic Review and Meta-analysis. **2021**, 4, e2134553	1
503	Regional Brain Volume, Brain Reserve and MMSE Performance in Healthy Aging From the NEUROAGE Cohort: Contributions of Sex, Education, and Depression Symptoms. **2021**, 13, 711301	0
502	Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum. **2021**,	1
501	Relationship between Amyloid-β Deposition and the Coupling between Structural and Functional Brain Networks in Patients with Mild Cognitive Impairment and Alzheimer's Disease. **2021**, 11,	1
500	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. **2021**, 22,	0
499	Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models. **2021**, 161, 105558	3
498	Evidence against altered excitatory/inhibitory balance in the posteromedial cortex of young adult APOE E4 carriers: A resting state 1H-MRS study. **2021**, 1, 100059	
497	Baseline [F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease. **2021**, 13, 196	2
496	Path integration in normal aging and Alzheimer's disease. **2021**,	3
495	Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core. **2021**, 52, 116528	0

494	Neurodegeneration/Demenz. **2021**, 200-208	
493	Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds.. **2021**, 13, e12241	0
492	Genetic Predisposition to Low-Density Lipoprotein Cholesterol May Increase Risks of Both Individual and Familial Alzheimer's Disease.. **2021**, 8, 798334	0
491	Can Exercise Training Teach Us How to Treat Alzheimer's disease?. **2022**, 75, 101559	0
490	A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.. **2021**, 74, 101542	1
489	Development of HANABI, an ultrasonication-forced amyloid fibril inducer.. **2021**, 153, 105270	0
488	Parsing neural circuits of fear learning and extinction across basic and clinical neuroscience: towards better translation.. **2021**, 134, 104502-104502	1
487	Alzheimer: Wie man nach einer kausalen Therapie sucht.	
486	Chapter 12. The Limits of Biomarkers: Contemporary Re-Phrasings of Canguilhem. **2020**, 469-497	
485	Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial.. **2022**, 12, 1346	3
484	Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults.. **2022**, 9, 297-305	
483	Alzheimer disease and neuroplasticity.. **2022**, 184, 473-479	3
482	Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults.. **2022**, 112, 181-190	1
481	Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases.. **2021**, 15, 806260	3
480	Late-Life Physical Activities Moderate the Relationship of Amyloid-Pathology with Neurodegeneration in Individuals Without Dementia.. **2022**,	
479	Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential.. **2022**, 12, 1019-1040	6
478	Extraversion is associated with lower brain amyloid deposition in cognitively normal older adults.	
477	Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.. **2022**, 2022, 9484217	4

476	APOE ε4 effects on hippocampal atrophy in the healthy elderly reflect future cognitive decline.	
475	The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress.. **2022**, 13, 37-60	2
474	Racial Residential Segregation in Young Adulthood and Brain Integrity in Middle Age: Can We Learn From Small Samples?. **2022**,	1
473	Lowering levels of reelin in entorhinal cortex layer II-neurons results in lowered levels of intracellular amyloid-β	0
472	Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults ≥55 Years Old. A Study Protocol for a Double-Blinded Randomized Controlled Clinical Trial.. **2022**, 9, 54-66	0
471	Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner.. **2021**, 12, 813536	0
470	CSF sphingomyelins in Alzheimer's disease, neurodegeneration, and neuroinflammation.	
469	Multiscale structural mapping of Alzheimer's disease neurodegeneration.. **2022**, 33, 102948	0
468	Neurogenetic disorders across the lifespan: from aberrant development to degeneration.. **2022**,	4
467	Identifying the regional substrates predictive of Alzheimer's disease progression through a convolutional neural network model and occlusion.	
466	Peripheral reaching in Alzheimer's disease and mild cognitive impairment.. **2022**, 149, 29-43	0
465	Simple Quantification of Surface Uptake in F-18 Florapronol PET/CT Imaging for the Validation of Alzheimer's Disease.. **2022**, 12,	0
464	Associations between Cortical Thickness and Metamemory in Alzheimer's Disease.. **2022**, 1	0
463	Longitudinal Amyloid Cognitive Composite in Preclinical Alzheimer's Disease.. **2021**,	1
462	Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial.. **2022**, 11,	1
461	Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.. **2022**,	0
460	Brain pathology and cognitive scores prior to onset of late-life depression.. **2022**, 37,	1
459	Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study.. **2022**, 376, e068005	4

458	Assessing Sex-Specific Circadian, Metabolic, and Cognitive Phenotypes in the A₽P/PS1 and APPNL´-F/NL´-F Models of Alzheimer's Disease.. **2021**,	0
457	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.. **2022**,	2
456	Neuroprotective Effect of HIIT against GFAP Hypertrophy through Mitochondrial Dynamics in APP/PS1 Mice.. **2022**, 2022, 1764589	1
455	Wireless USB-like electrochemical platform for individual electrochemical sensing in microdroplets.. **2022**, 1197, 339526	1
454	Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognition.. **2022**, 1866, 130097	0
453	Fallacies in Neuroscience: The Alzheimer's Edition.. **2022**, 9,	1
452	Impact of sex and 4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults.. **2022**, 14, e12271	0
451	Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons.. **2022**,	0
450	Theta band-power shapes amyloid-driven longitudinal EEG changes in pre-clinical Alzheimer Disease.	0
449	Associations Between Total Sleep Duration and Cognitive Function Among Middle-Aged and Older Chinese Adults: Does Midday Napping Have an Effect on It?. **2022**, 15, 1381-1391	0
448	Slowing gait speed precedes cognitive decline by several years.. **2022**,	1
447	Inferring protein expression changes from mRNA in Alzheimer's dementia using deep neural networks.. **2022**, 13, 655	3
446	Summary statistics of memory-related fMRI activity reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging.	0
445	The spike-and-slab elastic net as a classification tool in Alzheimer's disease.. **2022**, 17, e0262367	0
444	Sulcal morphology as cognitive decline predictor in older adults with memory complaints.. **2022**, 113, 84-94	
443	The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.. **2021**, 64, 17656-17689	4
442	Impact of the Age of Cecal Material Transfer Donors on Alzheimer's Disease Pathology in 5xFAD Mice.. **2021**, 9,	3
441	Lack of association between bridging integrator 1 () rs744373 polymorphism and tau-PET load in cognitively intact older adults.. **2022**, 8, e12227	

440	Difference in Amyloid Load Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Study from the SILCODE.. **2021**,	
439	Neurological signs of ageing. **2022**, 561-569	
438	Amyloid-β stimulated hippocampal lactate release is coupled to glutamate uptake.. **2022**, 12, 2775	0
437	Clear-headed into old age: Resilience and resistance against brain aging - A PET imaging perspective.. **2022**,	0
436	Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology.	
435	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.. **2022**,	2
434	Association of social isolation, loneliness and genetic risk with incidence of dementia: UK Biobank Cohort Study.. **2022**, 12, e053936	1
433	Model of glymphatic clearance of aggregating proteins from the brain interstitium.. **2022**, 105, 024405	0
432	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.. **2022**,	1
431	The Humanistic and Economic Burden of Alzheimer's Disease.. **2022**, 1	5
430	Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment.. **2022**,	0
429	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease.. **2022**, 12,	2
428	Amyloid Positive Hydrocephalus: A Hydrocephalic Variant of Alzheimer's Disease?. **2021**,	1
427	Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis.. **2022**, 14,	1
426	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies.. **2022**, 48674221081773	
425	The canonical pattern of Alzheimer's disease atrophy is linked to white matter hyperintensities in normal controls, differently in normal controls compared to in AD.. **2022**,	0
424	A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer's disease.. **2022**, 14, 45	3
423	Alzheimer's Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing. **2022**, 34-44	

422	Long-term physical activity participation trajectories were associated with subsequent cognitive decline, risk of dementia and all-cause mortality among adults aged ≥50 years: a population-based cohort study.. **2022**, 51,	0
421	Alzheimer's Disease: Epidemiology and Clinical Progression.. **2022**, 1	4
420	Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI.	1
419	Stage dependent differential influence of metabolic and structural networks on memory across Alzheimer's disease continuum.	
418	Neurochemical and cognitive changes precede structural abnormalities in the TgF344-AD rat model.. **2022**, 4, fcac072	0
417	Serum folate deficiency and the risks of dementia and all-cause mortality: a national study of old age.. **2022**,	2
416	Association of serum thyroid hormone levels with positron emission tomography imaging in non-demented older adults.. **2022**,	0
415	Exploring common genetic contributors to neuroprotection from amyloid pathology.. **2022**, 4, fcac066	1
414	Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies.. **2022**,	1
413	Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies.. **2022**,	0
412	Investigating the temporal pattern of neuroimaging-based brain age estimation as a biomarker for Alzheimer's Disease related neurodegeneration.	
411	The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease.. **2022**, 1-4	1
410	Yoga Prevents Gray Matter Atrophy in Women at Risk for Alzheimer's Disease: A Randomized Controlled Trial.. **2022**,	1
409	Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.. **2022**, 14, 831807	1
408	Individualized Gaussian Process-based Prediction of Memory Performance and Biomarker Status in Ageing and Alzheimer's disease.	
407	Personalized Management and Treatment of Alzheimer's Disease.. **2022**, 12,	0
406	Alzheimer's disease - the journey of a healthy brain into organ failure.. **2022**, 17, 18	3
405	Voxel-based morphometry and a deep learning model for the diagnosis of early Alzheimer's disease based on cerebral gray matter changes.. **2022**,	2

404	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression.. **2022**,	1
403	Von symptombasierter Diagnostik hin zu einem biologischen Konzept. **2022**, 33, 36-43	
402	Frequency of preclinical Alzheimer's disease in Japanese clinical study settings: a meta-analysis.	
401	Blood Biomarkers Predict Future Cognitive Decline after Military-Related Traumatic Brain Injury.. **2022**,	
400	Modifiable lifestyle activities affect cognition in cognitively healthy middle-aged individuals at risk for late-life Alzheimer's Disease.	0
399	A Single Multipurpose FSHβ-blocking Therapeutic for Osteoporosis and Obesity.	
398	Island Study Linking Aging and Neurodegenerative Disease (ISLAND) Targeting Dementia Risk Reduction: Protocol for a Prospective Web-Based Cohort Study.. **2022**, 11, e34688	0
397	Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease.. **2022**, 1	0
396	Wolframin is a novel regulator of tau pathology and neurodegeneration.. **2022**, 1	3
395	The role of clearance in neurodegenerative diseases.	
394	Quantification of amyloid PET for future clinical use: a state-of-the-art review.. **2022**, 1	1
393	Diminished preparatory physiological responses in frontotemporal lobar degeneration syndromes.. **2022**, 4, fcac075	0
392	Brain charts for the human lifespan.. **2022**,	15
391	Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.. **2022**,	2
390	Association of Genetic Variants Linked to Late-Onset Alzheimer Disease With Cognitive Test Performance by Midlife.. **2022**, 5, e225491	0
389	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging.. **2022**, 251, 119020	0
388	SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer's disease.. **2022**, 113, 73-83	
387	Apolipoprotein ε4 modifies obesity-related atrophy in the hippocampal formation of cognitively healthy adults.. **2022**, 113, 39-54	

386	Late Combination shows that MEG adds to MRI in classifying MCI versus Controls.. **2022**, 119054	0
385	P-tau217 in Alzheimer's disease.. **2022**, 531, 100-111	1
384	Kinetics of amyloid accumulation in physiological viscosity.. **2022**, 214, 112449	
383	Glucose-lowering drugs, cognition, and dementia: The clinical evidence.. **2022**, 137, 104654	0
382	Cognitive reserve, cognition, and real-world functioning in MCI: A systematic review and meta-analysis.. **2022**, 1-15	4
381	A Fusion of Multi-view 2D and 3D Convolution Neural Network based MRI for Alzheimer's Disease Diagnosis. **2021**, 2021, 3317-3321	0
380	Relationship between Resting State Heart Rate Variability and Sleep Quality in Older Adults with Mild Cognitive Impairment.. **2021**, 18,	
379	Social isolation and the aging brain Social isolation is linked to declining grey matter structure and cognitive functions in the LIFE-Adult panel study.	0
378	Intra-individual cognitive variability in neuropsychological assessment: a sign of neural network dysfunction.. **2021**, 1-25	0
377	Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid-PET.	1
376	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	0
375	[Association between sleep duration in adulthood and risk of dementia].. **2021**, 37, 1183-1185	
374	Vascular Cognitive Impairment (VCI).. **2021**, 1	4
373	Neurodegeneration and Vascular Burden on Cognition After Midlife: A Plasma and Neuroimaging Biomarker Study.. **2021**, 15, 735063	0
372	Cross-Modality Generation of Amyloid PET from FDG PET for Alzheimer Disease Diagnosis. **2021**,	1
371	Air pollution and dementia in older adults in the Ginkgo Evaluation of Memory Study.. **2022**,	1
370	Young Adults with a Parent with Dementia Show Early Abnormalities in Brain Activity and Brain Volume in the Hippocampus: A Matched Case-Control Study.. **2022**, 12,	1
369	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease.. **2022**, 119228	1

368	Long-term weight change and its temporal relation to later-life dementia in the Health and Retirement Study.. **2022**,	1
367	Associations of late-life sleep medication use with incident dementia in the Atherosclerosis Risk in Communities (ARIC) Study.. **2022**,	0
366	In-depth insights into Alzheimer's disease by using explainable machine learning approach.. **2022**, 12, 6508	1
365	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.. **2022**, 143, 571	0
364	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.. **2022**,	1
363	Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.. **2022**,	
362	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease.. **2022**,	0
361	Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.. **2022**,	0
360	Table_1.PDF. **2018**,	
359	Data_Sheet_1.docx. **2020**,	
358	Table_1.DOCX. **2018**,	
357	Table_2.docx. **2018**,	
356	Table_3.DOCX. **2018**,	
355	Table_4.DOCX. **2018**,	
354	Data_Sheet_1.docx. **2018**,	
353	Data_Sheet_1.pdf. **2018**,	
352	Data_Sheet_1.ZIP. **2018**,	
351	Data_Sheet_2.docx. **2018**,	

350 Data_Sheet_3.docx. **2018**,

349 Data_Sheet_4.docx. **2018**,

348 Table_1.DOCX. **2019**,

347 Table_1.docx. **2019**,

346 Image1.JPEG. **2018**,

345 Image2.JPEG. **2018**,

344 Image3.JPEG. **2018**,

343 Table_1.DOCX. **2019**,

342 Image_1.PDF. **2018**,

341 Table_1.doc. **2018**,

340 Table_2.docx. **2018**,

339 Data_Sheet_1.PDF. **2019**,

338 Table_1.XLSX. **2019**,

337 Data_Sheet_1.docx. **2019**,

336 Image_1.JPEG. **2020**,

335 Image_2.JPEG. **2020**,

334 Table_1.XLSX. **2020**,

333 Table_2.XLSX. **2020**,

332	Table_3.XLSX. **2020**,	
331	Table_4.XLSX. **2020**,	
330	DataSheet_1.docx. **2020**,	
329	Image_1.jpeg. **2020**,	
328	Image_2.jpeg. **2020**,	
327	Image_3.jpeg. **2020**,	
326	Image_4.jpeg. **2020**,	
325	Sex Differences in Cognition Across Aging.. **2022**,	0
324	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.. **2022**, 1	2
323	The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals.. **2022**, 14, 57	2
322	Validating MARK2 Gene Polymorphism as a Predictor of Response to Lithium Treatment in Bipolar Patients.. **2021**,	
321	Deviation From Model of Normal Aging in Alzheimer disease: Application of Deep Learning to Structural MRI data and Cognitive Tests. **2022**, 1-1	1
320	Network-wise concordance of multimodal neuroimaging features across the Alzheimer's disease continuum.. **2022**, 14, e12304	0
319	Sex-Driven Differences in the Effectiveness of Individualized Clinical Management of Alzheimer Disease Risk.	
318	Dementia in People with Intellectual Disabilities. **2022**, 719-756	0
317	Correlation Between Brain Structure Atrophy and Plasma Amyloid- and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnestic Mild Cognitive Impairment Explored by Surface-Based Morphometry.. **2022**, 14, 816043	1
316	Functional Imaging for Neurodegenerative Diseases.. **2022**, 104121	0
315	AD Resemblance Atrophy Index of Brain Magnetic Resonance Imaging in Predicting the Progression of Mild Cognitive Impairment Carrying Apolipoprotein E- Allele.. **2022**, 14, 859492	0

314	Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease.. **2022**, 27,	0
313	The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.. **2022**,	0
312	Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments.. **2022**, 14, 847315	1
311	Biomarker modeling of Alzheimer disease using PET-based Braak staging.	2
310	Associations Between Dietary Patterns and Neuroimaging Markers: A Systematic Review.. **2022**, 9, 806006	1
309	Associations of Parity With Change in Global Cognition and Incident Cognitive Impairment in Older Women. **2022**, 14,	
308	Modulation of GPCR receptors common to gut inflammatory diseases and neuronal disorders, Alzheimer's and Parkinson's diseases as druggable targets through bioactives: an study.. **2022**, 1-19	0
307	Disrupted Value-Directed Strategic Processing in Individuals with Mild Cognitive Impairment: Behavioral and Neural Correlates. **2022**, 7, 56	
306	Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease.. **2022**, 208, 2283-2299	0
305	Multimer Detection System-Oligomerized Amyloid Beta (MDS-OA): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia.. **2022**, 2022, 9960832	0
304	PET Imaging of Dementia: Update 2022.. **2022**,	0
303	Frontal lobe microglia, neurodegenerative protein accumulation, and cognitive function in people with HIV.. **2022**, 10, 69	0
302	Impact of cerebral blood flow and amyloid load on SUVR bias.. **2022**, 12, 29	0
301	Better cognitive function in younger generations - Insights from two cohort studies of middle-aged to older adults in Wisconsin.. **2022**, 162, 31-36	0
300	Amyloid- Oligomers: Multiple Moving Targets. **2022**, 2, 91-110	2
299	Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model.. **2022**,	1
298	Proteomic analysis identifies circulating proteins associated with plasma amyloid ta and incident dementia. **2022**,	
297	Molecular mechanisms of amyloid formation in living systems.	3

296	Sleep-disordered breathing was associated with lower health-related quality of life and cognitive function in a cross-sectional study of older adults.. **2022**,	0
295	Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre-Mild Cognitive Impairment.. **2022**,	0
294	NeuroProtect, a Candidate Formula From Traditional Chinese Medicine, Attenuates Amyloid- and Restores Synaptic Structures in APP/PS1 Transgenic Mice.. **2022**, 13, 850175	
293	Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum. **2022**, 8,	0
292	Slowing of Frontocentral Beta Oscillations in Atypical Parkinsonism.	0
291	Understanding How Physical Exercise Improves Alzheimer Disease: Cholinergic and Monoaminergic Systems. **2022**, 14,	0
290	Longitudinal associations of childhood fitness and obesity profiles with midlife cognitive function: an Australian cohort study. **2022**,	0
289	Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer Disease. **2022**, 1-7	0
288	Systemic Inflammation Predicts Alzheimer Pathology in Community Samples without Dementia. **2022**, 10, 1240	0
287	CSF Phosphorylated Tau as an Indicator of Subsequent Tau Accumulation. **2022**,	0
286	Impact of different processing methods on phenolics and neuroprotective activity of Fragaria ananassa Duch. extracts in a D-galactose and aluminum chloride induced rat model of aging.	
285	Brain Iron Imaging in Aging and Cognitive Disorders: MRI Approaches. **2022**, 83, 527	
284	Neuroimaging Modalities in Alzheimer Disease: Diagnosis and Clinical Features. **2022**, 23, 6079	0
283	Association of Dual Decline in Cognition and Gait Speed With Risk of Dementia in Older Adults. **2022**, 5, e2214647	3
282	A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset. **2022**, 119344	0
281	The Relationships Among Metal Homeostasis, Mitochondria, and Locus Coeruleus in Psychiatric and Neurodegenerative Disorders: Potential Pathogenetic Mechanism and Therapeutic Implications.	1
280	Lifestyle affects amyloid burden and cognition differently in men and women.	0
279	Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer Disease. 14,	0

278	Impact of APOE ε4 Carrier Status on Associations Between Subthreshold, Positive Amyloid-β Deposition, Brain Function, and Cognitive Performance in Cognitively Normal Older Adults: A Prospective Study. 14,	0
277	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. **2022**, 81, 387-413	0
276	Hippocampal representations for deep learning on Alzheimer's disease. **2022**, 12,	1
275	FRACTAL DIMENSION OF THE BRAIN IN NEURODEGENERATIVE DISEASE AND DEMENTIA: A SYSTEMATIC REVIEW. **2022**, 101651	0
274	Associations of Midlife Diet Quality with Incident Dementia and Brain Structure: Findings from the UK Biobank Study.	0
273	Exploring the ATN classification system using Brain Morphology.	
272	18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. **2022**, 63, 2S-12S	1
271	A toy model of misfolded protein aggregation and neural damage propagation in neurodegenerative diseases. **2022**, 144, 104083	1
270	A Histochemical Analysis of Neurofibrillary Tangles in Olfactory Epithelium, a Study Based on an Autopsy Case of Juvenile Alzheimer's Disease. **2022**,	0
269	Histoire naturelle et diagnostic de la maladie d'Alzheimer. **2022**, 143-161	
268	Assessment of Instrumental Activities of Daily Living in Preclinical Alzheimer Disease. 153944922211007	
267	Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimer's Disease-related neurodegenerative diseases from an unselected memory clinic cohort. **2022**, 12,	
266	Epigenetics in Alzheimer's Disease. 14,	4
265	Mapping the Genetic-Imaging-Clinical Pathway with Applications to Alzheimer's Disease. 1-30	0
264	Ultrasensitive Detection of Biomarkers in a Color-Switchable Microcavity-Reactor Laser. 2202326	0
263	Ganglioside Nanocluster-Targeting Peptidyl Inhibitor Prevents Amyloid β Fibril Formation on the Neuronal Membrane.	0
262	Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to β-amyloid positivity.	0
261	Normalization of MRI T1w between-scan effects for improved longitudinal volumetric estimates.	

260	Staging of Alzheimer's disease: past, present, and future perspectives. **2022**,	1
259	Effect of cerebellum stimulation on cognitive recovery in patients with Alzheimer disease: A randomized clinical trial. **2022**, 15, 910-920	0
258	Order selection for regression-based hidden Markov model. **2022**, 192, 105061	1
257	Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. **2022**, 8,	
256	Brain Mitochondrial Dysfunction: A Possible Mechanism Links Early Life Anxiety to Alzheimer's Disease in Later Life. **2022**, 13, 1127	1
255	Phosphatidylethanolamine Binding Protein´1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation. **2022**, 1-10	
254	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. 1-13	0
253	Metacognition, cortical thickness, and tauopathy in aging. **2022**,	
252	Alzheimer's disease, cerebrovascular disease and dementia: lump, split or integrate?.	
251	Extraversion Is Associated With Lower Brain Beta-Amyloid Deposition in Cognitively Normal Older Adults. 14,	
250	Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity. 14,	1
249	FMRI complexity correlates with tau-PET in Late-Onset and Autosomal Dominant Alzheimer's Disease.	
248	Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. **2022**, 1-11	
247	RNASE6 is a novel modifier of APOE-ε4 effects on cognition. **2022**,	0
246	A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer's Disease. **2022**, 10, 1713	0
245	Brain imaging and neuropsychological assessment of individuals recovered from mild to moderate SARS-CoV-2 infection.	2
244	Cognitive and neuroimaging correlates of financial exploitation vulnerability in older adults without dementia: Implications for early detection of Alzheimer's disease. **2022**, 140, 104773	0
243	Mathematical model of Alzheimer's disease with prion proteins interactions and treatment. **2022**, 433, 127377	1

242	A multiscale brain network model links Alzheimer's disease-mediated neuronal hyperactivity to large-scale oscillatory slowing. **2022**, 14,	0
241	Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78–94.	0
240	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. **2022**, 20, e3001694	3
239	The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. **2022**, 103125	
238	Exercise for the prevention of Alzheimer's Disease: multiple pathways to promote non-amyloidogenic APP processing. **2022**, 100093	0
237	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	4
236	Independent effect of body mass index variation on amyloid-β positivity. 14,	0
235	[11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer's disease. **2022**, 13,	0
234	Early β-amyloid accumulation and hypoconnectivity in the default mode network are related to its disengagement from global brain activity.	0
233	Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology. **2022**, 1-12	
232	Identifying the regional substrates predictive of Alzheimer's disease progression through a convolutional neural network model and occlusion.	1
231	Supersaturation-Dependent Formation of Amyloid Fibrils. **2022**, 27, 4588	0
230	Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects' MissionAD tau sub-study. **2022**, 14,	0
229	Adenosine receptor signalling in Alzheimer's disease. **2022**, 18, 359-381	0
228	Pharmacological activation of the C5a receptor leads to stimulation of the β-adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer's disease. 13,	
227	Evaluating the performance of Bayesian and frequentist approaches for longitudinal modeling: application to Alzheimer's disease. **2022**, 12,	
226	Associations Between Sub-Threshold Amyloid-β Deposition, Cortical Volume, and Cognitive Function Modulated by APOE e4 Carrier Status in Cognitively Normal Older Adults. **2022**, 1-14	
225	Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.	0

224	Proteomic Markers and Early Prediction of Alzheimer's Disease. **2022**, 87, 762-776	
223	Densité des dépôts de la protéine Tau versus activité métabolique cortico-cérébrale chez des patients atteints de maladie d'Alzheimer ou de pathologies apparentées. **2022**, 46, 183-190	
222	Residual reserve index modifies the effect of amyloid pathology on fluorodeoxyglucose metabolism: Implications for efficiency and capacity in cognitive reserve. 14,	0
221	Microglia activation linking amyloid-β drive tau spatial propagation in Alzheimer's disease. 16,	1
220	Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.	0
219	Temporal and sex-linked protein expression dynamics in a familial model of Alzheimer's Disease. **2022**, 100280	1
218	The CORCOBIA study: Cut-off points of Alzheimer's disease CSF biomarkers in a clinical cohort. **2022**,	1
217	Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: Integration of the glutamate/GABA-glutamine cycle. **2022**, 217, 102331	2
216	DAFT: A universal module to interweave tabular data and 3D images in CNNs. **2022**, 260, 119505	1
215	Change in brain amyloid load and cognition in patients with amnestic mild cognitive impairment: a 3-year follow-up study. **2022**, 12,	0
214	Theta Band-Power Shapes Amyloid-Driven Longitudinal EEG Changes in Elderly Subjective Memory Complainers At-Risk for Alzheimer's Disease. **2022**, 1-16	0
213	Investigating the temporal pattern of neuroimaging-based brain age estimation as a biomarker for Alzheimer's Disease related neurodegeneration. **2022**, 263, 119621	0
212	Effective connectivity in individuals with Alzheimer's disease and mild cognitive impairment: A systematic review. **2022**, 2, 100104	1
211	Development of novel near-infrared GFP chromophore-based fluorescent probes for imaging of amyloid-β plaque and viscosity. **2022**, 372, 132648	0
210	Considerations for measuring individual outcomes across contexts in Down syndrome: Implications for research and clinical trials. **2022**, 191-225	1
209	The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations. **2022**, 8,	0
208	Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction. **2022**, 14,	0
207	Sex and gender differences in dementia. **2022**, 179-233	0

206	Sleep duration and biomarkers of inflammation in African American and white participants with a parental history of Alzheimer's disease. **2022**, 8,	0
205	Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling. **2022**, 36, 103144	0
204	Amyloid Conversion is Related to Risk Factors For Dementia.	0
203	Roadmap for ecosystem-based approach for patients with Alzheimer disease in Russia: current needs, barriers, and possible solutions (resolution of the scientific and practical experts meeting). **2022**, 122, 121	0
202	Pharmacogenomics of Alzheimer Disease: Novel Strategies for Drug Utilization and Development. **2022**, 275-387	1
201	Mitochondria in Cell Death Regulation. **2022**,	0
200	Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome. **2022**, 227-263	1
199	Alzheimer's Disease Clinical Scores Prediction based on the Label Distribution Learning using Brain Structural MRI. **2022**,	0
198	Soluble TREM2 mediates earliest amyloid-associated p-tau increases and cerebral glucose hypermetabolism in Alzheimer disease.	0
197	To donate, or not to donate, that is the question: Latino insights into brain donation.	0
196	Socio-cognitive mindfulness predicts memory complaint and cognitive performance of older adults with different years of education. 1-8	0
195	Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.	2
194	Estudio CORCOBIA: determinaci n de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte cl nica. **2022**,	0
193	Interpretable deep learning of myelin histopathology in age-related cognitive impairment. **2022**, 10,	0
192	Value assessment of new interventions for Alzheimer disease dementia in Japan based on literature review and group interview. 1-8	0
191	Landscape of immune infiltration in entorhinal cortex of patients with Alzheimer disease. 13,	0
190	Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer disease continuum. 11,	0
189	Predicting conversion of brain amyloid positivity in amyloid-negative individuals. **2022**, 14,	0

188	Genetic, clinical underpinnings of subtle early brain change along Alzheimer dimensions.	0
187	Linear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer Disease. Publish Ahead of Print,	0
186	The relationship between mild cognitive impairment and postoperative delirium undergoing total knee arthroplasty: The PNDABLE study. 14,	0
185	Circulating serum metabolites as predictors of dementia: a machine learning approach in a 21-year follow-up of the Whitehall II cohort study. **2022**, 20,	0
184	High Soluble Amyloid-2 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer Disease-Causing Mutations. **2022**, 1-15	7
183	Sensing red blood cell nano-mechanics: Toward a novel blood biomarker for Alzheimer disease. 14,	1
182	FSH-blocking therapeutic for osteoporosis. 11,	0
181	A Review of Application of A2/40 Ratio in Diagnosis and Prognosis of Alzheimer Disease. **2022**, 1-18	1
180	Carbon Nanotube and Its Derived Nanomaterials Based High Performance Biosensing Platform. **2022**, 12, 731	5
179	Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning.	0
178	Neuronal injury assessment with early-phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol amyloid-PET recordings.	0
177	Exploration of cortical Amyloid load in Alzheimer disease using quantitative susceptibility mapping at 9.4T.	0
176	Cerebrospinal Fluid Sphingomyelins in Alzheimer Disease, Neurodegeneration, and Neuroinflammation. **2022**, 1-14	0
175	Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer disease. **2022**, 18, e1010294	0
174	Mental health care for older adults: recent advances and new directions in clinical practice and research. **2022**, 21, 336-363	1
173	Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy. **2022**, 14,	0
172	Prediction of misfolded proteins spreading in Alzheimer's disease using machine learning.	0
171	Thyroid-stimulating hormone and the risk of Alzheimer's disease: an ADNI cohort study.	0

170	Towards an understanding of the pathological basis of senile depression and incident dementia: implications for treatment.	1
169	Contribution of smoking towards the association between socioeconomic position and dementia: 32-year follow-up of the Whitehall II prospective cohort study. **2022**, 23, 100516	0
168	Neuroimaging and clinical characteristics of cognitive migration in community-dwelling older adults. **2022**, 36, 103232	0
167	Non-parametric ODE-Based Disease Progression Model of ´Brain Biomarkers in ´Alzheimer Disease. **2022**, 95-103	0
166	Intrinsic Brain Activity and Resting State Networks. **2022**, 1939-1990	0
165	Health economic modeling for Alzheimer's disease: Expert perspectives. **2022**, 8,	0
164	Adulthood cognitive trajectories over 26 years and brain health at 70 years of age: Findings from the 1946 British Birth Cohort. **2022**,	0
163	Identifying Alzheimer disease from 4D fMRI using hybrid 3DCNN and GRU networks. **2022**,	0
162	Magnetic Resonance Images Implicate That Glymphatic Alterations Mediate Cognitive Dysfunction in Alzheimer Disease.	0
161	Blood Transcript Biomarkers Selected by Machine Learning Algorithm Classify Neurodegenerative Diseases including Alzheimer Disease. **2022**, 12, 1592	0
160	Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta. 14,	0
159	Physical Functional Impairment and the Risk of Incident Mild Cognitive Impairment in an Observational Study of World Trade Center Responders. 10.1212/CPJ.0000000000200089	1
158	Perivascular spaces as a potential biomarker of Alzheimer disease. 16,	0
157	Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials.	0
156	Quantitative Systems Pharmacology Model of the Amyloid Pathway in Alzheimer Disease: Insights into the Therapeutic Mechanisms of Clinical Candidates.	0
155	CSF Alzheimer Disease Biomarkers. **2022**, 99, e1640-e1650	2
154	Body Mass Index Trajectories Preceding Incident Mild Cognitive Impairment and Dementia.	1
153	Directed functional brain connectivity is altered in sub-threshold amyloid- accumulators.	0

152	Association of change in cardiovascular risk factors with incident dementia.	0
151	Prediction of amyloid accumulation from multiple biomarkers using a hierarchical Bayesian model.	0
150	Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. **2022**, 7,	0
149	Influence of Gender on Tau Precipitation in Alzheimer Disease According to ATN Research Framework.	0
148	Neurofilaments contribution in clinic: state of the art. 14,	0
147	Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. **2022**,	1
146	Moderating effect of cognitive reserve on brain integrity and cognitive performance. 14,	0
145	SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline. **2022**, 17, e0276392	0
144	Potential role of dietary nitrate in relation to cardiovascular and cerebrovascular health, cognition, cognitive decline and dementia: a review.	0
143	Parkinson's disease and related disorders. **2023**, 3-19	0
142	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer Disease and Identifying Promising Drug Targets. **2022**, 12, 1676	3
141	Integrated bioinformatics-based identification of diagnostic markers in Alzheimer disease. 14,	1
140	Disease specific and nonspecific metabolic brain networks in behavioral variant of frontotemporal dementia.	0
139	Alzheimer Disease: Treatment Strategies and Their Limitations. **2022**, 23, 13954	0
138	Examining real-world Alzheimer disease heterogeneity using neuroanatomical normative modelling.	0
137	The contributions of bacteria metabolites to the development of hepatic encephalopathy. **2022**,	0
136	Post-GWAS multiomic functional investigation of theTNIP1locus in Alzheimer disease implicates mediation throughGPX3.	0
135	PET molecular imaging for pathophysiological visualization in Alzheimer disease.	1

134	Predicting Cognitive Decline in Nondemented Elders Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration. 10.1212/WNL.0000000000201572	0
133	Can dementia risk be reduced by following the American Heart Association's Life's Simple 7? A systematic review and dose-response meta-analysis. **2022**, 101788	1
132	Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.	1
131	Review of Quantitative Methods for the Detection of Alzheimer Disease with Positron Emission Tomography. **2022**, 12, 11463	0
130	Vascular endothelial-cadherin as a marker of endothelial injury in preclinical Alzheimer disease.	0
129	Forgetful, sad and old: Do vascular cognitive impairment and depression share a common pre-disease network and how is it impacted by ageing?. **2022**, 156, 611-627	1
128	A and Tau Prions Causing Alzheimer Disease. **2023**, 293-337	0
127	A predictive model for the risk of cognitive impairment in community middle-aged and older adults. **2023**, 79, 103380	0
126	Alzheimer disease-like cortical atrophy mediates the effect of air pollution on global cognitive function. **2023**, 171, 107703	0
125	Time-lagged relationships between a decade of air pollution exposure and first hospitalization with Alzheimer's disease and related dementias. **2023**, 171, 107694	0
124	Degenerate mapping of environmental location presages deficits in object-location encoding and memory in the 5xFAD mouse model for Alzheimer's disease. **2023**, 176, 105939	0
123	Nanomedicine-based immunotherapy for Alzheimer's disease. **2023**, 144, 104973	0
122	Exploiting task relationships for Alzheimer disease cognitive score prediction via multi-task learning. **2023**, 152, 106367	0
121	Direct coupling of fiber-in-tube solid-phase microextraction with tandem mass spectrometry to determine amyloid beta peptides as biomarkers for Alzheimer's disease in cerebrospinal fluid samples. **2023**, 254, 124186	0
120	Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood. **2022**, 14,	0
119	Late Midlife Subclinical Infarct Burden and Risk of Dementia: The Atherosclerosis Risk in Communities Neurocognitive Study. **2022**, 1-7	0
118	MASCoD Multidimensional Assessment of Subjective Cognitive Decline. 13,	0
117	Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer disease pathology. **2022**, 2, 1138-1144	2

116	Dementia Detection from Speech Using Machine Learning and Deep Learning Architectures. **2022**, 22, 9311	1
115	Constructing brain functional network by Adversarial Temporal-Spatial Aligned Transformer for early AD analysis. 16,	0
114	Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks. 14,	0
113	Update FDG-PET in der Demenzdiagnostik. **2022**, 45, 297-314	0
112	Modifiable Lifestyle Activities Affect Cognition in Cognitively Healthy Middle-Aged Individuals at Risk for Late-Life Alzheimer's Disease. **2022**, 1-14	0
111	Multiparametric Quantitative Imaging Biomarker as a Multivariate Descriptor of Health: A Roadmap. **2022**,	1
110	Obesity-Associated Neurodegeneration Pattern Mimics Alzheimer's Disease in an Observational Cohort Study. **2022**, 1-11	1
109	Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer's disease in midlife women.	0
108	Current Pharmacotherapy and Multi-Target Approaches for Alzheimer's Disease. **2022**, 15, 1560	2
107	Weight Loss and Alzheimer's Disease in Down Syndrome. **2022**, 1-12	0
106	Synaptic degeneration in Alzheimer disease.	3
105	Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score. **2022**, 22,	0
104	Changes in hippocampal volume during a preceding 10-year period do not correlate with cognitive performance and hippocampal blood-brain barrier permeability in cognitively normal late-middle-aged men.	0
103	Gray to White Matter Signal Ratio as a novel biomarker of neurodegeneration in Alzheimer's disease. **2022**, 103303	0
102	E/I unbalance and aberrant oscillation dynamics predict preclinical Alzheimer's disease.	0
101	Sex and menopause impact 31P-Magnetic Resonance Spectroscopy brain mitochondrial function in association with 11C-PiB PET amyloid-beta load. **2022**, 12,	0
100	Medial temporal tau predicts memory decline in cognitively unimpaired elderly.	0
99	Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial. **2022**, 1-10	0

98	Vascular contributions to Alzheimer's disease. **2022**,	1
97	Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings.	0
96	Neurocognitive Underpinning of Neurological Disorders: Role of Default Mode Network. **2022**, 269-297	0
95	Analysis of A□nduced neurotoxicity and microglial responses in simple two- and three-dimensional human iPSC-derived cortical culture systems. **2023**, 102023	0
94	Hippocampal functional connectivity across age in an App knock-in mouse model of Alzheimer's disease. 14,	0
93	Integration of amyloid-□oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis. 13,	0
92	Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?.	0
91	Plasma A□2/A□0 ratios are not reduced in older people living with HIV.	0
90	sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease.	1
89	Sex differences in the associations between risk for late-life AD, protective lifestyle factors and cognition in mid-life.	0
88	Neurodegenerative disease of the brain: a survey of interdisciplinary approaches. **2023**, 20,	1
87	A TREM2-activating antibody with a blood□brain barrier transport vehicle enhances microglial metabolism in Alzheimer□ disease models.	0
86	Insomnia Symptoms and Biomarkers of Alzheimer□ Disease in the Community. **2023**, 1-12	0
85	APOE □ status and plasma p-tau181 interact to influence cognitive performance among non-demented older adults. **2023**, 796, 137052	0
84	Comprehensive Understanding of Hispanic Caregivers: Focus on Innovative Methods and Validations. 1-18	1
83	Dynamic changes of CSF clusterin levels across the Alzheimer□ disease continuum. **2022**, 22,	0
82	Language Patterns in Japanese Patients with Alzheimer Disease: A Machine Learning Approach.	0
81	Update on Alzheimer□ Disease. 82-90	0

80	APOE4 potentiates Aβ effects on longitudinal tangle accumulation via tau phosphorylation.	0
79	Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer's disease.	0
78	Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer's Disease. **2023**, 13, 232	0
77	Fully Connected Multi-Kernel Convolutional Neural Network Based on Alzheimer's Disease Diagnosis. **2023**, 1-20	0
76	Marital Status of Never Married with Rey Auditory Verbal Learning Test Cognition Performance Is Associated with Mild Cognitive Impairment. **2023**, 13, 1656	0
75	Amyloid-PET and White Matter Hyperintensities Have Independent Effects on Baseline Cognitive Function and Synergistic Effects on Longitudinal Executive Function. **2023**, 13, 218	0
74	Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease. **2023**, 15,	0
73	The theoretical problems of "prodrome" and "phenoconversion" in neurodegeneration. **2023**, 155-167	0
72	Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. **2023**, 172, 107800	0
71	Impact of Mild Behavioral Impairment on Longitudinal Changes in Cognition.	0
70	Age-related changes in prepulse inhibition of the startle response. 14,	0
69	HGM-cNet: Integrating hippocampal gray matter probability map into a cascaded deep learning framework improves hippocampus segmentation. **2023**, 162, 110771	0
68	The action of phosphodiesterase-5 inhibitors on β-amyloid pathology and cognition in experimental Alzheimer's disease: A systematic review. **2023**, 320, 121570	0
67	Abnormal white matter changes in Alzheimer's disease based on diffusion tensor imaging: A systematic review. **2023**, 87, 101911	0
66	The association of dietary and nutrient patterns on neurocognitive decline: A systematic review of MRI and PET studies. **2023**, 87, 101892	0
65	Association between gout at midlife and cognitive impairment at late life - The Singapore Chinese Health Study. **2023**, 111, 104996	0
64	Treatment of Alzheimer's disease by microcapsule regulates neurotransmitter release via microfluidic technology. **2023**, 4, 183-192	0
63	Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative. **2023**, 127, 33-42	0

62	Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer's disease.	0
61	Genetic Risk for Alzheimer Disease and Plasma Tau Are Associated With Accelerated Parietal Cortex Thickness Change in Middle-Aged Adults. **2023**, 9, e200053	1
60	Brain region-specific myelinogenesis is not directly linked to amyloid-β in APP/PS1 transgenic mice. **2023**, 362, 114344	0
59	Path integration selectively predicts midlife risk of Alzheimer's disease.	0
58	Deep neural network heatmaps capture Alzheimer's disease patterns reported in a large meta-analysis of neuroimaging studies. **2023**, 269, 119929	0
57	The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells. **2023**, 13, 313	1
56	Evaluation of advanced, pathophysiologic new targets for imaging of CNS.	0
55	Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment. 19,	0
54	Effects of sex and APOE ε4 genotype on brain mitochondrial high-energy phosphates in midlife individuals at risk for Alzheimer's disease: A 31Phosphorus MR spectroscopy study. **2023**, 18, e0281302	0
53	Neuroimaging in Dementia. **2023**, 29, 219-254	0
52	Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort. **2023**, 15,	0
51	Longitudinal changes in participant and informant reports of subjective cognitive complaints are associated with dementia risk. 15,	0
50	A multidimensional ODE-based model of Alzheimer's disease progression. **2023**, 13,	0
49	Hypoglycemic medicines in the treatment of Alzheimer's disease: Pathophysiological links between AD and glucose metabolism. 14,	0
48	Association of Cancer History with Structural Brain Aging Markers of Alzheimer's Disease and Dementia Risk.	0
47	Neurocognitive Disorders. **2023**, 407-435	0
46	Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels. 15,	0
45	Unexpected Classes of Aquaporin Channels Detected by Transcriptomic Analysis in Human Brain Are Associated with Both Patient Age and Alzheimer's Disease Status. **2023**, 11, 770	0

44	Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort.	0
43	Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia.	0
42	Protective Effects of Cannabis in Neuroinflammation-Mediated Alzheimer's Disease. **2023**, 48-75	0
41	Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases.	0
40	Retinal Alterations as Potential Biomarkers of Structural Brain Changes in Alzheimer's Disease Spectrum Patients. **2023**, 13, 460	0
39	A comprehensive characterization of hippocampal feature ensemble serves as individualized brain signature for Alzheimer's disease: deep learning analysis in 3238 participants worldwide.	0
38	Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology. **2023**,	0
37	Accumulation of network redundancy marks the early stage of Alzheimer's disease.	0
36	Machine learning of cerebello-cerebral functional networks for mild cognitive impairment detection.	0
35	Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study. **2023**, 21,	0
34	Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer's disease. 15,	0
33	Dityrosine cross-linking and its potential roles in Alzheimer's disease. 17,	0
32	Emerging Links between Cerebral Blood Flow Regulation and Cognitive Decline: A Role for Brain Microvascular Pericytes. **2022**, 0	0
31	Patient-specific multi-modal modeling uncovers neurotransmitter receptor involvement in motor and non-motor axes of Parkinson's disease.	0
30	Prefrontal EEG slowing, synchronization, and ERP peak latency in association with predementia stages of Alzheimer's disease. 15,	0
29	The Future of Cognitive Screening in Neurodegenerative Diseases. **2023**, 1-13	0
28	Exploring the ATN classification system using brain morphology. **2023**, 15,	0
27	Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. **2023**, 15,	0

26	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease. **2023**, 15,	0
25	A Hybrid-Layered Framework for Detection and Diagnosis of Alzheimer Disease (AD) from Fundus Images. **2023**,	0
24	Clinical Management in Alzheimer Disease in the Era of Disease-Modifying Therapies. **2023**, 25, 121-133	0
23	Pioneering the Early Diagnosis of Alzheimer Disease: A Oligomers-Sensing Probe for Cerebrospinal Fluid Analysis in Patients.	0
22	Single-value scores of memory-related brain activity reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging.	0
21	Diagnostic Performance of MRI Radiomics for Classification of Alzheimer disease, Mild Cognitive Impairment, and Normal Subjects: A Systematic Review and Meta-analysis.	0
20	Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study.	0
19	Visual-somatosensory integration (VSI) as a novel marker of Alzheimer disease: A comprehensive overview of the VSI study. 15,	0
18	Directed Functional Brain Connectivity is Altered in Sub-threshold Amyloid- Accumulation in Cognitively Normal Individuals. **2023**, 18, 263310552311616	0
17	Nonlinear changes in delayed functional network topology in Alzheimer disease: relationship with amyloid and tau pathology.	0
16	Sex-specific age-related changes in glymphatic function assessed by resting-state functional magnetic resonance imaging.	0
15	Annual stability of the plasma A 40/42 ratio and associated factors.	0
14	NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid- and Tau Levels in the Continuum of Alzheimer Disease. **2023**, 92, 1303-1321	0
13	A unique color-coded visualization system with multimodal information fusion and deep learning in a longitudinal study of Alzheimer's disease. **2023**, 140, 102543	0
12	Associations of Serum Antimicrobial Peptide LL-37 with Longitudinal Cognitive Decline and Neurodegeneration Among Older Adults with Memory Complaints. **2023**, 1-9	0
11	18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer Disease Biomarkers in Subjective Cognitive Decline Population. **2023**, 1-10	0
10	GFP-based red-emissive fluorescent probes for dual imaging of amyloid plaques and mitochondrial viscosity. **2023**, 136, 106540	0
9	Partial Least Squares Regression Analysis of Alzheimer Disease Biomarkers, Modifiable Health Variables, and Cognitive Change in Older Adults with Mild Cognitive Impairment. **2023**, 1-19	0

8	Gene Co-Expression Analysis of Multiple Brain Tissues Reveals Correlation of FAM222A Expression with Multiple Alzheimer's Disease-Related Genes. **2023**, 1-15	0
7	Multimodal imaging of microstructural cerebral changes and loss of synaptic density in Alzheimer's disease.	0
6	Inter- and intra-operator variations in manual segmentation of hippocampus from MRI. **2023**, 101249	0
5	How to Prevent and/or Revert Alzheimer's Disease Continuum During Preclinical Phases. 1-8	0
4	Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer's disease: an updated overview of nonpharmacological therapies. **2023**, 18,	0
3	Association between APOE genotype and microglial cell morphology.	0
2	Lipid nanoparticle-mediated drug delivery to the brain. **2023**, 197, 114861	0
1	Retinal microvascular complexity as a putative biomarker of biological age – a pilot study.	0